EP4186896A1 - Shp2 inhibitor and composition and application thereof - Google Patents
Shp2 inhibitor and composition and application thereof Download PDFInfo
- Publication number
- EP4186896A1 EP4186896A1 EP21847300.7A EP21847300A EP4186896A1 EP 4186896 A1 EP4186896 A1 EP 4186896A1 EP 21847300 A EP21847300 A EP 21847300A EP 4186896 A1 EP4186896 A1 EP 4186896A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- amino
- piperidin
- dihydrospiro
- prop
- pyrazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 title claims abstract description 44
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 title claims abstract description 37
- 239000003112 inhibitor Substances 0.000 title abstract description 9
- 239000000203 mixture Substances 0.000 title description 30
- 150000001875 compounds Chemical class 0.000 claims abstract description 597
- 238000002360 preparation method Methods 0.000 claims abstract description 210
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 238
- 125000000623 heterocyclic group Chemical group 0.000 claims description 127
- 229910052739 hydrogen Inorganic materials 0.000 claims description 88
- 239000001257 hydrogen Substances 0.000 claims description 88
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 77
- 229910052757 nitrogen Inorganic materials 0.000 claims description 73
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 71
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 67
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims description 64
- -1 benzobisoxazolyl Chemical group 0.000 claims description 61
- 125000001424 substituent group Chemical group 0.000 claims description 61
- 229910052736 halogen Inorganic materials 0.000 claims description 53
- 150000002367 halogens Chemical class 0.000 claims description 53
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 52
- 125000004043 oxo group Chemical group O=* 0.000 claims description 49
- 150000003839 salts Chemical class 0.000 claims description 47
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 44
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 40
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 39
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 36
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 36
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 36
- 239000000651 prodrug Substances 0.000 claims description 31
- 229940002612 prodrug Drugs 0.000 claims description 31
- 239000012453 solvate Substances 0.000 claims description 30
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 29
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 29
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 29
- 239000000126 substance Substances 0.000 claims description 28
- 239000013522 chelant Substances 0.000 claims description 26
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 125000003118 aryl group Chemical group 0.000 claims description 25
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 24
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 19
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 19
- 125000001072 heteroaryl group Chemical group 0.000 claims description 18
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 16
- 125000006706 (C3-C6) carbocyclyl group Chemical group 0.000 claims description 11
- 125000004429 atom Chemical group 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 125000005842 heteroatom Chemical group 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 229920006395 saturated elastomer Polymers 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 8
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 7
- 201000005202 lung cancer Diseases 0.000 claims description 7
- 208000020816 lung neoplasm Diseases 0.000 claims description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 7
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000002541 furyl group Chemical group 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 206010029748 Noonan syndrome Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 125000001041 indolyl group Chemical group 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 125000002971 oxazolyl group Chemical group 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 5
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 125000000335 thiazolyl group Chemical group 0.000 claims description 5
- 125000001544 thienyl group Chemical group 0.000 claims description 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 claims description 4
- 206010029260 Neuroblastoma Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 241000282373 Panthera pardus Species 0.000 claims description 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 208000025402 neoplasm of esophagus Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- MZBVNYACSSGXID-UHFFFAOYSA-N 2,3,4,5-tetrahydro-1h-1-benzazepine Chemical compound N1CCCCC2=CC=CC=C21 MZBVNYACSSGXID-UHFFFAOYSA-N 0.000 claims description 3
- QNXYOIMKVPJYBB-HHHXNRCGSA-N 2-[3-[3-[5-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-(hydroxymethyl)pyrazin-2-yl]prop-2-ynoxy]phenyl]acetamide Chemical compound N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCOC1=CC=CC(CC(N)=O)=C1 QNXYOIMKVPJYBB-HHHXNRCGSA-N 0.000 claims description 3
- YILGFEKENNDFRV-HHHXNRCGSA-N 2-[4-[3-[5-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-(hydroxymethyl)pyrazin-2-yl]prop-2-ynoxy]phenyl]propan-2-ol Chemical compound CC(C)(C(C=C1)=CC=C1OCC#CC1=NC(CO)=C(N(CC2)CCC2(CC2=CC=CC=C22)[C@@H]2N)N=C1)O YILGFEKENNDFRV-HHHXNRCGSA-N 0.000 claims description 3
- POJQKZGHSHKRSN-XMMPIXPASA-N 2-[4-[3-[5-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-(hydroxymethyl)pyrazin-2-yl]prop-2-ynoxy]pyrazol-1-yl]acetamide Chemical compound N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCOC1=CN(CC(N)=O)N=C1 POJQKZGHSHKRSN-XMMPIXPASA-N 0.000 claims description 3
- TZOYXRMEFDYWDQ-UHFFFAOYSA-N 3,4-dihydro-1h-quinolin-2-one Chemical compound C1=CC=C2NC(=O)CCC2=C1 TZOYXRMEFDYWDQ-UHFFFAOYSA-N 0.000 claims description 3
- UACDKBOKZLVORJ-AREMUKBSSA-N 3-[3-[5-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-(hydroxymethyl)pyrazin-2-yl]prop-2-ynoxy]benzonitrile Chemical compound N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCOC1=CC=CC(C#N)=C1 UACDKBOKZLVORJ-AREMUKBSSA-N 0.000 claims description 3
- BGPWAVSLDUFJSU-AREMUKBSSA-N 4-[3-[5-[(1S)-1-amino-6-methoxyspiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-(hydroxymethyl)pyrazin-2-yl]prop-2-ynoxy]benzamide Chemical compound COC1=CC=C(CC(CC2)(CCN2C(N=C2)=C(CO)N=C2C#CCOC(C=C2)=CC=C2C(N)=O)[C@@H]2N)C2=C1 BGPWAVSLDUFJSU-AREMUKBSSA-N 0.000 claims description 3
- KWQKMXQDGHZOQG-RUZDIDTESA-N 4-[3-[5-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-(hydroxymethyl)pyrazin-2-yl]prop-2-ynoxy]-2-chlorobenzamide Chemical compound N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCOC(C=C1)=CC(Cl)=C1C(N)=O KWQKMXQDGHZOQG-RUZDIDTESA-N 0.000 claims description 3
- SBVVTGMSNXGYJC-RUZDIDTESA-N 4-[3-[5-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-(hydroxymethyl)pyrazin-2-yl]prop-2-ynoxy]-2-fluorobenzamide Chemical compound N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCOC(C=C1)=CC(F)=C1C(N)=O SBVVTGMSNXGYJC-RUZDIDTESA-N 0.000 claims description 3
- XNDYIGYLCPCNBU-AREMUKBSSA-N 4-[3-[5-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-(hydroxymethyl)pyrazin-2-yl]prop-2-ynyl-methylamino]benzamide Chemical compound CN(CC#CC1=NC(CO)=C(N(CC2)CCC2(CC2=CC=CC=C22)[C@@H]2N)N=C1)C(C=C1)=CC=C1C(N)=O XNDYIGYLCPCNBU-AREMUKBSSA-N 0.000 claims description 3
- YBZZRLNQOOLEBM-RUZDIDTESA-N 4-[3-[5-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]pyrazin-2-yl]prop-2-ynoxy]-2-chlorobenzamide Chemical compound N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=CN=C1C#CCOC(C=C1)=CC(Cl)=C1C(N)=O YBZZRLNQOOLEBM-RUZDIDTESA-N 0.000 claims description 3
- RVDSSOLRZKMXIY-JOCHJYFZSA-N 4-[3-[5-[(4S)-4-aminospiro[4,6-dihydrocyclopenta[d][1,3]oxazole-5,4'-piperidine]-1'-yl]-6-(hydroxymethyl)pyrazin-2-yl]prop-2-ynoxy]benzamide Chemical compound N[C@@H](C(C1)(CC2)CCN2C(N=C2)=C(CO)N=C2C#CCOC(C=C2)=CC=C2C(N)=O)C2=C1OC=N2 RVDSSOLRZKMXIY-JOCHJYFZSA-N 0.000 claims description 3
- FHZKUIOWBKXELG-JOCHJYFZSA-N 4-[3-[5-[(4S)-4-aminospiro[4,6-dihydrocyclopenta[d][1,3]thiazole-5,4'-piperidine]-1'-yl]-6-(hydroxymethyl)pyrazin-2-yl]prop-2-ynoxy]benzamide Chemical compound N[C@@H](C(C1)(CC2)CCN2C(N=C2)=C(CO)N=C2C#CCOC(C=C2)=CC=C2C(N)=O)C2=C1SC=N2 FHZKUIOWBKXELG-JOCHJYFZSA-N 0.000 claims description 3
- ZFIZUSNDQVDQRW-RUZDIDTESA-N 5-[3-[5-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-(hydroxymethyl)pyrazin-2-yl]prop-2-ynoxy]-1-methylpyridin-2-one Chemical compound CN(C=C(C=C1)OCC#CC2=NC(CO)=C(N(CC3)CCC3(CC3=CC=CC=C33)[C@@H]3N)N=C2)C1=O ZFIZUSNDQVDQRW-RUZDIDTESA-N 0.000 claims description 3
- BKHXONIZKKCURT-AREMUKBSSA-N 5-[3-[5-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-(hydroxymethyl)pyrazin-2-yl]prop-2-ynoxy]-2,3-dihydroisoindol-1-one Chemical compound N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCOC(C=C1CN2)=CC=C1C2=O BKHXONIZKKCURT-AREMUKBSSA-N 0.000 claims description 3
- KDRPUQDJARCJSA-XMMPIXPASA-N 5-[3-[5-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-(hydroxymethyl)pyrazin-2-yl]prop-2-ynoxy]pyridine-2-carboxamide Chemical compound N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCOC(C=C1)=CN=C1C(N)=O KDRPUQDJARCJSA-XMMPIXPASA-N 0.000 claims description 3
- LMXWCHSJYNHLAR-HHHXNRCGSA-N 6-[3-[5-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-(hydroxymethyl)pyrazin-2-yl]prop-2-ynoxy]-3,4-dihydro-2H-isoquinolin-1-one Chemical compound N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCOC(C=C1CCN2)=CC=C1C2=O LMXWCHSJYNHLAR-HHHXNRCGSA-N 0.000 claims description 3
- IEJLWEWHZVCKCE-AREMUKBSSA-N 6-[3-[5-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-(hydroxymethyl)pyrazin-2-yl]prop-2-ynoxy]isoindol-1-one Chemical compound N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCOC1=CC=C(C=NC2=O)C2=C1 IEJLWEWHZVCKCE-AREMUKBSSA-N 0.000 claims description 3
- WYXXMFZJXFNYND-XMMPIXPASA-N 6-[3-[5-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-(hydroxymethyl)pyrazin-2-yl]prop-2-ynoxy]pyridin-3-ol Chemical compound N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCOC(N=C1)=CC=C1O WYXXMFZJXFNYND-XMMPIXPASA-N 0.000 claims description 3
- RYTUZUSCWYDYTI-HHHXNRCGSA-N CC(C1=CC(OCC#CC2=NC(CO)=C(N(CC3)CCC3(CC3=CC=CC=C33)[C@@H]3N)N=C2)=CC=C1)=O Chemical compound CC(C1=CC(OCC#CC2=NC(CO)=C(N(CC3)CCC3(CC3=CC=CC=C33)[C@@H]3N)N=C2)=CC=C1)=O RYTUZUSCWYDYTI-HHHXNRCGSA-N 0.000 claims description 3
- LCLHHYJCSUJMKG-HHHXNRCGSA-N CC(NC(C=C1)=CC=C1OCC#CC1=NC(CO)=C(N(CC2)CCC2(CC2=CC=CC=C22)[C@@H]2N)N=C1)=O Chemical compound CC(NC(C=C1)=CC=C1OCC#CC1=NC(CO)=C(N(CC2)CCC2(CC2=CC=CC=C22)[C@@H]2N)N=C1)=O LCLHHYJCSUJMKG-HHHXNRCGSA-N 0.000 claims description 3
- SLNQUNDMPAYPJL-HHHXNRCGSA-N CC(NC1=CC(OCC#CC2=NC(CO)=C(N(CC3)CCC3(CC3=CC=CC=C33)[C@@H]3N)N=C2)=CC=C1)=O Chemical compound CC(NC1=CC(OCC#CC2=NC(CO)=C(N(CC3)CCC3(CC3=CC=CC=C33)[C@@H]3N)N=C2)=CC=C1)=O SLNQUNDMPAYPJL-HHHXNRCGSA-N 0.000 claims description 3
- AGWZTTGQTOFRHB-JOCHJYFZSA-N N[C@@H](C(C1)(CC2)CCN2C(N=C2)=C(CO)N=C2C#CCOC(C=C2)=CC=C2C(N)=O)C2=C1NC=N2 Chemical compound N[C@@H](C(C1)(CC2)CCN2C(N=C2)=C(CO)N=C2C#CCOC(C=C2)=CC=C2C(N)=O)C2=C1NC=N2 AGWZTTGQTOFRHB-JOCHJYFZSA-N 0.000 claims description 3
- SGXDNOZGZYAMOC-RUZDIDTESA-N N[C@@H](C(C1)(CC2)CCN2C(N=C2)=C(CO)N=C2C#CCOC2=CC=C(C(F)(F)F)C=C2)C2=C1C=CC=C2 Chemical compound N[C@@H](C(C1)(CC2)CCN2C(N=C2)=C(CO)N=C2C#CCOC2=CC=C(C(F)(F)F)C=C2)C2=C1C=CC=C2 SGXDNOZGZYAMOC-RUZDIDTESA-N 0.000 claims description 3
- RWDXHUSBSGQFIE-HHHXNRCGSA-N N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCCC(C1=CC=CC=C1)=O Chemical compound N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCCC(C1=CC=CC=C1)=O RWDXHUSBSGQFIE-HHHXNRCGSA-N 0.000 claims description 3
- USLAGEKARJZYHT-AREMUKBSSA-N N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCOC(C=C1)=CC=C1C#N Chemical compound N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCOC(C=C1)=CC=C1C#N USLAGEKARJZYHT-AREMUKBSSA-N 0.000 claims description 3
- XYNNWLHXPQCZBT-RUZDIDTESA-N N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCOC1=CC(C(F)(F)F)=CC=C1 Chemical compound N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCOC1=CC(C(F)(F)F)=CC=C1 XYNNWLHXPQCZBT-RUZDIDTESA-N 0.000 claims description 3
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 3
- XYJFMDNSSNYYKI-AREMUKBSSA-N [3-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-[3-(1H-indazol-5-yloxy)prop-1-ynyl]pyrazin-2-yl]methanol Chemical compound N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C1=NC=C(C#CCOC2=CC=C3NN=CC3=C2)N=C1CO XYJFMDNSSNYYKI-AREMUKBSSA-N 0.000 claims description 3
- NBCSYXKKXBSODM-RUZDIDTESA-N [3-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-[3-(2-methoxypyridin-4-yl)oxyprop-1-ynyl]pyrazin-2-yl]methanol Chemical compound COC1=NC=CC(OCC#CC(N=C2CO)=CN=C2N(CC2)CCC2(CC2=CC=CC=C22)[C@@H]2N)=C1 NBCSYXKKXBSODM-RUZDIDTESA-N 0.000 claims description 3
- QOYMTEPTQAONER-AREMUKBSSA-N [3-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-[3-(3-methoxyphenyl)sulfanylprop-1-ynyl]pyrazin-2-yl]methanol Chemical compound COC1=CC=CC(SCC#CC(N=C2CO)=CN=C2N(CC2)CCC2(CC2=CC=CC=C22)[C@@H]2N)=C1 QOYMTEPTQAONER-AREMUKBSSA-N 0.000 claims description 3
- SRKUFDFDOXKSLU-HHHXNRCGSA-N [3-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-[3-[(2-methyl-3H-benzimidazol-5-yl)oxy]prop-1-ynyl]pyrazin-2-yl]methanol Chemical compound CC1=NC(C=C(C=C2)OCC#CC(N=C3CO)=CN=C3N(CC3)CCC3(CC3=CC=CC=C33)[C@@H]3N)=C2N1 SRKUFDFDOXKSLU-HHHXNRCGSA-N 0.000 claims description 3
- KHSGGTCVBQMGQF-HSZRJFAPSA-N [3-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-[3-[2-(methylamino)pyrimidin-5-yl]oxyprop-1-ynyl]pyrazin-2-yl]methanol Chemical compound CNC(N=C1)=NC=C1OCC#CC(N=C1CO)=CN=C1N(CC1)CCC1(CC1=CC=CC=C11)[C@@H]1N KHSGGTCVBQMGQF-HSZRJFAPSA-N 0.000 claims description 3
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims description 3
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 3
- WQAWEUZTDVWTDB-UHFFFAOYSA-N dimethyl(oxo)phosphanium Chemical compound C[P+](C)=O WQAWEUZTDVWTDB-UHFFFAOYSA-N 0.000 claims description 3
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 3
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 3
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 claims description 3
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical compound C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 claims description 3
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims description 3
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 claims description 3
- WGLUNLJVYNJMBU-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-n-[(3-methyl-1-oxo-2,4-dihydroisoquinolin-3-yl)methyl]decanamide Chemical compound C1=CC=C2C(=O)NC(CN(CCN(C)C)C(=O)CCCCCCCCC)(C)CC2=C1 WGLUNLJVYNJMBU-UHFFFAOYSA-N 0.000 claims description 3
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims description 3
- 125000006085 pyrrolopyridyl group Chemical group 0.000 claims description 3
- 229930185107 quinolinone Natural products 0.000 claims description 3
- 125000005493 quinolyl group Chemical group 0.000 claims description 3
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 3
- NFECNFKKESNKDJ-HHHXNRCGSA-N 2-[4-[3-[5-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-(hydroxymethyl)pyrazin-2-yl]prop-2-ynoxy]phenyl]acetamide Chemical compound N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCOC1=CC=C(CC(N)=O)C=C1 NFECNFKKESNKDJ-HHHXNRCGSA-N 0.000 claims description 2
- ZWHOWRNBQKTXQX-AREMUKBSSA-N 4-[3-[5-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-(hydroxymethyl)pyrazin-2-yl]prop-2-ynoxy]-2-methylbenzamide Chemical compound CC(C=C(C=C1)OCC#CC2=NC(CO)=C(N(CC3)CCC3(CC3=CC=CC=C33)[C@@H]3N)N=C2)=C1C(N)=O ZWHOWRNBQKTXQX-AREMUKBSSA-N 0.000 claims description 2
- DDIQUCVDZOUFEE-MUUNZHRXSA-N 4-[3-[5-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-(hydroxymethyl)pyrazin-2-yl]prop-2-ynoxy]-N-cyclopropylbenzamide Chemical compound N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCOC(C=C1)=CC=C1C(NC1CC1)=O DDIQUCVDZOUFEE-MUUNZHRXSA-N 0.000 claims description 2
- WZHZWLHANHEUDO-AREMUKBSSA-N 4-[3-[5-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-(hydroxymethyl)pyrazin-2-yl]prop-2-ynoxy]-N-methylbenzamide Chemical compound CNC(C(C=C1)=CC=C1OCC#CC1=NC(CO)=C(N(CC2)CCC2(CC2=CC=CC=C22)[C@@H]2N)N=C1)=O WZHZWLHANHEUDO-AREMUKBSSA-N 0.000 claims description 2
- QRLUGPNWKOPBGT-XMMPIXPASA-N 4-[3-[5-[(3R)-3-aminospiro[3H-1-benzofuran-2,4'-piperidine]-1'-yl]-6-(hydroxymethyl)pyrazin-2-yl]prop-2-ynoxy]benzamide Chemical compound N[C@@H]1C(C=CC=C2)=C2OC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCOC(C=C1)=CC=C1C(N)=O QRLUGPNWKOPBGT-XMMPIXPASA-N 0.000 claims description 2
- UDOIINHTMNFOCQ-MUUNZHRXSA-N 7-[3-[5-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-(hydroxymethyl)pyrazin-2-yl]prop-2-ynylamino]-3,4-dihydro-1H-quinolin-2-one Chemical compound N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCNC1=CC=C(CCC(N2)=O)C2=C1 UDOIINHTMNFOCQ-MUUNZHRXSA-N 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- HBEKLEICGJLMSR-HHHXNRCGSA-N N-[3-[3-[5-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-(hydroxymethyl)pyrazin-2-yl]prop-2-ynylamino]phenyl]acetamide Chemical compound CC(NC1=CC(NCC#CC2=NC(CO)=C(N(CC3)CCC3(CC3=CC=CC=C33)[C@@H]3N)N=C2)=CC=C1)=O HBEKLEICGJLMSR-HHHXNRCGSA-N 0.000 claims description 2
- JNONESGULJSSLY-JOCHJYFZSA-N N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C1=NC=C(C#CCOC2=CN=C(N)N=C2)N=C1CO Chemical compound N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C1=NC=C(C#CCOC2=CN=C(N)N=C2)N=C1CO JNONESGULJSSLY-JOCHJYFZSA-N 0.000 claims description 2
- TYYDHUQCMVLPFT-HHHXNRCGSA-N [3-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-[3-(3,4-dimethoxyanilino)prop-1-ynyl]pyrazin-2-yl]methanol Chemical compound COC(C=CC(NCC#CC(N=C1CO)=CN=C1N(CC1)CCC1(CC1=CC=CC=C11)[C@@H]1N)=C1)=C1OC TYYDHUQCMVLPFT-HHHXNRCGSA-N 0.000 claims description 2
- SQMXNNHLWWPPRL-HHHXNRCGSA-N [3-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-[3-(4-dimethylphosphorylphenoxy)prop-1-ynyl]pyrazin-2-yl]methanol Chemical compound CP(C)(C(C=C1)=CC=C1OCC#CC1=NC(CO)=C(N(CC2)CCC2(CC2=CC=CC=C22)[C@@H]2N)N=C1)=O SQMXNNHLWWPPRL-HHHXNRCGSA-N 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 208000030533 eye disease Diseases 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 34
- FBXGQDUVJBKEAJ-UHFFFAOYSA-N 4h-oxazin-3-one Chemical compound O=C1CC=CON1 FBXGQDUVJBKEAJ-UHFFFAOYSA-N 0.000 claims 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 1
- CUCYNLKMEQNDTJ-UHFFFAOYSA-N C1=CC=CC=C1.O1NC(CC=C1)=O Chemical compound C1=CC=CC=C1.O1NC(CC=C1)=O CUCYNLKMEQNDTJ-UHFFFAOYSA-N 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- QNLOWBMKUIXCOW-UHFFFAOYSA-N indol-2-one Chemical compound C1=CC=CC2=NC(=O)C=C21 QNLOWBMKUIXCOW-UHFFFAOYSA-N 0.000 claims 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 5
- 101710204864 Tyrosine-protein phosphatase 2 Proteins 0.000 abstract description 4
- 230000004663 cell proliferation Effects 0.000 abstract description 3
- 230000006907 apoptotic process Effects 0.000 abstract description 2
- 230000012292 cell migration Effects 0.000 abstract description 2
- 238000013508 migration Methods 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 315
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 280
- 239000000243 solution Substances 0.000 description 151
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 145
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 145
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 137
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 134
- 229910001868 water Inorganic materials 0.000 description 132
- 239000007787 solid Substances 0.000 description 129
- 238000004809 thin layer chromatography Methods 0.000 description 128
- 235000019439 ethyl acetate Nutrition 0.000 description 99
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 97
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 92
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 88
- 239000012074 organic phase Substances 0.000 description 88
- 239000012043 crude product Substances 0.000 description 77
- 238000004440 column chromatography Methods 0.000 description 74
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 70
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 68
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 50
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 48
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 48
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 46
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 41
- 239000000706 filtrate Substances 0.000 description 41
- 210000004027 cell Anatomy 0.000 description 40
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 37
- 238000005160 1H NMR spectroscopy Methods 0.000 description 37
- YNHIGQDRGKUECZ-UHFFFAOYSA-L PdCl2(PPh3)2 Substances [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 36
- 229910000027 potassium carbonate Inorganic materials 0.000 description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- XXFUZSHTIOFGNV-UHFFFAOYSA-N 1-bromoprop-1-yne Chemical compound CC#CBr XXFUZSHTIOFGNV-UHFFFAOYSA-N 0.000 description 26
- 238000003756 stirring Methods 0.000 description 26
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 18
- 239000007788 liquid Substances 0.000 description 17
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- 239000000843 powder Substances 0.000 description 13
- 239000002994 raw material Substances 0.000 description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 11
- 239000000543 intermediate Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- 238000000605 extraction Methods 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 9
- 239000012065 filter cake Substances 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- 235000011152 sodium sulphate Nutrition 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 101001087416 Homo sapiens Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 239000012224 working solution Substances 0.000 description 5
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000012054 celltiter-glo Methods 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
- 238000007405 data analysis Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 210000003722 extracellular fluid Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 4
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 102000016914 ras Proteins Human genes 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000007805 chemical reaction reactant Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000001853 liver microsome Anatomy 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000001630 malic acid Substances 0.000 description 3
- 235000011090 malic acid Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940098779 methanesulfonic acid Drugs 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 3
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 3
- 125000002098 pyridazinyl group Chemical group 0.000 description 3
- 108010014186 ras Proteins Proteins 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
- JNUZADQZHYFJGW-JOCHJYFZSA-N (2R)-N-[3-[5-fluoro-2-(2-fluoro-3-methylsulfonylanilino)pyrimidin-4-yl]-1H-indol-7-yl]-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide Chemical compound FC=1C(=NC(=NC=1)NC1=C(C(=CC=C1)S(=O)(=O)C)F)C1=CNC2=C(C=CC=C12)NC([C@@H](COC)N1CCN(CC1)C)=O JNUZADQZHYFJGW-JOCHJYFZSA-N 0.000 description 2
- OEGPRYNGFWGMMV-UHFFFAOYSA-N (3,4-dimethoxyphenyl)methanol Chemical compound COC1=CC=C(CO)C=C1OC OEGPRYNGFWGMMV-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- LCFFREMLXLZNHE-GBOLQPHISA-N (e)-2-[(3r)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile Chemical compound C12=C(N)N=CN=C2N([C@@H]2CCCN(C2)C(=O)C(/C#N)=C/C(C)(C)N2CCN(CC2)C2COC2)N=C1C(C(=C1)F)=CC=C1OC1=CC=CC=C1 LCFFREMLXLZNHE-GBOLQPHISA-N 0.000 description 2
- MXHZAYVEIKSPIA-ZHACJKMWSA-N 1-[(E)-4-[5-carbamoyl-7-[3-(dimethylamino)propoxy]-2-[(2-ethyl-5-methylpyrazole-3-carbonyl)amino]benzimidazol-1-yl]but-2-enyl]-2-[(2-ethyl-5-methylpyrazole-3-carbonyl)amino]-7-methoxybenzimidazole-5-carboxamide Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN(C)C)=C12)C(N)=O)C(N)=O MXHZAYVEIKSPIA-ZHACJKMWSA-N 0.000 description 2
- KJUCPVIVNLPLEE-UHFFFAOYSA-N 2,6-difluoro-n-[2-fluoro-5-[5-[2-[(6-morpholin-4-ylpyridin-3-yl)amino]pyrimidin-4-yl]-2-propan-2-yl-1,3-thiazol-4-yl]phenyl]benzenesulfonamide Chemical compound S1C(C(C)C)=NC(C=2C=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C(F)=CC=2)=C1C(N=1)=CC=NC=1NC(C=N1)=CC=C1N1CCOCC1 KJUCPVIVNLPLEE-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- AKSVALRPYDVQBS-CABCVRRESA-N 2-[(3R)-3-[1-[1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-3-(trifluoromethyl)pyrazolo[3,4-b]pyrazin-6-yl]azetidin-3-yl]piperidin-1-yl]ethanol Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)N1CC(C1)[C@@H]1CN(CCC1)CCO)C(F)(F)F AKSVALRPYDVQBS-CABCVRRESA-N 0.000 description 2
- KDDPNNXAZURUGP-UHFFFAOYSA-N 2-[2-(3,4-dichlorophenyl)-3-[2-(piperidin-3-ylamino)pyrimidin-4-yl]imidazol-4-yl]acetonitrile Chemical compound ClC=1C=C(C=CC=1Cl)C=1N(C(=CN=1)CC#N)C1=NC(=NC=C1)NC1CNCCC1 KDDPNNXAZURUGP-UHFFFAOYSA-N 0.000 description 2
- BWSQKOKULIALEW-UHFFFAOYSA-N 2-[2-[4-fluoro-3-(trifluoromethyl)phenyl]-3-[2-(piperidin-3-ylamino)pyrimidin-4-yl]imidazol-4-yl]acetonitrile Chemical compound FC1=C(C=C(C=C1)C=1N(C(=CN=1)CC#N)C1=NC(=NC=C1)NC1CNCCC1)C(F)(F)F BWSQKOKULIALEW-UHFFFAOYSA-N 0.000 description 2
- FQHWQFIPEVBFKT-UHFFFAOYSA-N 2-[5-[cyclopropylmethyl(1,2-dihydroacenaphthylen-5-yl)amino]-3-methoxypyridine-2-carbonyl]cyclopropane-1-carboxylic acid Chemical compound C1(CC1)CN(C=1C=C(C(=NC=1)C(=O)C1C(C1)C(=O)O)OC)C1=CC=C2CCC=3C=CC=C1C=32 FQHWQFIPEVBFKT-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- KPRPFTOLWQQUAV-OCVAFRRMSA-N 2-amino-N-(4-hydroxy-1-bicyclo[2.2.2]octanyl)-5-[4-[(1R,5S)-3-(oxan-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl]phenyl]pyridine-3-carboxamide Chemical compound NC1=C(C(=O)NC23CCC(CC2)(CC3)O)C=C(C=N1)C1=CC=C(C=C1)[C@@]12CN(C[C@H]2C1)C1CCOCC1 KPRPFTOLWQQUAV-OCVAFRRMSA-N 0.000 description 2
- WEHOIIGXTMKVRG-UHFFFAOYSA-N 3-(2,4-dimethoxyphenyl)-4-thiophen-3-yl-1h-pyrrolo[2,3-b]pyridine Chemical compound COC1=CC(OC)=CC=C1C1=CNC2=NC=CC(C3=CSC=C3)=C12 WEHOIIGXTMKVRG-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- ASHGTJPOSUFTGB-UHFFFAOYSA-N 3-methoxyphenol Chemical compound COC1=CC=CC(O)=C1 ASHGTJPOSUFTGB-UHFFFAOYSA-N 0.000 description 2
- SFXVRNLGOSAWIV-UHFFFAOYSA-N 4-amino-N-[4-(methoxymethyl)phenyl]-7-(1-methylcyclopropyl)-6-(3-morpholin-4-ylprop-1-ynyl)pyrrolo[2,3-d]pyrimidine-5-carboxamide Chemical compound NC=1C2=C(N=CN=1)N(C(=C2C(=O)NC1=CC=C(C=C1)COC)C#CCN1CCOCC1)C1(CC1)C SFXVRNLGOSAWIV-UHFFFAOYSA-N 0.000 description 2
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 2
- QXSAKPUBHTZHKW-UHFFFAOYSA-N 4-hydroxybenzamide Chemical compound NC(=O)C1=CC=C(O)C=C1 QXSAKPUBHTZHKW-UHFFFAOYSA-N 0.000 description 2
- HQQTZCPKNZVLFF-UHFFFAOYSA-N 4h-1,2-benzoxazin-3-one Chemical compound C1=CC=C2ONC(=O)CC2=C1 HQQTZCPKNZVLFF-UHFFFAOYSA-N 0.000 description 2
- DZANYXOTJVLAEE-UHFFFAOYSA-N 6,8-difluoro-4-methylumbelliferyl phosphate Chemical compound FC1=C(OP(O)(O)=O)C(F)=CC2=C1OC(=O)C=C2C DZANYXOTJVLAEE-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- BWJHJLINOYAPEG-HOTGVXAUSA-N 8-chloro-6-[(6-chloropyridin-3-yl)methyl]-3-[(1S,2S)-2-hydroxycyclopentyl]-7-methyl-2H-1,3-benzoxazin-4-one Chemical compound ClC1=C(C(=CC=2C(N(COC=21)[C@@H]1[C@H](CCC1)O)=O)CC=1C=NC(=CC=1)Cl)C BWJHJLINOYAPEG-HOTGVXAUSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- XMDCQODNJVFFNR-HHHXNRCGSA-N COC(C=CC(OCC#CC(N=C1CO)=CN=C1N(CC1)CCC1(CC1=CC=CC=C11)[C@@H]1N)=C1)=C1OC Chemical compound COC(C=CC(OCC#CC(N=C1CO)=CN=C1N(CC1)CCC1(CC1=CC=CC=C11)[C@@H]1N)=C1)=C1OC XMDCQODNJVFFNR-HHHXNRCGSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 108010067218 Guanine Nucleotide Exchange Factors Proteins 0.000 description 2
- 102000016285 Guanine Nucleotide Exchange Factors Human genes 0.000 description 2
- 239000007836 KH2PO4 Substances 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- MKCAULWLJOQLKU-RUZDIDTESA-N N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCOC(C=C1)=CC=C1S(N)(=O)=O Chemical compound N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCOC(C=C1)=CC=C1S(N)(=O)=O MKCAULWLJOQLKU-RUZDIDTESA-N 0.000 description 2
- KAROSQNINWCZQO-HHHXNRCGSA-N N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCOC(C=CC1=C2)=CC1=NC2=O Chemical compound N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCOC(C=CC1=C2)=CC1=NC2=O KAROSQNINWCZQO-HHHXNRCGSA-N 0.000 description 2
- AUQYBSYQDXIBMH-MUUNZHRXSA-N N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCOC1=CC=C(C=CC(N2)=O)C2=C1 Chemical compound N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCOC1=CC=C(C=CC(N2)=O)C2=C1 AUQYBSYQDXIBMH-MUUNZHRXSA-N 0.000 description 2
- YECWZBZHFZRFJI-RUZDIDTESA-N N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCOC1=CC=CC(C(N)=O)=C1 Chemical compound N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCOC1=CC=CC(C(N)=O)=C1 YECWZBZHFZRFJI-RUZDIDTESA-N 0.000 description 2
- ZBEPMOZEXLGCTF-UHFFFAOYSA-N O=C(C1CC1)N1CCCC(C1)NC1=NC(=CC=N1)N1C(CC#N)=CN=C1C1=CC2=C(OC=C2)C=C1 Chemical compound O=C(C1CC1)N1CCCC(C1)NC1=NC(=CC=N1)N1C(CC#N)=CN=C1C1=CC2=C(OC=C2)C=C1 ZBEPMOZEXLGCTF-UHFFFAOYSA-N 0.000 description 2
- UQONAEXHTGDOIH-AWEZNQCLSA-N O=C(N1CC[C@@H](C1)N1CCCC1=O)C1=CC2=C(NC3(CC3)CCO2)N=C1 Chemical compound O=C(N1CC[C@@H](C1)N1CCCC1=O)C1=CC2=C(NC3(CC3)CCO2)N=C1 UQONAEXHTGDOIH-AWEZNQCLSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 102000052575 Proto-Oncogene Human genes 0.000 description 2
- 108700020978 Proto-Oncogene Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- 102000003901 Ras GTPase-activating proteins Human genes 0.000 description 2
- 108090000231 Ras GTPase-activating proteins Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 description 2
- 101710183617 Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 description 2
- RBTRTWSVHNGFEW-RUZDIDTESA-N [3-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-[3-(3-chloro-2-fluorophenoxy)prop-1-ynyl]pyrazin-2-yl]methanol Chemical compound N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C1=NC=C(C#CCOC(C=CC=C2Cl)=C2F)N=C1CO RBTRTWSVHNGFEW-RUZDIDTESA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 230000003281 allosteric effect Effects 0.000 description 2
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 2
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- XUZICJHIIJCKQQ-ZDUSSCGKSA-N eclitasertib Chemical compound C(C1=CC=CC=C1)C=1NC(=NN=1)C(=O)N[C@@H]1C(N(C2=C(OC1)C=CC=N2)C)=O XUZICJHIIJCKQQ-ZDUSSCGKSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- XGZNHFPFJRZBBT-UHFFFAOYSA-N ethanol;titanium Chemical compound [Ti].CCO.CCO.CCO.CCO XGZNHFPFJRZBBT-UHFFFAOYSA-N 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 101150098203 grb2 gene Proteins 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 229940045996 isethionic acid Drugs 0.000 description 2
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229940057952 methanol Drugs 0.000 description 2
- OHKYQPNNVGHVOT-UHFFFAOYSA-N methyl 3,6-dibromopyrazine-2-carboxylate Chemical compound COC(=O)C1=NC(Br)=CN=C1Br OHKYQPNNVGHVOT-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- VZUGBLTVBZJZOE-KRWDZBQOSA-N n-[3-[(4s)-2-amino-1,4-dimethyl-6-oxo-5h-pyrimidin-4-yl]phenyl]-5-chloropyrimidine-2-carboxamide Chemical compound N1=C(N)N(C)C(=O)C[C@@]1(C)C1=CC=CC(NC(=O)C=2N=CC(Cl)=CN=2)=C1 VZUGBLTVBZJZOE-KRWDZBQOSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- XULSCZPZVQIMFM-IPZQJPLYSA-N odevixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C=3C=CC(O)=CC=3)C=C2S(=O)(=O)NC(CCCC)(CCCC)CN1C1=CC=CC=C1 XULSCZPZVQIMFM-IPZQJPLYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002336 repolarization Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- OEBIHOVSAMBXIB-SJKOYZFVSA-N selitrectinib Chemical compound C[C@@H]1CCC2=NC=C(F)C=C2[C@H]2CCCN2C2=NC3=C(C=NN3C=C2)C(=O)N1 OEBIHOVSAMBXIB-SJKOYZFVSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- JMXKSZRRTHPKDL-UHFFFAOYSA-N titanium(IV) ethoxide Substances [Ti+4].CC[O-].CC[O-].CC[O-].CC[O-] JMXKSZRRTHPKDL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- VQAASJGFZOYIGR-UHFFFAOYSA-N 1,3-dibromo-2H-pyrazine Chemical compound C1C(=NC=CN1Br)Br VQAASJGFZOYIGR-UHFFFAOYSA-N 0.000 description 1
- ACTKAGSPIFDCMF-UHFFFAOYSA-N 1,3-oxazol-2-amine Chemical compound NC1=NC=CO1 ACTKAGSPIFDCMF-UHFFFAOYSA-N 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- MWKYMZXCGYXLPL-ZDUSSCGKSA-N 1-[(3s)-3-[[6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-7,8-dihydro-5h-pyrido[4,3-d]pyrimidin-4-yl]amino]pyrrolidin-1-yl]propan-1-one Chemical compound C1N(C(=O)CC)CC[C@@H]1NC1=NC=NC2=C1CN(C=1C=C(C(OC)=NC=1)C(F)(F)F)CC2 MWKYMZXCGYXLPL-ZDUSSCGKSA-N 0.000 description 1
- AGVNLFCRZULMKK-UHFFFAOYSA-N 1-[4-(4-hydroxyphenyl)piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C1=CC=C(O)C=C1 AGVNLFCRZULMKK-UHFFFAOYSA-N 0.000 description 1
- NLSHADGRAUSZNZ-DCWQJPKNSA-N 1-[4-[3-[5-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-(hydroxymethyl)pyrazin-2-yl]prop-2-ynoxy]phenyl]-2,2,2-trifluoroethanol Chemical compound N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCOC1=CC=C(C(C(F)(F)F)O)C=C1 NLSHADGRAUSZNZ-DCWQJPKNSA-N 0.000 description 1
- KAUABWYBFARJAF-UHFFFAOYSA-N 1h-pyrazol-4-ol Chemical compound OC=1C=NNC=1 KAUABWYBFARJAF-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- HQNIMNQVKVPZES-UHFFFAOYSA-N 2-amino-1h-pyridin-4-one Chemical compound NC1=CC(O)=CC=N1 HQNIMNQVKVPZES-UHFFFAOYSA-N 0.000 description 1
- IXGDWINMKUVPCT-UHFFFAOYSA-N 2-aminophenol;benzenesulfonamide Chemical compound NC1=CC=CC=C1O.NS(=O)(=O)C1=CC=CC=C1 IXGDWINMKUVPCT-UHFFFAOYSA-N 0.000 description 1
- YXGBFUHYIISYSS-UHFFFAOYSA-N 2-chloro-4-hydroxybenzamide Chemical compound NC(=O)C1=CC=C(O)C=C1Cl YXGBFUHYIISYSS-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- REIVHYDACHXPNH-UHFFFAOYSA-N 2-fluoro-4-hydroxybenzonitrile Chemical compound OC1=CC=C(C#N)C(F)=C1 REIVHYDACHXPNH-UHFFFAOYSA-N 0.000 description 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
- LRNDOTVCAIEGPH-UHFFFAOYSA-N 2-methoxy-1h-pyridin-4-one Chemical compound COC1=CC(O)=CC=N1 LRNDOTVCAIEGPH-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- CESUXLKAADQNTB-SSDOTTSWSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@](N)=O CESUXLKAADQNTB-SSDOTTSWSA-N 0.000 description 1
- JESRNIJXVIFVOV-UHFFFAOYSA-N 2-methylpyrazol-3-amine Chemical compound CN1N=CC=C1N JESRNIJXVIFVOV-UHFFFAOYSA-N 0.000 description 1
- LGDHZCLREKIGKJ-UHFFFAOYSA-N 3,4-dimethoxyaniline Chemical compound COC1=CC=C(N)C=C1OC LGDHZCLREKIGKJ-UHFFFAOYSA-N 0.000 description 1
- TWCACYWIPUIXAR-UHFFFAOYSA-N 3,6-dibromopyrazine-2-carboxamide Chemical compound NC(=O)C1=NC(Br)=CN=C1Br TWCACYWIPUIXAR-UHFFFAOYSA-N 0.000 description 1
- UGEJOEBBMPOJMT-UHFFFAOYSA-N 3-(trifluoromethyl)phenol Chemical compound OC1=CC=CC(C(F)(F)F)=C1 UGEJOEBBMPOJMT-UHFFFAOYSA-N 0.000 description 1
- GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 description 1
- SGHBRHKBCLLVCI-UHFFFAOYSA-N 3-hydroxybenzonitrile Chemical compound OC1=CC=CC(C#N)=C1 SGHBRHKBCLLVCI-UHFFFAOYSA-N 0.000 description 1
- FVMDYYGIDFPZAX-UHFFFAOYSA-N 3-hydroxyphenylacetic acid Chemical compound OC(=O)CC1=CC=CC(O)=C1 FVMDYYGIDFPZAX-UHFFFAOYSA-N 0.000 description 1
- QMVAZEHZOPDGHA-UHFFFAOYSA-N 3-methoxybenzenethiol Chemical compound COC1=CC=CC(S)=C1 QMVAZEHZOPDGHA-UHFFFAOYSA-N 0.000 description 1
- RTZZCYNQPHTPPL-UHFFFAOYSA-N 3-nitrophenol Chemical compound OC1=CC=CC([N+]([O-])=O)=C1 RTZZCYNQPHTPPL-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QIKYZXDTTPVVAC-UHFFFAOYSA-N 4-Aminobenzamide Chemical compound NC(=O)C1=CC=C(N)C=C1 QIKYZXDTTPVVAC-UHFFFAOYSA-N 0.000 description 1
- VNTCGXMLDSKOKN-OAHLLOKOSA-N 4-[4-[[(3r)-3-methyl-4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]methyl]-1h-pyrazol-5-yl]benzonitrile Chemical compound C([C@H](N(CC1)C=2N=CC(=CC=2)C(F)(F)F)C)N1CC=1C=NNC=1C1=CC=C(C#N)C=C1 VNTCGXMLDSKOKN-OAHLLOKOSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 1
- VSMDINRNYYEDRN-UHFFFAOYSA-N 4-iodophenol Chemical compound OC1=CC=C(I)C=C1 VSMDINRNYYEDRN-UHFFFAOYSA-N 0.000 description 1
- NLNNRNIJRFYGFB-UHFFFAOYSA-N 5-hydroxy-2,3-dihydroisoindol-1-one Chemical compound OC1=CC=C2C(=O)NCC2=C1 NLNNRNIJRFYGFB-UHFFFAOYSA-N 0.000 description 1
- BWIOURVJVDKDOC-UHFFFAOYSA-N 6-bromo-1-(chloromethyl)-2-methoxynaphthalene Chemical compound C1=C(Br)C=CC2=C(CCl)C(OC)=CC=C21 BWIOURVJVDKDOC-UHFFFAOYSA-N 0.000 description 1
- TYNQFYSVGOMKOS-UHFFFAOYSA-N 6-hydroxy-3,4-dihydro-2h-isoquinolin-1-one Chemical compound O=C1NCCC2=CC(O)=CC=C21 TYNQFYSVGOMKOS-UHFFFAOYSA-N 0.000 description 1
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 description 1
- LKLSFDWYIBUGNT-UHFFFAOYSA-N 7-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical compound C1CC(=O)NC2=CC(O)=CC=C21 LKLSFDWYIBUGNT-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- XTJZKALDRPVFSN-HNNXBMFYSA-N 8-n-[(2s)-3,3-dimethylbutan-2-yl]-2-n-[2-methoxy-4-(1-methylpyrazol-4-yl)phenyl]pyrido[3,4-d]pyrimidine-2,8-diamine Chemical compound C=1C=C(NC=2N=C3C(N[C@@H](C)C(C)(C)C)=NC=CC3=CN=2)C(OC)=CC=1C=1C=NN(C)C=1 XTJZKALDRPVFSN-HNNXBMFYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- YCIPQJTZJGUXND-UHFFFAOYSA-N Aglaia odorata Alkaloid Natural products C1=CC(OC)=CC=C1C1(C(C=2C(=O)N3CCCC3=NC=22)C=3C=CC=CC=3)C2(O)C2=C(OC)C=C(OC)C=C2O1 YCIPQJTZJGUXND-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101710117545 C protein Proteins 0.000 description 1
- XPEXOILDOSJEHT-HHHXNRCGSA-N CN(C)C(C1=CC(OCC#CC2=NC(CO)=C(N(CC3)CCC3(CC3=CC=CC=C33)[C@@H]3N)N=C2)=CC=C1)=O Chemical compound CN(C)C(C1=CC(OCC#CC2=NC(CO)=C(N(CC3)CCC3(CC3=CC=CC=C33)[C@@H]3N)N=C2)=CC=C1)=O XPEXOILDOSJEHT-HHHXNRCGSA-N 0.000 description 1
- IRPIISMQTCPDDC-AREMUKBSSA-N CNC(C1=CC(OCC#CC2=NC(CO)=C(N(CC3)CCC3(CC3=CC=CC=C33)[C@@H]3N)N=C2)=CC=C1)=O Chemical compound CNC(C1=CC(OCC#CC2=NC(CO)=C(N(CC3)CCC3(CC3=CC=CC=C33)[C@@H]3N)N=C2)=CC=C1)=O IRPIISMQTCPDDC-AREMUKBSSA-N 0.000 description 1
- RTOHBDDCKRPTCQ-HHHXNRCGSA-N CP(C)(C1=CC(OCC#CC2=NC(CO)=C(N(CC3)CCC3(CC3=CC=CC=C33)[C@@H]3N)N=C2)=CC=C1)=O Chemical compound CP(C)(C1=CC(OCC#CC2=NC(CO)=C(N(CC3)CCC3(CC3=CC=CC=C33)[C@@H]3N)N=C2)=CC=C1)=O RTOHBDDCKRPTCQ-HHHXNRCGSA-N 0.000 description 1
- MSACNODAXJVUDF-UHFFFAOYSA-N CP(C)[O] Chemical compound CP(C)[O] MSACNODAXJVUDF-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- ZKXDGKXYMTYWTB-UHFFFAOYSA-N N-nitrosomorpholine Chemical compound O=NN1CCOCC1 ZKXDGKXYMTYWTB-UHFFFAOYSA-N 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- RXTHVPKDMKHNNI-RUZDIDTESA-N N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCNC(C1=CC=CC=C1)=O Chemical compound N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCNC(C1=CC=CC=C1)=O RXTHVPKDMKHNNI-RUZDIDTESA-N 0.000 description 1
- LVCJPDXEKHHSPA-RUZDIDTESA-N N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCOC(C=C1)=CC=C1C(N)=O Chemical compound N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCOC(C=C1)=CC=C1C(N)=O LVCJPDXEKHHSPA-RUZDIDTESA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108010032107 Non-Receptor Type 11 Protein Tyrosine Phosphatase Proteins 0.000 description 1
- 102000007607 Non-Receptor Type 11 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 101150048674 PTPN11 gene Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000001788 Proto-Oncogene Proteins c-raf Human genes 0.000 description 1
- 108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 108010059447 Son of Sevenless Proteins Proteins 0.000 description 1
- 102000005588 Son of Sevenless Proteins Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ONXFNBOZJKXCNC-ZJSXRUAMSA-N [(3aR,9bR)-9b-(4-fluorophenyl)sulfonyl-7-(1,1,1,2,3,3,3-heptafluoropropan-2-yl)-2,3a,4,5-tetrahydro-1H-benzo[e]indol-3-yl]-(4-hydroxy-1,1-dioxothian-4-yl)methanone Chemical compound OC1(CCS(=O)(=O)CC1)C(=O)N1CC[C@@]2([C@H]1CCc1cc(ccc21)C(F)(C(F)(F)F)C(F)(F)F)S(=O)(=O)c1ccc(F)cc1 ONXFNBOZJKXCNC-ZJSXRUAMSA-N 0.000 description 1
- VYGVBJXOYXIYQC-OAQYLSRUSA-N [3-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-[3-(1,3-oxazol-2-ylamino)prop-1-ynyl]pyrazin-2-yl]methanol Chemical compound N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCNC1=NC=CO1 VYGVBJXOYXIYQC-OAQYLSRUSA-N 0.000 description 1
- OVEWMSWMTDTUTN-XMMPIXPASA-N [3-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-[3-[6-(trifluoromethyl)pyridin-3-yl]oxyprop-1-ynyl]pyrazin-2-yl]methanol Chemical compound N[C@@H]1C2=CC=CC=C2CC1(CC1)CCN1C(N=C1)=C(CO)N=C1C#CCOC1=CC=C(C(F)(F)F)N=C1 OVEWMSWMTDTUTN-XMMPIXPASA-N 0.000 description 1
- FVNNZCOJRSOQAY-XMMPIXPASA-N [3-[(1S)-1-aminospiro[1,3-dihydroindene-2,4'-piperidine]-1'-yl]-6-[3-[[6-(trifluoromethyl)pyridin-3-yl]amino]prop-1-ynyl]pyrazin-2-yl]methanol Chemical compound N[C@@H](C(C1)(CC2)CCN2C(N=C2)=C(CO)N=C2C#CCNC2=CN=C(C(F)(F)F)C=C2)C2=C1C=CC=C2 FVNNZCOJRSOQAY-XMMPIXPASA-N 0.000 description 1
- FDSYOFCVZBGPOV-UHFFFAOYSA-N [4-(cyclopropylamino)piperidin-1-yl]-[6-[[5-fluoro-4-(2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-yl]amino]-2-methylpyridin-3-yl]methanone Chemical compound CC(C)n1c(C)nc2ccc(cc12)-c1nc(Nc2ccc(C(=O)N3CCC(CC3)NC3CC3)c(C)n2)ncc1F FDSYOFCVZBGPOV-UHFFFAOYSA-N 0.000 description 1
- NSGAOVRUPINXOM-UHFFFAOYSA-N [N]=O.N1CCCCC1 Chemical compound [N]=O.N1CCCCC1 NSGAOVRUPINXOM-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 230000008850 allosteric inhibition Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000001908 autoinhibitory effect Effects 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 238000011095 buffer preparation Methods 0.000 description 1
- STOASOOVVADOKH-UHFFFAOYSA-N but-3-ynyl 4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(=O)(=O)OCCC#C)C=C1 STOASOOVVADOKH-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229940047583 cetamide Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229960001632 labetalol Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000002796 luminescence method Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- QLNWXBAGRTUKKI-UHFFFAOYSA-N metacetamol Chemical compound CC(=O)NC1=CC=CC(O)=C1 QLNWXBAGRTUKKI-UHFFFAOYSA-N 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000004879 molecular function Effects 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- VJMRKWPMFQGIPI-UHFFFAOYSA-N n-(2-hydroxyethyl)-5-(hydroxymethyl)-3-methyl-1-[2-[[3-(trifluoromethyl)phenyl]methyl]-1-benzothiophen-7-yl]pyrazole-4-carboxamide Chemical compound OCC1=C(C(=O)NCCO)C(C)=NN1C1=CC=CC2=C1SC(CC=1C=C(C=CC=1)C(F)(F)F)=C2 VJMRKWPMFQGIPI-UHFFFAOYSA-N 0.000 description 1
- BLIJXOOIHRSQRB-PXYINDEMSA-N n-[(2s)-1-[3-(3-chloro-4-cyanophenyl)pyrazol-1-yl]propan-2-yl]-5-(1-hydroxyethyl)-1h-pyrazole-3-carboxamide Chemical compound C([C@H](C)NC(=O)C=1NN=C(C=1)C(C)O)N(N=1)C=CC=1C1=CC=C(C#N)C(Cl)=C1 BLIJXOOIHRSQRB-PXYINDEMSA-N 0.000 description 1
- SKEAGJWUKCNICJ-LSDHHAIUSA-N n-[(4-fluoro-3-methoxyphenyl)methyl]-6-[2-[[(2s,5r)-5-(hydroxymethyl)-1,4-dioxan-2-yl]methyl]tetrazol-5-yl]-2-methylpyrimidine-4-carboxamide Chemical compound C1=C(F)C(OC)=CC(CNC(=O)C=2N=C(C)N=C(C=2)C2=NN(C[C@@H]3OC[C@@H](CO)OC3)N=N2)=C1 SKEAGJWUKCNICJ-LSDHHAIUSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- LIIWIMDSZVNYHY-UHFFFAOYSA-N n-hydroxy-2-[(1-phenylcyclopropyl)amino]pyrimidine-5-carboxamide Chemical compound N1=CC(C(=O)NO)=CN=C1NC1(C=2C=CC=CC=2)CC1 LIIWIMDSZVNYHY-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 102000045222 parkin Human genes 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000017363 positive regulation of growth Effects 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical compound NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- SWGJCIMEBVHMTA-UHFFFAOYSA-K trisodium;6-oxido-4-sulfo-5-[(4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N=NC3=C4C(=CC(=CC4=CC=C3O)S([O-])(=O)=O)S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 SWGJCIMEBVHMTA-UHFFFAOYSA-K 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000001875 tumorinhibitory effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
Definitions
- the present invention relates to series of compounds as inhibitors of Src homologyregion 2-containing protein tyrosine phosphatase 2 (SHP2), methods and pharmaceutical compositions thereof.
- SHP2 Src homologyregion 2-containing protein tyrosine phosphatase 2
- the present invention also relates to the use of the compounds or pharmaceutical compositions thereof for the treatment of SHP2-mediated diseases.
- Src homologyregion 2-containing protein tyrosine phosphatase 2 (SHP2) is a non-receptor protein tyrosine phosphatase encoded by the PTPN11 gene.
- PTPN11 is the first discovered proto-oncogene encoding tyrosine phosphokinase( Chan R J et al.
- PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase.
- N-SHP2 domain N-terminal SHP2 domain
- C-SHP2 domain C-terminal SHP2 domain
- PDP protein phosphatase catalyzed domain
- Y542 and Y580 two C-terminal tyrosine residues
- Pro proline-rich
- SOS can catalyze the conversion of membrane-bound protein Ras from inactive Ras-GDP to active Ras-GTP.
- Ras-GTP further connects with the downstream signaling system, activates the Ser/Thr kinase Raf1, etc., and then activates ERK under the action of the regulatory kinase MEK.
- ERK directly acts on cytoplasmic target molecules or transfers to the nucleus to regulate genes Transcribe to make cells proliferate or differentiate.
- This process may also be influenced by SHP2-binding proteins and substrates (SHP substrate-1, SHPS-1), Ras-GTPase activating protein (Ras-GAP), and other Src members.
- SHP2 protein not only regulates the Ras/ERK signaling pathway, but also regulates multiple signaling pathways such as JAK-STAT3, NF- ⁇ B, PI3K/Akt, RHO and NFAT, thereby regulating cell proliferation, differentiation, migration, apoptosis and other physiology Function.
- SHP2 inhibitors have received more and more attention as a potential therapeutic approach.
- this target has not yet been marketed at home and abroad. Therefore, it is of great research significance to develop small-molecule drugs that can target and inhibit the activity of SHP2 and provide patients with safer and more effective SHP2 inhibitors.
- the structure of compound 243 is disclosed as follows: According to the patent, the IC 50 of compound 243 in the SHP2 allosteric inhibition test is greater than 50nM and less than or equal to 1 ⁇ M, which needs further improvement.
- the present invention relates to a compound as an inhibitor of Src homology region 2 protein tyrosine phosphatase 2 (SHP2), or a pharmaceutically acceptable salt, deuterated product, cis-trans isomer and tautomer thereof, solvate, chelate, non-covalent complex or prodrug, the compound is shown in Formula I: wherein,
- ring C is selected from 3- to 10-membered saturated or partially saturated heterocyclyl, C 6-10 aryl or 5- to 10-membered heteroaryl.
- the ring D is C 6-10 aryl, 5- to 10-membered heteroaryl, C 3-8 carbocyclyl or 3- to 8- membered heterocyclyl; wherein, the C 3-8 carbocyclyl or 3- to 8- membered heterocyclyl optionally contains double bond.
- ring A is selected from 6- to 10-membered heteroaryl or a 6- to 10- membered heterocyclyl; the 6- to 10- membered heterocyclyl contains at least one double bond.
- ring A is selected from a 6- membered heteroaryl or a 6- membered heterocyclyl; the 6- membered heterocyclyl contains at least one double bond.
- ring A is selected from wherein, X 1 , X 2 , X 3 , X 4 are independently selected from -NR 1 or -CR 1 R 1 ; - - - - - - - is single bond or double bond.
- ring A is selected from wherein, X 1 , X 2 are independently selected from -NR 1 or -CR 1 R 1 ; - - - - - - - is single bond or double bond.
- ring A is selected from 9- to 10-membered heteroaryl or 9- to 10- membered heterocyclyl; the 9- to 10- membered heterocyclyl contains at least one double bond.
- ring A is selected from the group consisting of pyridyl, pyrazinyl, pyrimidinone, pyrimidinyl, thienyl, thiazolyl, furanyl, oxazolyl, indolyl, indazolyl , quinolyl and isoquinolyl.
- ring A is selected from
- the ring C is selected from C 3-10 carbocyclyl or 3- to 10- membered heterocyclyl.
- the ring C is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, morpholinyl, piperazinyl, or piperidinyl.
- the ring C is selected from C 6-10 aryl or 5- to 10- membered heteroaryl.
- ring C is selected from phenyl, pyrrolyl, furyl, thienyl, oxazolyl, imidazolyl, pyrazolyl, thiazolyl, pyridyl, pyrimidinyl, Pyridazinyl, pyrazinyl, pyridinone, indolyl, benzoxazolyl, indazolyl, benzimidazolyl, benzotriazolyl, pyrrolopyridyl, quinolyl, naphthyl, dihydro Isobenzofuranyl, benzobisoxazolyl, tetrahydroquinolinyl, dihydropyrrolopyridyl, dihydronaphthyridinyl, dihydropyridopyrimidinonyl, isoindolinyl, dihydropyrazole pyrimidyl, cyclohexenyl, t
- the ring C is selected from
- ring C is selected from
- n 1
- n 2
- R c1 , R c2 are independently selected from hydrogen, halogen, C 1-4 alkyl or -OR 5 .
- R c1 , R c2 are independently selected from hydrogen, -CH 3 , -F, -OH.
- R c1 , R c2 with connected atom form a cyclopropyl.
- M is selected from -O- or -CR 1b R 1c -.
- R 1b and R 1c are independently selected from hydrogen, C 1-3 alkyl, C 3-6 cycloalkyl, 3- to 6- membered heterocyclyl, -OR 1d or -NR 1e R 1f .
- Y 1 is selected from -NR 3a - and Y 2 is selected from -CR 4b R 4c -.
- Y 1 is selected from -CR 3b R 3c -, and Y 2 is selected from -NR 4a -.
- Y 1 is selected from -CR 3b R 3c - and Y 2 is selected from -CR 4b R 4c -.
- the ring D is a C 6-10 aryl or a 5- to 10-membered heteroaryl.
- the ring D is
- the ring D is
- each R 4 is independently selected from hydrogen, halogen, oxo, C 1-8 alkyl or -OR 5 .
- each R 4 is independently selected from hydrogen, oxo, -CH 3 or -OCH 3 .
- X is selected from -O-.
- X is selected from -N(R 1X )-,
- R 1X is selected from hydrogen or methyl.
- p is 0, 1 or 2 or 3.
- q is 0, 1 or 2.
- r is 0, 1, or 2.
- the compound of Formula I or a pharmaceutically acceptable salt, deuterated compound, cis-trans isomer, tautomer, solvate, chelate, non-covalent complex or precursor thereof, selected from Formula II:
- the ring C is selected from C 3-10 carbocyclyl or 3- to 10- membered heterocyclyl.
- the ring C is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, morpholinyl, piperazinyl, or piperidinyl.
- the ring C is selected from C 6-10 aryl or 5- to 10- membered heteroaryl.
- the ring C is selected from phenyl, pyrrolyl, furyl, thienyl, oxazolyl, imidazolyl, pyrazolyl, thiazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyridinone, indolyl, benzoxazolyl, indazolyl, benzimidazolyl, benzotriazolyl, pyrrolopyridyl, quinolinyl, naphthyl, dihydro Isobenzofuranyl, benzobisoxazolyl, tetrahydroquinolinyl, dihydropyrrolopyridyl, dihydronaphthyridinyl, dihydropyridopyrimidinonyl, isoindolinyl, dihydropyrazole pyrimidyl, cyclohexenyl, imidazolyl,
- the ring C is selected from
- the ring C is selected from
- R 1 is selected from hydrogen, halogen or C 1-4 alkyl.
- R 1 is selected from hydrogen
- each R 4 is independently selected from hydrogen, halogen, oxo, C 1-8 alkyl or -OR 5 .
- each R 4 is independently selected from hydrogen or -OCH 3 .
- X is selected from -O-.
- X is selected from -N(R 1X )-,
- R 1X is selected from hydrogen or methyl.
- q is 0 or 1.
- r is 0, 1, or 2.
- the compound of Formula I or a pharmaceutically acceptable salt, deuterated compound, cis-trans isomer, tautomer, solvate, chelate, non-covalent complex or precursor, selected from any of the following Formula III-Formula V:
- the compound of Formula I is selected from:
- the present invention also provides a pharmaceutical composition, which is characterized in that it comprises a therapeutically effective amount of at least one compound represented by Formula I and at least one pharmaceutically acceptable adjuvant.
- the present invention further provides a pharmaceutical composition, characterized in that the mass percentage of the therapeutically effective amount of at least one compound represented by Formula I and pharmaceutically acceptable adjuvants is 0.0001:1-10.
- the present invention provides the application of the compound represented by the structural Formula I or the pharmaceutical composition in the preparation of medicine.
- the present invention further provides the preferred technical solution of the application:
- the application is for the preparation of a medicament for treating, preventing, delaying or preventing cancer, cancer metastasis, cardiovascular disease, immune disease, fibrosis or eye disease.
- the application is in the preparation of a medicament for treating diseases mediated by SHP2.
- the disease is cancer.
- the cancer is selected from Noonan syndrome, leopard spot syndrome, juvenile myelomonocytic leukemia, neuroblastoma, melanoma, head and neck squamous cell carcinoma, acute myeloid leukemia, breast cancer, esophageal tumor , lung cancer, colon cancer, head cancer, stomach cancer, lymphoma, glioblastoma, pancreatic cancer, or a combination thereof.
- the application is for the preparation of SHP2 inhibitors.
- the present invention also provides a method for treating and/or preventing diseases mediated by SHP2, comprising administering to a subject a therapeutically effective amount of at least any compound or pharmaceutical composition represented by structural Formula I.
- the SHP2-mediated disease is cancer.
- the present invention also provides a method for treating cancer, comprising administering a therapeutically effective amount of at least any one compound or pharmaceutical composition represented by structural Formula I to a treatment subject.
- the cancer is selected from Noonan syndrome, leopard spot syndrome, juvenile myelomonocytic leukemia, neuroblastoma, melanoma, head and neck squamous cell carcinoma, acute myeloid leukemia, breast cancer, esophageal tumor , lung cancer, colon cancer, head cancer, stomach cancer, lymphoma, glioblastoma, pancreatic cancer, or a combination thereof.
- the treatment subject is human.
- alkyl includes straight, branched or cyclic saturated alkyl groups.
- alkyl include, but are not limited to, methyl, ethyl, propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclobutyl, n-pentyl, 3-(2-methyl)butyl, 2-pentyl, 2-methylbutyl, neopentyl, cyclopentyl, n-hexyl, 2-hexyl, 2-methylpentyl, cyclohexyl and the like.
- C 1-8 in "C 1-8 alkyl” refers to a linear, branched or cyclic arrangement containing 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms.
- alkenyl and alkynyl include straight chain, branched or cyclic alkenyl and alkynyl.
- C 2-8 alkenyl and “C 2-8 alkynyl” refer to alkenes containing 2, 3, 4, 5, 6, 7 or 8 carbon atoms arranged in straight chain, branched chain or cyclic form radical or alkynyl.
- alkoxy refers to the oxyether forms of the aforementioned linear, branched or cyclic alkyl groups.
- aryl refers to an unsubstituted or substituted monocyclic or polycyclic aromatic group including carbon atoms. Preferably it is a 6- to 10-membered monocyclic or bicyclic aromatic group. Preferred are phenyl and naphthyl. Most preferred is phenyl.
- heteroaryl refers to a monovalent heteroatom group formed by the removal of a hydrogen atom from a carbon atom of a parent heteroaromatic ring system.
- Heteroaryl groups include: 5- to 7- membered aromatic, monocyclic rings, including at least one heteroatom selected from N, O or S, eg, 1 to 4 heteroatoms, or preferably 1 to 3 heteroatoms, other atoms on the ring are carbon; polyheteroaryl rings include at least one heteroatom selected from N, O or S, for example, 1 to 4 heteroatoms, or preferably 1 to 3 heteroatoms, other atoms on the ring is carbon, and at least one heteroatom is on aromatic ring; it also includes bicyclic or polycyclic rings, but at least one of the bicyclic or polycyclic rings is aromatic.
- heteroaryl are C 3-10 heteroaryl groups including, but not limited to, pyrrolyl, furyl, thienyl, pyridyl, pyranyl, pyrazolyl, pyrimidinyl, pyridazinyl, pyridyl azinyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, triazolyl, indolyl, benzofuranyl, benzothiazolyl, benzimidazolyl, benzopyrazolyl, benzoyl Triazolyl, carbazolyl, quinolinyl, isoquinolinyl, purinyl and the like.
- Carbocyclyl refers to a cyclyl that is saturated or unsaturated but not aromatic. Depending on their particular level of saturation, the terms “cycloalkyl”, “cycloalkenyl” or “cycloalkynyl” are used, respectively.
- Representative carbocyclyl include, but are not limited to, cyclopropane, cyclobutane, cyclopentane, cyclohexane or cyclohexene and the like.
- Heterocyclyl means a saturated or unsaturated, but non-aromatic, cyclyl in which one or more carbon atoms (and attached hydrogen atoms) may be replaced by the same or different heterocyclyl respectively atom and the corresponding attached hydrogen atom.
- Representative heteroatoms substituted for carbon atoms include, but are not limited to, N, P, O, S, and Si.
- heterocyclyl include, but are not limited to, epoxy, imidazolidine, morpholine, piperazine, piperidine, pyrazolidine, pyrrolidine, quinuclidine, tetrahydrofuran or tetrahydropyran and the like.
- heterocycloalkyl and carbocyclyl cross or contain each other.
- at least one percarbocycle is fused to a heterocycloalkyl to form a bi-, poly- or spiro-ring, it will still be defined as a heterocycloalkyl.
- heteroaryl group is fused with a heterocyclyl to form a bi-, poly- or spiro-ring, it will be defined as heterocyclyl rather than heteroaryl.
- Halogen means fluorine (F), chlorine (Cl), bromine (Br) or iodine (I). Preferred halogens are fluorine, chlorine and bromine.
- Halo means a fluoro, chloro, bromo or iodo. Preferred halo refer to fluoro and chloro.
- Substituted means that one or more hydrogen atoms in a group are replaced by the same or different substituents, respectively.
- Representative substituents include, but are not limited to, halogen, amino, hydroxyl, oxo, carbonyl, cyano, -C(O)NH 2 , alkyl, alkoxy, aryl, cycloalkyl, heterocyclyl, heteroaryl.
- substituents include, but are not limited to, halogen, amino, hydroxy, cyano, methyl, -CH 2 OH, -C(O)NH 2 , -OCH 3 , trifluoromethyl.
- alkyl or “aryl” or its prefix root appears in the name of a substituent (eg, aralkyl, or dialkylAmino)
- alkyl and aryl should be "Definition defines a limited interpretation of the substituents.
- a specified number of carbon atoms eg, C 1-6
- Compounds as used herein include compounds of Formula I, and all pharmaceutically acceptable forms thereof. These pharmaceutically acceptable forms include salts, solvates, non-covalent complexes, chelates, stereoisomers (including diastereomers, enantiomers and racemates), cis-trans Isomers, isotopically labeled compounds, tautomers, prodrugs, or any mixture of all of the above.
- cis-trans isomer is a stereoisomerism that exists in certain double bond compounds or cyclic compounds. The free rotation of these molecules is hindered due to the presence of double bonds or rings, resulting in two isomers that are not identical in physical or chemical properties, called cis (cis) and trans (trans) isomers, respectively.
- the compounds of the present invention are intended to include all such possible cis-trans isomers, including cis-configured compounds ⁇ trans-configured compounds and mixtures of cis-trans isomers in any ratio.
- Cis-trans isomers can be separated using conventional techniques (eg, on a Prep-HPLC column).
- the “pharmaceutically acceptable” refers to those known to be used in animal, especially in human.
- composition in the present invention includes a product containing the specified components in the specified amounts, as well as any product obtained directly or indirectly from the specified amounts of the specified components. Accordingly, pharmaceutical compositions comprising the compounds of the present invention as active ingredients and methods of preparing the compounds are the subject of the present invention.
- a “therapeutically effective amount” refers to a compound that when administered to a subject is sufficient to treat and prevent and/or inhibit at least one clinical symptom of a disease, condition, symptom, indication and/or disorder.
- the specific "therapeutically effective dose” may vary depending on the compound, the route of administration, the age of the patient, the weight of the patient, the type, symptoms and severity of the disease or disorder being treated, and the like. Wherever possible, an appropriate dose will be apparent to those skilled in the art or may be determined by routine experimentation.
- the compounds provided herein may exist in the form of "pharmaceutically acceptable salts".
- the salts of the compounds provided by the present invention refer to non-toxic pharmaceutically acceptable salts.
- Pharmaceutically acceptable salt forms include pharmaceutically acceptable acid/anion or base/cation salts.
- Pharmaceutically acceptable acid/anion salts generally exist in the protonated form of the basic nitrogen with an inorganic or organic acid.
- Typical organic or inorganic acids include hydrochloric, hydrobromic, hydroiodic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic , tartaric acid, citric acid, ⁇ -ketoglutaric acid, hippuric acid, benzoic acid, mandelic acid, methanesulfonic acid, isethionic acid, benzenesulfonic acid, oxalic acid, pamoic acid, 2-naphthalenesulfonic acid, p-toluenesulfonic acid acid, cyclohexylamine sulfonic acid, salicylic acid, saccharinic acid or trifluoroacetic acid.
- Pharmaceutically acceptable base/cation salts including, but not limited to, aluminum, calcium, chloroprocaine, choline, diethanolamine, ethylenediamine, lithium, magnesium, potassium, sodium salt and zinc salt
- Prodrugs of the compounds of the present invention are included within the scope of the present invention.
- the prodrugs are functional derivatives that are readily converted in vivo to the desired compound.
- the term "administration" in reference to the methods of treatment provided by the present invention includes the administration of a compound disclosed herein, or, although not expressly disclosed, but capable of being converted in vivo to a compound disclosed herein after administration to a subject to treat the various described disease.
- Conventional procedures for the selection and preparation of suitable prodrug derivatives are described in, for example, Design of Prodrugs ( Design of Prodrugs, ed. H. Bundgaard, Elsevier, 1985 ).
- any substituent or position-specific variable in one molecule is independent of the definition of any substituent or position-specific variable in other molecules. It is easy to understand that the compounds in the present invention can select suitable substituents or substitution forms according to the prior art in this subject, so as to provide chemical stability and be easily prepared and synthesized by the methods described in the prior art in this subject or in the present invention.
- the present invention includes any possible solvates and polymorphs.
- the type of solvent that forms the solvate is not particularly limited as long as the solvent is pharmacologically acceptable.
- water, ethanol, propanol, acetone and similar solvents can be used.
- salts refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids.
- acids their corresponding salts can be prepared from pharmaceutically acceptable non-toxic base, including inorganic and organic base.
- Salts derived from inorganic base include aluminum, ammonium, calcium, copper (ic and ous), iron, ferrous, lithium, magnesium, manganese (ic and ous), potassium, sodium, zinc and the like. In particular, ammonium, calcium, magnesium, potassium and sodium salts are preferred.
- Nontoxic organic bases that can be derivatized into pharmaceutically acceptable salts include primary, secondary, and tertiary amines, as well as cyclic amines and substituted amines, such as naturally occurring and synthetic substituted amines.
- Other pharmaceutically acceptable nontoxic organic bases capable of forming salts including ion exchange resins and arginine, betaine, caffeine, choline, N',N'-dibenzylethylenediamine, diethylamine, 2-DiethylAminoethanol, 2-DimethylAminoethanol, Ethanolamine, Ethylenediamine, N-Ethylmorpholine, N-Ethylpiperidine, Reduced Glucosamine, Glucosamine, Histidine, Haramine, Isopropylamine , lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resin, procaine, purine, theobromine, triethylamine, trimethylamine,
- acids include, for example, acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, isethionic acid, formic acid, fumaric acid, gluconic acid, glutamic acid, hydrobromic acid, hydrochloric acid, lactic acid, maleic acid, malic acid, mandelic acid, alpha-ketoglutaric acid, hippuric acid, methanesulfonic acid, mucic acid, nitric acid, pamoic acid, pantothenic acid, phosphoric acid, succinic acid, sulfuric acid, tartaric acid, p-toluenesulfonic acid acid etc.
- acids include, for example, acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, isethionic acid, formic acid, fumaric acid, gluconic acid, glut
- malic acid citric acid, hydrobromic acid, hydrochloric acid, methanesulfonic acid, maleic acid, phosphoric acid, sulfuric acid and tartaric acid. More preferably, phosphoric acid, hydrochloric acid and malic acid. Since the compound of Formula I will be used as a pharmaceutical, it is preferred to use a substantially pure form, for example, at least 60% pure, more suitably at least 75% pure, particularly suitably at least 98% pure (% is by weight).
- the pharmaceutical composition provided by the present invention includes the compound represented by Formula I (or a pharmaceutically acceptable salt thereof) as an active component, a pharmaceutically acceptable excipient and other optional therapeutic components or adjuvants.
- the pharmaceutical compositions of the present invention include oral, rectal, topical and pharmaceutical compositions for parenteral (including subcutaneous, intramuscular, intravenous) administration.
- the pharmaceutical compositions of the present invention may conveniently be presented in unit dosage form and prepared by any of the methods of preparation well known in the art of pharmacy.
- the compound represented by the Formula I of the present invention can be combined with the drug as the active component, and mixed with the drug carrier to form a drug combination thing.
- the pharmaceutical carrier can take a wide variety of forms, depending on the intended mode of administration, eg, oral or injection (including intravenous). Accordingly, the pharmaceutical compositions of the present invention may take the form of discrete units suitable for oral administration, such as capsules, cachets or tablets containing a predetermined dose of the active ingredient.
- the pharmaceutical compositions of the present invention may take the form of powders, granules, solutions, aqueous suspensions, non-aqueous liquids, oil-in-water emulsions, or water-in-oil emulsions.
- the compound of Formula I or a pharmaceutically acceptable salt thereof can also be administered by means of controlled release and/or delivery device.
- the pharmaceutical composition of the present invention can be prepared by any pharmaceutical method. In general, such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more essential ingredients.
- the pharmaceutical compositions are prepared by homogeneous intimate admixture of the active ingredient with liquid carriers or finely divided solid carriers, or a mixture of both.
- the product can be easily prepared to the desired appearance.
- the pharmaceutical composition of the present invention comprises a pharmaceutically acceptable carrier and a compound represented by Formula I, or a pharmaceutically acceptable salt thereof.
- the compound of Formula I, or a pharmaceutically acceptable salt thereof, and one or more other compounds having therapeutic activity in combination are also included in the pharmaceutical composition of the present invention.
- the pharmaceutical carrier employed in the present invention can be, for example, solid carrier, liquid carrier or gaseous carrier.
- solid carriers include, lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid, mannitol, sorbitol, microcrystalline cellulose, inorganic salts, starch, pregelatinized starch, powdered sugar, dextrin, etc.
- liquid carriers include syrup, peanut oil, olive oil and water.
- gaseous carriers include carbon dioxide and nitrogen. In the preparation of pharmaceutical oral Formulations, any convenient pharmaceutical medium may be employed.
- water, glycols, oils, alcohols, flavor enhancers, preservatives, colorants, etc. can be used in oral liquid preparations such as suspensions, elixirs and solutions; and carriers such as starches, sugars, Microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, etc. can be used for oral solid preparations such as powders, capsules and tablets.
- oral liquid preparations such as suspensions, elixirs and solutions
- carriers such as starches, sugars, Microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, etc.
- oral solid preparations such as powders, capsules and tablets.
- tablets and capsules are preferred for oral Formulations.
- the tablet coating can use standard aqueous or non-aqueous Formulation techniques.
- Tablets containing the compounds or pharmaceutical compositions of the present invention may be prepared by mixing, compressing or molding, optionally with one or more accessory ingredients or adjuvants.
- Compressed tablets may be prepared by compressing the active ingredient in a free-flowing form such as powder or granules with a lubricant, inert diluent, surface-active or dispersing agent, by compression in a suitable machine.
- Molded tablets may be made by wetting the powdered compound or pharmaceutical composition with an inert liquid diluent and molding in a suitable machine.
- each tablet contains about 0.01 mg to 5 g of active ingredient and each cachet or capsule contains about 0.1 mg to 0.5 g of active ingredient.
- a dosage form intended for oral administration to humans contains from about 0.1 mg to about 0.5 g of the active ingredient in admixture with suitable and conveniently metered adjunct materials ranging from about 5% to 99.99% of the total pharmaceutical composition .
- Unit dosage forms generally contain from about 0.1 mg to about 0.5 g of the active ingredient, typically 0.1 mg, 0.2 mg, 0.5 mg, 1 mg, 2 mg, 2.5 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg mg, 200 mg, 300 mg, 400 mg or 500 mg.
- the pharmaceutical composition suitable for parenteral administration provided by the present invention can be prepared as an aqueous solution or suspension by adding the active ingredient to water.
- Suitable surfactants such as sodium lauryl sulfate, polysorbate-80 (Tween-80), polyoxyethylene hydrogenated castor oil, poloxamers may be included.
- Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, preservatives may also be included in the pharmaceutical compositions of the present invention to prevent the growth of harmful microorganisms.
- the present invention provides pharmaceutical compositions suitable for injectable use, including sterile aqueous solutions or dispersions.
- the above-mentioned pharmaceutical compositions can be prepared in the form of sterile powders that can be used for the extemporaneous preparation of sterile injectable solutions.
- the final injectable form must be sterile and, for ease of injection, must be readily flowable.
- the pharmaceutical compositions must be stable during manufacture and storage. Therefore, preservation against contamination by microorganisms such as bacteria and fungi is preferred.
- the carrier can be a solvent or dispersion medium, for example, water, ethanol, polyol (eg, glycerol, propylene glycol, liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.
- compositions provided by the present invention may be in a form suitable for topical administration, for example, aerosol, cream, ointment, lotion, dusting powder, or other similar dosage forms. Further, the pharmaceutical composition provided by the present invention can be in a form suitable for use in a transdermal drug delivery device.
- These formulations can be prepared by conventional processing methods using the compound represented by Formula I of the present invention, or a pharmaceutically acceptable salt thereof.
- a cream or ointment is prepared by adding a hydrophilic material and water to the above compound (the total amount of both being about 5 wt % to 50 wt % of the compound) to produce a cream or ointment having the desired consistency.
- the pharmaceutical composition provided by the present invention can be prepared in form suitable for rectal administration with solid as carrier. Suppositories of admixture to form unit doses are the most preferred dosage forms. Suitable excipients include cocoa butter and other materials commonly used in the art. Suppositories can be conveniently prepared by first mixing the pharmaceutical composition with softened or melted excipients, then cooling and moulding.
- the above-mentioned pharmaceutical preparations may also include, as appropriate, one or more additional adjuvant components, such as diluents, buffers, flavoring agents, binders, surfactants, enhancers Thickeners, lubricants, preservatives (including antioxidants), etc. Further, other adjuvants may also include osmotic enhancers that adjust the isotonic pressure of the drug and blood.
- additional adjuvant components such as diluents, buffers, flavoring agents, binders, surfactants, enhancers Thickeners, lubricants, preservatives (including antioxidants), etc.
- other adjuvants may also include osmotic enhancers that adjust the isotonic pressure of the drug and blood.
- the pharmaceutical composition containing the compound represented by Formula I, or a pharmaceutically acceptable salt thereof can also be prepared in the form of a powder or a concentrated solution.
- reaction solution was cooled to 0 °C, quenched with 500 mL of ice water, extracted with EtOAc (500 mL ⁇ 3), the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was filtered through a column Chromatographic purification yielded 29.00 g of brown oil M1-3.
- reaction solution was quenched with 200 mL of saturated brine, extracted with EtOAc (300 mL ⁇ 2), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography to obtain 11.06 g of compound M30-5.
- Example78 1-(4-((3-(5-((S)-1-amino-1,3-dihy drospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxyl) methyl)pyrazin-2-yl)prop-2-yn-1-yl)o xy)phenyl)ethan-1-ol 485.25
- Example79 (A79) (S)-2-(4-((3-(5-(1-amino-1,3-dihydros piro[indene-2,4'-piperidin]-1'-yl)-6-(hy droxyl Methyl)pyrazin-2-yl)prop-2-yn-1-yl)o
- SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step results in the release of the autoinhibitory interface of SHP2, which in turn activates the SHP2 protein tyrosine phosphatase (PTP) and is available for substrate recognition and reaction catalysis.
- PTP protein tyrosine phosphatase
- the catalytic activity of SHP2 was monitored using the surrogate DiFMUP in a rapid fluorescence assay format. experiment procedure:
- Conversion_sample is the conversion rate reading of the sample
- Conversion_min is the average value of blank control wells, representing the conversion rate readings of wells without enzymatic activity
- Conversion_max is the mean ratio of positive control wells, representing the conversion rate readings of wells without compound inhibition.
- the log(inhibitor) vs. response-Variable slope of the analysis software GraphPad Prism was used to fit the dose-response curve, and the IC 50 value of the compound for the enzymatic activity was calculated.
- the compounds of the present invention have an allosteric inhibitory effect on SHP2 protein.
- the effects of the compounds of the invention on the proliferation of leukemia cells MV-4-11 and lung cancer cells NCI-H358 were evaluated using in vitro cell assays.
- the detection method used in the experiment is the CELL TITER-GLO (CTG) luminescence method, which can detect the number of viable cells by quantifying ATP. Because ATP participates in a variety of enzymatic reactions in vivo, it is an indicator of the metabolism of living cells, and its content directly reflects the number and state of cells.
- CCG CELL TITER-GLO
- the compounds of the present invention have a good inhibitory effect on the proliferation of MV-4-11 cells and NCI-H358 cells.
- test sample diluent Dilute the test sample diluent in sequence with extracellular fluid to prepare detection solutions with final concentrations of 0.3 ⁇ M, 1 ⁇ M, 3 ⁇ M, 10 ⁇ M and 30 ⁇ M. The solubility of the samples to be tested was visually checked.
- the cell line was derived from HEK293 cells and cultured in a 37 °C, 5% CO 2 incubator. In order to prevent cell senescence caused by contact inhibition, when the cell culture confluence should not exceed 80%, the cells should be passaged every 3/4 days, and the inoculation density of each T175 flask should be 2*106 cells. Pre-wash with Phosphate Buffered Saline (PBS), then trypsin/EDTA for 2-3 minutes, stop digestion by adding cell culture medium, and transfer to a new culture bottle.
- PBS Phosphate Buffered Saline
- HEK293 cells overexpressing the hERG potassium channel were cultured overnight at a cell density below 50%.
- Experimental cells were transferred to a cell bath embedded in an inverted microscope stage(Diaphot, Nikon) and perfused with extracellular fluid.
- the extracellular fluid contained 130 mM NaCl, 4 mM KCI, 1.8 mM CaCl 2 , 1 mM MgCl 2 , 10 mM glucose and 10 mM HEPES (pH 7.4 with NaOH) at a perfusion rate of 4 ml/min.
- the inner tube contains 130 mM KCl, 1 mM MgCl 2 , 5 mM EGTA, 5 mM MgATP and 10 mM HEPES (pH 7.2 with KOH).
- Membrane currents were recorded using a HEKA EPC-10 patch-clamp amplifier and PATCHMASTER acquisition system (HEKA Instruments Inc., D-67466 Lambrecht, Pfalz, Germany). All experiments were done at room temperature (22-23 °C).
- Electrodes (BF150-86-10) were straightened during the experiments using a P-97 microelectrode puller (Sutter Instrument Company, One Digital Drive, Novato, CA 94949).
- the inner diameter of the electrode is 1-1.5 mm, and the water entry resistance after filling with internal liquid is 2-4 M ⁇ .
- Electrophysiological stimulation protocol
- the whole-cell seal When the whole-cell seal is formed, wait for the current to stabilize for 2 minutes (the current decay is less than 5% within 5 minutes, and the tail current value is greater than 500 pA). At this time, the peak value of the tail current is the control current value.
- the extracellular fluid containing the drug to be tested is then perfused. The same procedure was repeated 3-5 times, exposing each cell to 4-6 increasing concentrations of compounds. Blocking and deactivation of hERG during compound exposure and washout were continuously recorded.
- the cell membrane voltage was clamped at -80 mV, depolarized for 2 seconds every 12 seconds, and the clamping voltage was depolarized from -80 mV to -50 mV under a 5-second repolarization pulse of -50 mV. Measure the peak tail current.
- Example D In vitro metabolic stability of human and rat liver microsomes
- Example E In vivo efficacy of MIA-PACA2 cell subcutaneous xenograft tumor model
- TGI (%) [(1-(average tumor volume at the end of administration of a certain treatment group - average tumor volume at the beginning of administration of this treatment group))/(average tumor volume at the end of treatment in the solvent control group Volume - the average tumor volume of the solvent control group at the beginning of treatment)] ⁇ 100%.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- The present invention relates to series of compounds as inhibitors of Src homologyregion 2-containing protein tyrosine phosphatase 2 (SHP2), methods and pharmaceutical compositions thereof. The present invention also relates to the use of the compounds or pharmaceutical compositions thereof for the treatment of SHP2-mediated diseases.
- Src homologyregion 2-containing protein tyrosine phosphatase 2 (SHP2) is a non-receptor protein tyrosine phosphatase encoded by the PTPN11 gene. PTPN11 is the first discovered proto-oncogene encoding tyrosine phosphokinase(Chan R J et al. PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood, 2007, 109:862-867), and its encoded SHP2 protein contains N-terminal SHP2 domain (N-SHP2), C-terminal SHP2 domain (C-SHP2), protein phosphatase catalyzed domain (PTP), two C-terminal tyrosine residues (Y542 and Y580) and a proline-rich (Pro) motif.
- In recent years, researches mainly believe that the Ras/ERK pathway is the most important signal transduction pathway for SHP2. The mechanism (Dance M et al. The molecular functions of SHP2 in the RAS/mitogen-activated protein kinase (ERK1/2) pathway. Cell Signal, 2008, 20:453-459) is roughly as follows: after activation of growth factor receptors, its tyrosine residues are autophosphorylated to provide docking sites for the phosphotyrosine-binding region SH2 of Grb2 and SHP2 (the SH2 domain-containing adaptor protein). Binding of Grb2 to phosphorylated growth factor receptors results in the accumulation of SOS proteins at the cell membrane. As a guanine nucleotide exchange factor (GEF), SOS can catalyze the conversion of membrane-bound protein Ras from inactive Ras-GDP to active Ras-GTP. Ras-GTP further connects with the downstream signaling system, activates the Ser/Thr kinase Raf1, etc., and then activates ERK under the action of the regulatory kinase MEK. After activation, ERK directly acts on cytoplasmic target molecules or transfers to the nucleus to regulate genes Transcribe to make cells proliferate or differentiate. This process may also be influenced by SHP2-binding proteins and substrates (SHP substrate-1, SHPS-1), Ras-GTPase activating protein (Ras-GAP), and other Src members.
- It is reported that SHP2 protein not only regulates the Ras/ERK signaling pathway, but also regulates multiple signaling pathways such as JAK-STAT3, NF-κB, PI3K/Akt, RHO and NFAT, thereby regulating cell proliferation, differentiation, migration, apoptosis and other physiology Function.
- SHP2 has been shown to be associated with various diseases, and Tartaglia et al. (Tartaglia M et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan sydrome. Nat Genet, 2001, 29:465-468) found that about 50% of Patients with Noonan syndrome have missense mutations in PTPN11. In addition, studies have found that PTPN11 mutation is an important cause of JMMLL and various leukemias (Tartaglia M et al. Nat Genet, 2003, 34: 148-150; Loh ML et al. Blood, 2004, 103: 2325-2331; Tartaglia M et al. Br J Haematol, 2005, 129:333-339; Xu R et al. Blood, 2005, 106:3142-3149.). With further study of PTPN11/SHP2, it has been found that it is related to the occurrence of lung cancer, gastric cancer, colon cancer, melanoma, thyroid cancer and other cancers (Tang Chunlan et al. Chinese Journal of Lung Cancer, 2010, 13:98- 101; Higuchi M et al. Cancer Sci, 2004, 95:442-447; Bentires-Alj M et al. Cancer Res, 2004, 64:8816-8820; Martinelli S et al. Cancer Genet Cytogenet, 2006, 166: 124-129).
- At present, SHP2 inhibitors have received more and more attention as a potential therapeutic approach. However, this target has not yet been marketed at home and abroad. Therefore, it is of great research significance to develop small-molecule drugs that can target and inhibit the activity of SHP2 and provide patients with safer and more effective SHP2 inhibitors.
- In the
WO2019183367 patent published on September 26, 2019 , the structure of compound 243 is disclosed as follows: According to the patent, the IC50 of compound 243 in the SHP2 allosteric inhibition test is greater than 50nM and less than or equal to 1µM, which needs further improvement. - The present invention relates to a compound as an inhibitor of Src homology region 2 protein tyrosine phosphatase 2 (SHP2), or a pharmaceutically acceptable salt, deuterated product, cis-trans isomer and tautomer thereof, solvate, chelate, non-covalent complex or prodrug, the compound is shown in Formula I:
- - - - - - - is a single bond or a double bond;
- ring A is selected from 5- to 10- membered heteroaryl (such as 6- membered heteroaryl, 9- membered heteroaryl, etc) or 5- to 10- membered heterocyclyl (such as 6- membered heterocyclyl, 9- membered heterocyclyl, etc.); Wherein, the 5- to 10-membered heteroaryl or the 5- to 10- membered heterocyclyl contains one or more O, N or S heteroatoms; the 5- to 10- membered heterocyclyl contains at least one double bond;
- ring C is selected from C3-10 carbocyclyl, 3- to 10- membered saturated or partially saturated heterocyclyl, C6-10 aryl or 5- to 10- membered heteroaryl;
- each Rc is independently selected from hydrogen, halogen, -CN, -NO2, oxo, -SF5, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 aryl, 5- to 10- membered heteroaryl, -OR5, -SR6, -NR7R8, -(C=O)R9, -C(=O)OR10, -C(=O)NR11R12, -S(=O)2R13, -S(=O)2OR14, -S(=O)2NR15R16, -O(CH2)sOR17, -O(CH2)sNR18R19, -NR20(CH2)tNR21R22, -NR23(CH2)tOR24, -NR25C(=O)R26, -OS(=O)2R27, -NR28S(=O)2R29, -OC(=O)R30, -S(=O)R31, -P(=O)R32R33, -OC2-6 alkenyl C1-6 alkoxy, -OC2-6 alkenyl, C6-10 aryl,
- two Rc together with the atom to which they are attached atoms form C3-8 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 aryl, 5- to 10- membered heteroaryl; wherein, the C3-8 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 aryl, 5- to 10- heteroaryl is optionally substituted with one or more substituents; the substituents are independently selected from hydrogen, halogen, -CN, -NO2, oxo, -SF5, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 membered aryl, 5- to 10- membered heteroaryl, -OR5, -SR6, -NR7R8, -(C=O)R9, -C(=O)OR10, -C(=O)NR11R12, -S(=O)2R13, -S(=O)2OR14, -S(=O)2NR15R16, -O(CH2)sOR17, -O(CH2)sNR18R19,-NR20(CH2)tNR21R22,-NR23(CH2)tOR24, -NR25C(=O)R26, -OS(=O)2R27, -NR28S(=O)2R29, -OC(=O)R30, -S(=O)R31, -P(=O)R32R33, -OC2-6 alkenyl, C1-6 alkoxy, -OC2-6 alkenyl, -C6-10 aryl,
- Rc1, Rc2 are independently selected from hydrogen, halogen, C1-4 alkyl or -OR5;
- or Rc1 and Rc2 with connected atoms form C3-6 carbocyclyl, 3- to 6- membered heterocyclyl;
- each R1 is independently selected from hydrogen, halogen, -CN, -NO2, oxo, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 carbocyclyl, 3- to 6- membered heterocyclyl, C6-10 aryl, 5- to 10- membered heteroaryl, -OR5, -SR6, -NR7R8, -(C=O)R9, -C(=O)OR10, -C(=O)NR11R12, -S(=O)2R13, -S(=O)2OR14, -S(=O)2NR15R16, -O(CH2)sOR17, -O(CH2)sNR18R19, -NR20(CH2)tNR21R22, -NR23(CH2)tOR24, -NR25C(=O)R26, -OS(=O)2R27, -NR28S(=O)2R29, -OC(=O)R30, -S(=O)R31, -P(=O)R32R33 ; wherein, the C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 carbocyclyl, 3-to 6- membered heterocyclyl, C6-10 aryl, 5- to 10- membered heteroaryl is optionally substituted by one or more substituents; the substituents are selected from hydrogen, halogen, -CN, -NO2, oxo, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 carbocyclyl, 3- to 6- membered heterocyclyl, C6-10 aryl, 5- to 10- membered heteroaryl, -OR5, -SR6, -NR7R8, -(C=O)R9, -C(=O)OR10 or -C(=O)NR11R12;
- X is selected from -O, -N(R1X), -S, -C(=O), -C(=O)O, -C(=O)N(R2X), -S(=O)2, -S(=O)2O, -S(=O)2N(R3X), -S(=O), -S(=O)O, -S(=O)N(R4X), -OS(=O)2O,
- R1X, R2X, R3X, R4X, R5X, R6X, R7X, R8X, R9X, R10X, R11X are independently selected from hydrogen, C1-3 alkyl, C3-6 cycloalkyl or 3- to 6- membered heterocyclyl;
- M is selected from -O, -NR1a or -CR1bR1c;
- R1a is selected from hydrogen, C1-3 alkyl, C3-6 cycloalkyl, 3- to 6- membered heterocyclyl or absent;
- R1b, R1c are independently selected from hydrogen, C1-3 alkyl, C3-6 cycloalkyl, 3-to 6- membered heterocyclyl, -OR1d, -NR1eR1f or absent;
- R1d, R1e, R1f are independently selected from hydrogen, C1-3 alkyl, C3-6 cycloalkyl or 3- to 6- membered heterocyclyl;
- Y1 is selected from -NR3a or -CR3bR3c;
- R3a is selected from hydrogen, C1-3 alkyl, C3-6 cycloalkyl, 3- to 6- membered heterocyclyl or absent;
- R3b, R3c are independently selected from hydrogen, C1-3 alkyl, C3-6 cycloalkyl, 3-to 6- membered heterocyclyl or absent;
- Y2 is selected from -NR4a or -CR4bR4c;
- R4a is selected from hydrogen, C1-3 alkyl, C3-6 cycloalkyl, 3- to 6- membered heterocyclyl or absent;
- R4b, R4c are independently selected from hydrogen, C1-3 alkyl, C3-6 cycloalkyl, 3-to 6- membered heterocyclyl or absent;
- The ring D is C6-10 aryl, 5- to 10- membered heteroaryl, C3-8 carbocyclyl, 3- to 8-membered heterocyclyl or absent; wherein, the C3-8 carbocyclyl or 3- to 8- membered heterocyclyl optionally contains double bond;
- each R4 is independently selected from hydrogen, halogen, -CN, -NO2, oxo, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 aryl, 5- to 10- membered heteroaryl, -OR5, -SR6, -NR7R8, -(C=O)R9, -C(=O)OR10, -C(=O)NR11R12, -S(=O)2R13, -S(=O)2OR14, -S(=O)2NR15R16, -O(CH2)sOR17, -O(CH2)sNR18R19, -NR20(CH2)tNR21R22, -NR23(CH2)tOR24; wherein, the C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 membered aryl, 5- to 10- membered heteroaryl is optionally substituted with one or more substituents; the substituents are selected from hydrogen, halogen, -CN, -NO2, oxo, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-10 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 aryl, 5- to 10- membered heteroaryl, -OR5, -SR6, -NR7R8, -(C=O)R9, -C(=O)OR10, -C(=O)NR11R12, -S(=O)2R13, -S(=O)2OR14, -S(=O)2NR15R16, -O(CH2)sOR17, -O(CH2)sNR18R19, -NR20(CH2)tNR21R22, -NR23(CH2)tOR24;
- R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40 are independently selected from hydrogen, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 carbon cyclyl, 3- to 10- membered heterocyclyl, C6-10 aryl, 5- to 10 membered heteroaryl; wherein, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 carbocyclyl, 3- to 10-membered heterocyclyl, C6-10 membered aryl, 5- to 10- membered heteroaryl are optionally substituted with one or more substituents; the substituents are selected from hydrogen, halogen, -CN, -NO2, oxo, -OH, -NH2, C1-4 alkyl, C1-4 alkoxy, C2-4 alkenyl, C2-4 alkynyl, C3-10 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 aryl, 5- to 10-membered heteroaryl;
- n is 0, 1, 2 or 3;
- p is 0, 1, 2, or 3;
- q is 0, 1, 2, 3 or 4;
- r is 0, 1, 2, 3 or 4;
- s is 1, 2, 3 or 4;
- t is 1, 2, 3 or 4.
- In some embodiments, in the Formula I, ring C is selected from 3- to 10-membered saturated or partially saturated heterocyclyl, C6-10 aryl or 5- to 10-membered heteroaryl.
- In some embodiments, in the Formula I, the ring D is C6-10 aryl, 5- to 10-membered heteroaryl, C3-8 carbocyclyl or 3- to 8- membered heterocyclyl; wherein, the C3-8 carbocyclyl or 3- to 8- membered heterocyclyl optionally contains double bond.
- In some embodiments, in the Formula I, ring A is selected from 6- to 10-membered heteroaryl or a 6- to 10- membered heterocyclyl; the 6- to 10- membered heterocyclyl contains at least one double bond.
- In some embodiments, in the Formula I, ring A is selected from a 6- membered heteroaryl or a 6- membered heterocyclyl; the 6- membered heterocyclyl contains at least one double bond.
-
-
- In some embodiments, in the Formula I, ring A is selected from 9- to 10-membered heteroaryl or 9- to 10- membered heterocyclyl; the 9- to 10- membered heterocyclyl contains at least one double bond.
- In some embodiments, in the Formula I, ring A is selected from the group consisting of pyridyl, pyrazinyl, pyrimidinone, pyrimidinyl, thienyl, thiazolyl, furanyl, oxazolyl, indolyl, indazolyl , quinolyl and isoquinolyl.
-
- In some embodiments, in the Formula I, the ring C is selected from C3-10 carbocyclyl or 3- to 10- membered heterocyclyl.
- In some embodiments, in the Formula I, the ring C is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, morpholinyl, piperazinyl, or piperidinyl.
- In some embodiments, in the Formula I, the ring C is selected from C6-10 aryl or 5- to 10- membered heteroaryl.
- In some embodiments, in the Formula I, ring C is selected from phenyl, pyrrolyl, furyl, thienyl, oxazolyl, imidazolyl, pyrazolyl, thiazolyl, pyridyl, pyrimidinyl, Pyridazinyl, pyrazinyl, pyridinone, indolyl, benzoxazolyl, indazolyl, benzimidazolyl, benzotriazolyl, pyrrolopyridyl, quinolyl, naphthyl, dihydro Isobenzofuranyl, benzobisoxazolyl, tetrahydroquinolinyl, dihydropyrrolopyridyl, dihydronaphthyridinyl, dihydropyridopyrimidinonyl, isoindolinyl, dihydropyrazole pyrimidyl, cyclohexenyl, tetrahydrobenzazepine, dihydrobenzimidazolone, indolinone, isoindolinone, dihydroquinolinone, dihydroisoquinolinone, benzoxazinone, quinolinone, benzobisoxazolyl, dihydrobenzodioxin, pyridone, indazolyl.
-
-
- In some embodiments, in the Formula I, n is 1.
- In some embodiments, in the Formula I, n is 2.
- In some embodiments, in the Formula I, each Rc is independently selected from hydrogen, halogen, -CN, -NO2, oxo, -SF5, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 membered aryl, 5- to 10-membered heteroaryl, -OR5, -SR6, -NR7R8, -(C=O)R9, -C(=O)OR10, -C(=O)NR11R12, -S(=O)2R13, -S(=O)2OR14, -S(=O)2NR15R16, -O(CH2)sOR17, -O(CH2)sNR18R19, -NR20(CH2)tNR21R22, -NR23(CH2)tOR24, -NR25C(=O)R26, -OS(=O)2R27 -NR28S(=O)2R29, -OC(=O)R30, -S(=O)R31, -P(=O)R32R33.
- In some embodiments, in the Formula I, each Rc is independently selected from hydrogen, oxo, -CH3, -OCH3, -OH, -OCF3, -CN, -F, -Cl, -CF3 , -NH2, -NHCH3, -NH(C=O)CH3, -CH2OH, -C(=O)CH3, -C(=O)NH2, -C(=O)NHCH3, -C(=O)N (CH3)2, -COOH, -COOEt, -S(=O)2CH3, -S(=O)2NH2, -P(=O)(CH3)2, -CH2OCH3, -CH2C(=O)NH2, ,
- In some embodiments, in the Formula I, Rc1, Rc2 are independently selected from hydrogen, halogen, C1-4 alkyl or -OR5.
- In some embodiments, in the Formula I, Rc1, Rc2 are independently selected from hydrogen, -CH3, -F, -OH.
- In some embodiments, in the Formula I, Rc1, Rc2 with connected atom form a cyclopropyl.
- In some embodiments, in the Formula I, each R1 is independently selected from hydrogen, halogen, oxo, C1-4 alkyl, -NR7R8, -C(=O)NR11R12; wherein, the C1-4 alkyl is optionally substituted with one or more substituents; the substituents are selected from hydrogen, halogen, -CN, -NO2, oxo, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 carbocyclyl, 3- to 6- membered heterocyclyl, C6-10 membered aryl, 5- to 10-membered heteroaryl, -OR5, -SR6, -NR7R8, -(C=O)R9, -C (=O)OR10 or -C(=O)NR11R12,
- In some embodiments, in the Formula I, each R1 is independently selected from hydrogen, oxo, -CH3, -NH2, -CH2OH, -C(=O)NH2.
- In some embodiments, in the Formula I, X is selected from -O-, -N(R1X)-, -C(=O)- or -C(=O)N(R2X)-.
- In some embodiments, in the Formula I, X is selected from -O-, -NH-, -C(=O)- or -C(=O)NH-.
- In some embodiments, in the Formula I, M is selected from -O- or -CR1bR1c-.
- In some embodiments, in the Formula I, R1b and R1c are independently selected from hydrogen, C1-3 alkyl, C3-6 cycloalkyl, 3- to 6- membered heterocyclyl, -OR1d or -NR1eR1f.
- In some embodiments, in the Formula I, Y1 is selected from -NR3a- and Y2 is selected from -CR4bR4c-.
- In some embodiments, in the Formula I, Y1 is selected from -CR3bR3c-, and Y2 is selected from -NR4a-.
- In some embodiments, in the Formula I, Y1 is selected from -CR3bR3c- and Y2 is selected from -CR4bR4c-.
- In some embodiments, in the Formula I, the ring D is a C6-10 aryl or a 5- to 10-membered heteroaryl.
-
-
- In some embodiments, in the Formula I, each R4 is independently selected from hydrogen, halogen, oxo, C1-8 alkyl or -OR5.
- In some embodiments, in the Formula I, each R4 is independently selected from hydrogen, oxo, -CH3 or -OCH3.
- In some embodiments, in the Formula I, X is selected from -O-.
- In some embodiments, in the Formula I, X is selected from -N(R1X)-,
- In some embodiments, in the Formula I, R1X is selected from hydrogen or methyl.
- In some embodiments, in the Formula I, p is 0, 1 or 2 or 3.
- In some embodiments, in the Formula I, q is 0, 1 or 2.
- In some embodiments, in the Formula I, r is 0, 1, or 2.
-
- ring C is selected from C3-10 carbocyclyl, 3- to 10- membered saturated or partially saturated heterocyclyl, C6-10 aryl or 5- to 10- membered heteroaryl;
- each Rc is independently selected from hydrogen, halogen, -CN, -NO2, oxo, -SF5, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 aryl, 5- to 10- membered heteroaryl, -OR5, -SR6, -NR7R8, -(C=O)R9, -C(=O)OR10, -C(=O)NR11R12, -S(=O)2R13, -S(=O)2OR14, -S(=O)2NR15R16, -O(CH2)sOR17, -O(CH2)sNR18R19, -NR20(CH2)tNR21R22, -NR23(CH2)tOR24, -NR25C(=O)R26, -OS(=O)2R27, -NR28S(=O)2R29, -OC(=O)R30, -S(=O)R31, -P(=O)R32R33, -OC2-6 alkenyl C1-6 alkoxy, -OC2-6 alkenyl C6-10 aryl,
- R1 is selected from hydrogen, halogen, -CN, -NO2, oxo, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, -OR5, -NR7R8, -O(CH2)sOR17, -O( CH2)sNR18R19, -NR20(CH2)tNR21R22, -NR23(CH2)tOR24; wherein, the C1-4 alkyl, C2-4 alkenyl or C2-4 alkynyl is optionally substituted by one or more substituents; the substituent is selected from hydrogen, halogen, -CN, -NO2, oxo, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 carbocyclyl, 3-6 membered heterocyclyl, C6-10 aryl, 5- to 10- membered heteroaryl, -OR5, -SR6, -NR7R8, -(C=O)R9, -C(=O)OR10 or -C(=O)NR11R12;
- X selected from -O-, -N(R1X)-, -S-, -C(=O)-, -C(=O)O-, -C(=O)N(R2X)-, -S(=O)2-, -S(=O)2O-, -S(=O)2N(R3X)-, -S(=O)-, -S(=O)O-, -S(=O)N(R4X)-, -OS(=O)2O-,
- R1X, R2X, R3X, R4X, R5X, R6X, R7X, R8X, R9X, R10X, R11X are independently selected from hydrogen, C1-3 alkyl, C3-6 cycloalkyl or 3- to 6- membered heterocyclyl;
- each R4 is independently selected from hydrogen, halogen, -CN, -NO2, oxo, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 aryl, 5- to 10- membered heteroaryl, -OR5, -SR6, -NR7R8, -(C=O)R9, -C(=O)OR10, -C(=O)NR11R12, -S(=O)2R13, -S(=O)2OR14, -S(=O)2NR15R16, -O(CH2)sOR17, -O(CH2)sNR18R19, -NR20(CH2)tNR21R22, -NR23(CH2)tOR24; wherein, the C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 aryl, 5- to 10- membered heteroaryl optionally substituted by one or more substituents; the substituents are selected from hydrogen, halogen, -CN, -NO2, oxo, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-10 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 aryl, 5- to 10- membered heteroaryl, -OR5, -SR6, -NR7R8, -(C=O)R9, -C(=O)OR10, -C(=O)NR11R12, -S(=O)2R13, -S(=O)2OR14, -S(=O)2NR15R16, -O(CH2)sOR17, -O(CH2)sNR18R19, -NR20(CH2)tNR21R22, -NR23(CH2)tOR24;
- R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, R40 independently selected from hydrogen, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 aryl, 5- to 10- membered heteroaryl; wherein, the C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 aryl, 5- to 10- heteroaryl is optionally substituted with one or more substituents; the substituents are selected from hydrogen, halogen,
- -CN, -NO2, oxo, -OH, -NH2, C1-4 alkyl, C1-4 alkoxy, C2-4 alkenyl, C2-4 alkynyl, C3-10 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 aryl, 5- to 10- membered heteroaryl;
- q is 0, 1, 2, 3 or 4;
- r is 0, 1, 2, 3 or 4;
- s is 1, 2, 3 or 4;
- t is 1, 2, 3 or 4.
- In some embodiments, in the Formula II, ring C is selected from 3- to 10-membered saturated or partially saturated heterocyclyl, C6-10 aryl or 5- to 10-membered heteroaryl;
- In some embodiments, in the Formula II, the ring C is selected from C3-10 carbocyclyl or 3- to 10- membered heterocyclyl.
- In some embodiments, in the Formula II, the ring C is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, morpholinyl, piperazinyl, or piperidinyl.
- In some embodiments, in the Formula II, the ring C is selected from C6-10 aryl or 5- to 10- membered heteroaryl.
- In some embodiments, in the Formula II, the ring C is selected from phenyl, pyrrolyl, furyl, thienyl, oxazolyl, imidazolyl, pyrazolyl, thiazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, pyridinone, indolyl, benzoxazolyl, indazolyl, benzimidazolyl, benzotriazolyl, pyrrolopyridyl, quinolinyl, naphthyl, dihydro Isobenzofuranyl, benzobisoxazolyl, tetrahydroquinolinyl, dihydropyrrolopyridyl, dihydronaphthyridinyl, dihydropyridopyrimidinonyl, isoindolinyl, dihydropyrazole pyrimidyl, cyclohexenyl, tetrahydrobenzazepine, dihydrobenzimidazolone, indolinone, isoindolinone, dihydroquinolinone, dihydroisoquinolinone, benzoxazinone, quinolinone, benzobisoxazolyl, dihydrobenzodioxin, pyridone, indazolyl.
-
-
- In some embodiments, in the Formula II, each Rc is independently selected from hydrogen, halogen, -CN, -NO2, oxo, -SF5, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 aryl, 5- to 10- membered heteroaryl, -OR5, -SR6, -NR7R8, -(C=O)R9, -C(=O)OR10, -C(=O)NR11R12, -S(=O)2R13, -S(=O)2OR14, -S(=O)2NR15R16, -O(CH2)sOR17, -O(CH2)sNR18R19, -NR20(CH2)tNR21R22, -NR23(CH2)tOR24, -NR25C(=O)R26, -OS(=O)2R27 -NR28S(=O)2R29, -OC(=O)R30, -S(=O)R31 -P(=O)R32R33.
- In some embodiments, in the Formula II, each Rc is independently selected from hydrogen, oxo, -CH3, -OCH3, -OH, -OCF3, -CN, -F, -Cl, -CF3, -NH2, -NHCH3, -NH(C=O)CH3, -CH2OH, -C(=O)CH3, -C(=O)NH2, -C(=O)NHCH3, -C(=O)N(CH3)2, -COOH, -COOEt, -S(=O)2CH3, -S(=O)2NH2, -P(=O)(CH3)2, -CH2OCH3 , -CH2C(=O)NH2,
- In some embodiments, in the Formula II, each Rc is independently selected from hydrogen, -CH3, -F, -Cl, -NH(C=O)CH3, -C(=O)NH2 or -C(=O)NHCH3.
- In some embodiments, in the Formula II, each Rc is independently selected from hydrogen, -S(=O)2NH2.
- In some embodiments, in the Formula II, R1 is selected from hydrogen, halogen or C1-4 alkyl.
- In some embodiments, in the Formula II, R1 is selected from hydrogen.
- In some embodiments, in the Formula II, each R4 is independently selected from hydrogen, halogen, oxo, C1-8 alkyl or -OR5.
- In some embodiments, in the Formula II, each R4 is independently selected from hydrogen or -OCH3.
- In some embodiments, in the Formula II, X is selected from -O-.
- In some embodiments, in the Formula II, X is selected from -N(R1X)-,
- In some embodiments, in the Formula II, R1X is selected from hydrogen or methyl.
- In some embodiments, in the Formula II, q is 0 or 1.
- In some embodiments, in the Formula II, r is 0, 1, or 2.
-
- In some embodiments, the compound of Formula I is selected from:
- (S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-phenoxyprop-1-yn-1-yl)pyrazin-2-yl)methanol;
- (S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-(3-methoxybenzene)oxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;
- (S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-(3-aminophenoxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;
- (S)-N-(3-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)phenyl)acetamide;
- (S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-(3-chloro-2-fluorophenoxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;
- (S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-((3-methoxybenzeneyl)thio)prop-1-yn-1-yl)pyrazin-2-yl)methanol;
- (S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-(phenylamino)prop-1-yn-1-yl)pyrazin-2-yl)methanol;
- (S)-N-(4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)phenyl)acetamide;
- (S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-(4-methoxybenzene)prop-1-yn-1-yl)pyrazin-2-yl)methanol;
- (S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-(2-methoxybenzene)prop-1-yn-1-yl)pyrazin-2-yl)methanol;
- (S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-(3,4-dimethoxyphenoxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;
- (S)-4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)benzonitrile;
- (S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-(3-(trifluoromethyl)phenoxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;
- (S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-(4-(trifluoromethyl)phenoxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;
- (S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-(3-(trifluoromethyl) phenoxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;
- (S)-1-(3-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)phenyl)ethane-1-one;
- (S)-4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)benzamide;
- (S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-(pyridin-4-oxyl)prop-1-yn-1-yl)pyrazin-2-yl)methanol;
- (S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-((2-Aminopyrimidine-5-yl)oxyl)prop-1-yn-1-yl)pyrazin-2-yl)methanol;
- (S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-(4-molinophenoloxyl)prop-1-yn-1-yl)pyrazin-2-yl)methanol;
- (S)-1-(4-(4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)piperazin-1-yl)ethane-1-one;
- (S)-7-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)-3,4-dihydroquinolin-2(1H)-one;
- (S)-6-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)-2H-benzo[b][1,4]oxazin-3(4H)-one;
- (S)-7-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)quinolin-2(1H)-one;
- (S)-6-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)indol-2-one;
- (S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-((2-Aminopyridine-4-yl)oxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;
- (S)-3-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)benzamide;
- (S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-(benzo[d][ 1,3]Dioxyol-5-oxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;
- (S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-(((2,3-dydrobenzo[b] [1,4]dioxin-6-yl)oxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;
- (S)-5-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)-1-methylpyridin-2(1H)-one;
- (S)-(6-(3-((1H-Indolazol-6-yl)oxy)prop-1-yn-1-yl)-3-(1-amino-1,3-dihydro spiro[indene-2,4'-piperidin]-1'-yl)pyrazin-2-yl)methanol;
- (S)-4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)benzenesulfonamide;
- (S)-3-((3-(2-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-oxo-1,6-dihydropyrimidin-5-yl)prop-2-yn-1-yl)oxy)benzamide;
- (S)-N-(3-((3-(2-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-1-methyl)yl-6-oxo-1,6-dihydropyrimidin-5-yl)prop-2-yn-1-yl)oxy)phenyl)acetamide;
- (S)-3-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)-N-methylbenzamide;
- (S)-3-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)-N,N-dimethylbenzamide;
- (S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-(3-(methylthio)acyl)phenoxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;
- (S)-(3-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)phenyl)dimethylphosphine oxide;
- (S)-4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)-1-methylpyridin-2(1H)-one;
- (S)-4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)-N-picolinamide;
- (S)-6-(3-(3-acetamidophenoxy)prop-1-yn-1-yl)-3-(1-amino-1,3-dihydrospiro[indene-2,4]'-piperidin]-1'-yl)pyrazine-2-carboxamide;
- (S)-3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-((3-oxoisooctanol)-5-yl)oxy)prop-1-yn-1-yl)pyrazine-2-carboxamide;
- (S)-5-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazine-2-yl)-1-phenylpent-4-yn-1-one;
- (S)-4-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazine-2-yl)-N-phenyl-3-alkynamide;
- (S)-N-(3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)benzamide;
- (S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(4-(phenylamino)butyl-1-yn-1-yl)pyrazin-2-yl)methanol;
- (S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-((3,4-dimethoxyphenyl)amino)prop-1-yn-1-yl)pyrazin-2-yl)methanol;
- (S)-4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)amino)benzamide;
- (S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-((2-methoxypyridine-4-yl)oxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;
- (S)-4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)-2-fluorobenzamide;
- (S)-5-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)isoindolin-1-one;
- (S)-6-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)-3,4-dihydroisoquinolin-1(2H)-one;
- (S)-3-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)benzonitrile;
- (S)-4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)-2-chlorobenzamide;
- (S)-4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)(methyl)amino)benzamide;
- (S)-5-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)pyridineamide;
- (S)-(4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)phenyl)dimethylphosphine oxide;
- (S)-4-((3-(5-(1-amino-6-methoxy-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)benzamide;
- (S)-2-(3-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)phenyl)acetamide;
- (S)-(3-(1-amino-1,3-dihydrospiro[inden-2,4'-piperidin]-1'-yl)-6-(3-(oxazol-2-ylAmino)prop-1-yn-1-yl)pyrazin-2-yl)methanol;
- (S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-((1-methyl-1H-pyrazol-5-yl)amino)prop-1-yn-1-yl)pyrazin-2-yl)methanol;
- (S)-4-((3-(5-(1-amino-1,3-dihydrospiro[inden-2,4'-piperidin]-1'-yl)pyrazin-2-yl)propane-2-yn-1-yl)oxy)-2-chlorobenzamide;
- (S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-((6-(trifluoromethyl)yl)pyridin-3-yl) amino)prop-1-yn-1-yl)pyrazin-2-yl)methanol;
- (S)-7-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)amino)-3,4-dihydroquinolin-2(1H)-one;
- (S)-N-(3-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxyl methyl)pyrazin-2-yl)prop-2-yn-1-yl)amino)phenyl)acetamide;
- (S)-6-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)isoindol-1-one;
- (S)-(6-(3-((1H-Indazol-5-yl)oxy)prop-1-yn-1-yl)-3-(1-amino-1,3-dihydrospiro[ indene-2,4'-piperidin]-1'-yl)pyrazin-2-yl)methanol;
- (S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-((2-(methylAmino)pyrimidin-5-yl)oxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;
- (S)-(3-(1-amino-1,3-dihydrospiro[inden-2,4'-piperidin]-1'-yl)-6-(3-((2-Aminobenzo[d]oxazol-5-yl)oxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;
- (S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-((6-(trifluoromethyl)yl)pyridin-3-yl)oxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;
- (S)-2-(4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)phenyl)acetamide;
- (S)-4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)-N-methylbenzamide;
- (S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-((2-methyl-1H-benzo[d]imidazol-5-yl)oxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;
- (S)-4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)-2-methylbenzamide;
- (S)-6-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)pyridin-3-ol;
- (S)-4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)-N-cyclopropylbenzamide;
- (S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-(4-((1-methy1)yl)-1H-pyrazol-5-yl)amino)phenoxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;
- 1-(4-((3-(5-((S)-1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxyl)methyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)phenyl)-2,2,2-trifluoroethane-1-ol;
- 1-(4-((3-(5-((S)-1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxyl)methyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)phenyl)ethane-1-ol;
- (S)-2-(4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxyl methyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)phenyl)propan-2-ol;
- (S)-3-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)amino)benzamide;
- (S)-2-(4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)-1H-pyrazol-1-yl)acetamide;
- (R)-4-((3-(5-(3-amino-3H-spiro[benzofuran-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazine-2-yl)prop-2-yn-1-yl)oxy)benzamide;
- (S)-4-((3-(5-(5-amino-5,7-dihydrospiro[cyclopenta[b]pyridin-6,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)benzamide;
- (S)-4-((3-(5-(4-amino-4,6-dihydrospiro[cyclopenta[d]thiazol-5,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)benzamide;
- (S)-4-((3-(5-(4-amino-4,6-dihydrospiro[cyclopenta[d]oxazol-5,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)benzamide;
- (S)-4-((3-(5-(4-amino-4,6-dihydro-1H-spiro[cyclopenta[d]imidazol-5,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)benzamide.
- The present invention also provides a pharmaceutical composition, which is characterized in that it comprises a therapeutically effective amount of at least one compound represented by Formula I and at least one pharmaceutically acceptable adjuvant.
- The present invention further provides a pharmaceutical composition, characterized in that the mass percentage of the therapeutically effective amount of at least one compound represented by Formula I and pharmaceutically acceptable adjuvants is 0.0001:1-10.
- The present invention provides the application of the compound represented by the structural Formula I or the pharmaceutical composition in the preparation of medicine.
- The present invention further provides the preferred technical solution of the application:
Preferably, the application is for the preparation of a medicament for treating, preventing, delaying or preventing cancer, cancer metastasis, cardiovascular disease, immune disease, fibrosis or eye disease. - Preferably, the application is in the preparation of a medicament for treating diseases mediated by SHP2. Preferably, the disease is cancer.
- Preferably, the cancer is selected from Noonan syndrome, leopard spot syndrome, juvenile myelomonocytic leukemia, neuroblastoma, melanoma, head and neck squamous cell carcinoma, acute myeloid leukemia, breast cancer, esophageal tumor , lung cancer, colon cancer, head cancer, stomach cancer, lymphoma, glioblastoma, pancreatic cancer, or a combination thereof.
- Preferably, the application is for the preparation of SHP2 inhibitors.
- The present invention also provides a method for treating and/or preventing diseases mediated by SHP2, comprising administering to a subject a therapeutically effective amount of at least any compound or pharmaceutical composition represented by structural Formula I.
- Preferably, in the above method, the SHP2-mediated disease is cancer.
- The present invention also provides a method for treating cancer, comprising administering a therapeutically effective amount of at least any one compound or pharmaceutical composition represented by structural Formula I to a treatment subject.
- Preferably, the cancer is selected from Noonan syndrome, leopard spot syndrome, juvenile myelomonocytic leukemia, neuroblastoma, melanoma, head and neck squamous cell carcinoma, acute myeloid leukemia, breast cancer, esophageal tumor , lung cancer, colon cancer, head cancer, stomach cancer, lymphoma, glioblastoma, pancreatic cancer, or a combination thereof.
- Preferably, in the above method, the treatment subject is human.
- Unless otherwise specified, the terms used in the present invention have the following meanings:
The term "alkyl" includes straight, branched or cyclic saturated alkyl groups. For example, alkyl include, but are not limited to, methyl, ethyl, propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclobutyl, n-pentyl, 3-(2-methyl)butyl, 2-pentyl, 2-methylbutyl, neopentyl, cyclopentyl, n-hexyl, 2-hexyl, 2-methylpentyl, cyclohexyl and the like. Similarly, "C1-8" in "C1-8 alkyl" refers to a linear, branched or cyclic arrangement containing 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms. - "Alkenyl" and "alkynyl" include straight chain, branched or cyclic alkenyl and alkynyl. Likewise, "C2-8 alkenyl" and "C2-8 alkynyl" refer to alkenes containing 2, 3, 4, 5, 6, 7 or 8 carbon atoms arranged in straight chain, branched chain or cyclic form radical or alkynyl.
- The term "alkoxy" refers to the oxyether forms of the aforementioned linear, branched or cyclic alkyl groups.
- The term "aryl" refers to an unsubstituted or substituted monocyclic or polycyclic aromatic group including carbon atoms. Preferably it is a 6- to 10-membered monocyclic or bicyclic aromatic group. Preferred are phenyl and naphthyl. Most preferred is phenyl.
- The term "heteroaryl" refers to a monovalent heteroatom group formed by the removal of a hydrogen atom from a carbon atom of a parent heteroaromatic ring system. Heteroaryl groups include: 5- to 7- membered aromatic, monocyclic rings, including at least one heteroatom selected from N, O or S, eg, 1 to 4 heteroatoms, or preferably 1 to 3 heteroatoms, other atoms on the ring are carbon; polyheteroaryl rings include at least one heteroatom selected from N, O or S, for example, 1 to 4 heteroatoms, or preferably 1 to 3 heteroatoms, other atoms on the ring is carbon, and at least one heteroatom is on aromatic ring; it also includes bicyclic or polycyclic rings, but at least one of the bicyclic or polycyclic rings is aromatic. Particularly preferred heteroaryl are C3-10 heteroaryl groups including, but not limited to, pyrrolyl, furyl, thienyl, pyridyl, pyranyl, pyrazolyl, pyrimidinyl, pyridazinyl, pyridyl azinyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, triazolyl, indolyl, benzofuranyl, benzothiazolyl, benzimidazolyl, benzopyrazolyl, benzoyl Triazolyl, carbazolyl, quinolinyl, isoquinolinyl, purinyl and the like.
- However, under no circumstances will heteroaryl and aryl groups intersect or contain each other. Thus, according to the above definition, if at least one all-carbon aromatic ring is fused to a heterocyclyl, a heteroaryl is obtained, not an aryl.
- "Carbocyclyl" refers to a cyclyl that is saturated or unsaturated but not aromatic. Depending on their particular level of saturation, the terms "cycloalkyl", "cycloalkenyl" or "cycloalkynyl" are used, respectively. Representative carbocyclyl include, but are not limited to, cyclopropane, cyclobutane, cyclopentane, cyclohexane or cyclohexene and the like.
- "Heterocyclyl" means a saturated or unsaturated, but non-aromatic, cyclyl in which one or more carbon atoms (and attached hydrogen atoms) may be replaced by the same or different heterocyclyl respectively atom and the corresponding attached hydrogen atom. Representative heteroatoms substituted for carbon atoms include, but are not limited to, N, P, O, S, and Si. When it is desired to describe a particular degree of saturation, the terms "heterocycloalkyl" or "heterocycloalkenyl", respectively, are used. Representative heterocyclyl include, but are not limited to, epoxy, imidazolidine, morpholine, piperazine, piperidine, pyrazolidine, pyrrolidine, quinuclidine, tetrahydrofuran or tetrahydropyran and the like. Substituent-containing heterocyclyl also include ring systems substituted with at least one oxygen-containing (=O) or oxide (-O-) substituent, such as: piperidine-nitrogen-oxide, morpholinyl-nitrogen-oxide, 1-oxo-1-thiomorpholinyl and 1 -dioxo-1 -thiomorpholinyl.
- However, under no circumstances will heterocycloalkyl and carbocyclyl cross or contain each other. Thus, according to the above definition, if at least one percarbocycle is fused to a heterocycloalkyl to form a bi-, poly- or spiro-ring, it will still be defined as a heterocycloalkyl.
- Additionally, if a heteroaryl group is fused with a heterocyclyl to form a bi-, poly- or spiro-ring, it will be defined as heterocyclyl rather than heteroaryl.
- "Halogen" means fluorine (F), chlorine (Cl), bromine (Br) or iodine (I). Preferred halogens are fluorine, chlorine and bromine.
- "Halo" means a fluoro, chloro, bromo or iodo. Preferred halo refer to fluoro and chloro.
- "Substituted" means that one or more hydrogen atoms in a group are replaced by the same or different substituents, respectively. Representative substituents include, but are not limited to, halogen, amino, hydroxyl, oxo, carbonyl, cyano, -C(O)NH2, alkyl, alkoxy, aryl, cycloalkyl, heterocyclyl, heteroaryl. In some embodiments, substituents include, but are not limited to, halogen, amino, hydroxy, cyano, methyl, -CH2OH, -C(O)NH2, -OCH3, trifluoromethyl.
- Whenever the term "alkyl" or "aryl" or its prefix root appears in the name of a substituent (eg, aralkyl, or dialkylAmino), the term "alkyl" and "aryl" should be "Definition defines a limited interpretation of the substituents. A specified number of carbon atoms (eg, C1-6) will independently represent the number of carbon atoms in an alkyl moiety or in the alkyl moiety of a larger substituent (where alkyl is the prefix root).
- "Compounds" as used herein include compounds of Formula I, and all pharmaceutically acceptable forms thereof. These pharmaceutically acceptable forms include salts, solvates, non-covalent complexes, chelates, stereoisomers (including diastereomers, enantiomers and racemates), cis-trans Isomers, isotopically labeled compounds, tautomers, prodrugs, or any mixture of all of the above.
- The "cis-trans isomer" is a stereoisomerism that exists in certain double bond compounds or cyclic compounds. The free rotation of these molecules is hindered due to the presence of double bonds or rings, resulting in two isomers that are not identical in physical or chemical properties, called cis (cis) and trans (trans) isomers, respectively.
- Unless otherwise stated, the compounds of the present invention are intended to include all such possible cis-trans isomers, including cis-configured compounds\trans-configured compounds and mixtures of cis-trans isomers in any ratio. Cis-trans isomers can be separated using conventional techniques (eg, on a Prep-HPLC column).
- The "pharmaceutically acceptable" refers to those known to be used in animal, especially in human.
- The term "composition" in the present invention includes a product containing the specified components in the specified amounts, as well as any product obtained directly or indirectly from the specified amounts of the specified components. Accordingly, pharmaceutical compositions comprising the compounds of the present invention as active ingredients and methods of preparing the compounds are the subject of the present invention.
- A "therapeutically effective amount" refers to a compound that when administered to a subject is sufficient to treat and prevent and/or inhibit at least one clinical symptom of a disease, condition, symptom, indication and/or disorder. The dose that produces an effect in the treatment of symptoms, indications, or discomfort. The specific "therapeutically effective dose" may vary depending on the compound, the route of administration, the age of the patient, the weight of the patient, the type, symptoms and severity of the disease or disorder being treated, and the like. Wherever possible, an appropriate dose will be apparent to those skilled in the art or may be determined by routine experimentation.
- The compounds provided herein may exist in the form of "pharmaceutically acceptable salts". In terms of pharmaceutical applications, the salts of the compounds provided by the present invention refer to non-toxic pharmaceutically acceptable salts. Pharmaceutically acceptable salt forms include pharmaceutically acceptable acid/anion or base/cation salts. Pharmaceutically acceptable acid/anion salts generally exist in the protonated form of the basic nitrogen with an inorganic or organic acid. Typical organic or inorganic acids include hydrochloric, hydrobromic, hydroiodic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic , tartaric acid, citric acid, α-ketoglutaric acid, hippuric acid, benzoic acid, mandelic acid, methanesulfonic acid, isethionic acid, benzenesulfonic acid, oxalic acid, pamoic acid, 2-naphthalenesulfonic acid, p-toluenesulfonic acid acid, cyclohexylamine sulfonic acid, salicylic acid, saccharinic acid or trifluoroacetic acid. Pharmaceutically acceptable base/cation salts including, but not limited to, aluminum, calcium, chloroprocaine, choline, diethanolamine, ethylenediamine, lithium, magnesium, potassium, sodium salt and zinc salts.
- Prodrugs of the compounds of the present invention are included within the scope of the present invention. Typically, the prodrugs are functional derivatives that are readily converted in vivo to the desired compound. Accordingly, the term "administration" in reference to the methods of treatment provided by the present invention includes the administration of a compound disclosed herein, or, although not expressly disclosed, but capable of being converted in vivo to a compound disclosed herein after administration to a subject to treat the various described disease. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described in, for example, Design of Prodrugs (Design of Prodrugs, ed. H. Bundgaard, Elsevier, 1985).
- Obviously, the definition of any substituent or position-specific variable in one molecule is independent of the definition of any substituent or position-specific variable in other molecules. It is easy to understand that the compounds in the present invention can select suitable substituents or substitution forms according to the prior art in this subject, so as to provide chemical stability and be easily prepared and synthesized by the methods described in the prior art in this subject or in the present invention.
- When the compounds of Formula I and pharmaceutically acceptable salts thereof are in the form of solvates or polymorphs, the present invention includes any possible solvates and polymorphs. The type of solvent that forms the solvate is not particularly limited as long as the solvent is pharmacologically acceptable. For example, water, ethanol, propanol, acetone and similar solvents can be used.
- The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids. When the compounds provided herein are acids, their corresponding salts can be prepared from pharmaceutically acceptable non-toxic base, including inorganic and organic base. Salts derived from inorganic base include aluminum, ammonium, calcium, copper (ic and ous), iron, ferrous, lithium, magnesium, manganese (ic and ous), potassium, sodium, zinc and the like. In particular, ammonium, calcium, magnesium, potassium and sodium salts are preferred. Nontoxic organic bases that can be derivatized into pharmaceutically acceptable salts include primary, secondary, and tertiary amines, as well as cyclic amines and substituted amines, such as naturally occurring and synthetic substituted amines. Other pharmaceutically acceptable nontoxic organic bases capable of forming salts, including ion exchange resins and arginine, betaine, caffeine, choline, N',N'-dibenzylethylenediamine, diethylamine, 2-DiethylAminoethanol, 2-DimethylAminoethanol, Ethanolamine, Ethylenediamine, N-Ethylmorpholine, N-Ethylpiperidine, Reduced Glucosamine, Glucosamine, Histidine, Haramine, Isopropylamine , lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resin, procaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, etc.
- When the compounds provided by the present invention are base, their corresponding salts can be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include, for example, acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, isethionic acid, formic acid, fumaric acid, gluconic acid, glutamic acid, hydrobromic acid, hydrochloric acid, lactic acid, maleic acid, malic acid, mandelic acid, alpha-ketoglutaric acid, hippuric acid, methanesulfonic acid, mucic acid, nitric acid, pamoic acid, pantothenic acid, phosphoric acid, succinic acid, sulfuric acid, tartaric acid, p-toluenesulfonic acid acid etc. Preferably, malic acid, citric acid, hydrobromic acid, hydrochloric acid, methanesulfonic acid, maleic acid, phosphoric acid, sulfuric acid and tartaric acid. More preferably, phosphoric acid, hydrochloric acid and malic acid. Since the compound of Formula I will be used as a pharmaceutical, it is preferred to use a substantially pure form, for example, at least 60% pure, more suitably at least 75% pure, particularly suitably at least 98% pure (% is by weight).
- The pharmaceutical composition provided by the present invention includes the compound represented by Formula I (or a pharmaceutically acceptable salt thereof) as an active component, a pharmaceutically acceptable excipient and other optional therapeutic components or adjuvants. Although the most suitable mode of administration of the active ingredient in any given situation will depend on the particular subject being administered, the nature of the subject and the severity of the condition, the pharmaceutical compositions of the present invention include oral, rectal, topical and pharmaceutical compositions for parenteral (including subcutaneous, intramuscular, intravenous) administration. The pharmaceutical compositions of the present invention may conveniently be presented in unit dosage form and prepared by any of the methods of preparation well known in the art of pharmacy.
- In fact, according to the conventional drug mixing technology, the compound represented by the Formula I of the present invention, or the prodrug, or the metabolite, or the pharmaceutically acceptable salt, can be combined with the drug as the active component, and mixed with the drug carrier to form a drug combination thing. The pharmaceutical carrier can take a wide variety of forms, depending on the intended mode of administration, eg, oral or injection (including intravenous). Accordingly, the pharmaceutical compositions of the present invention may take the form of discrete units suitable for oral administration, such as capsules, cachets or tablets containing a predetermined dose of the active ingredient. Further, the pharmaceutical compositions of the present invention may take the form of powders, granules, solutions, aqueous suspensions, non-aqueous liquids, oil-in-water emulsions, or water-in-oil emulsions. In addition, in addition to the common dosage forms mentioned above, the compound of Formula I or a pharmaceutically acceptable salt thereof can also be administered by means of controlled release and/or delivery device. The pharmaceutical composition of the present invention can be prepared by any pharmaceutical method. In general, such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more essential ingredients. In general, the pharmaceutical compositions are prepared by homogeneous intimate admixture of the active ingredient with liquid carriers or finely divided solid carriers, or a mixture of both. In addition, the product can be easily prepared to the desired appearance.
- Therefore, the pharmaceutical composition of the present invention comprises a pharmaceutically acceptable carrier and a compound represented by Formula I, or a pharmaceutically acceptable salt thereof. The compound of Formula I, or a pharmaceutically acceptable salt thereof, and one or more other compounds having therapeutic activity in combination are also included in the pharmaceutical composition of the present invention.
- The pharmaceutical carrier employed in the present invention can be, for example, solid carrier, liquid carrier or gaseous carrier. Examples of solid carriers include, lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid, mannitol, sorbitol, microcrystalline cellulose, inorganic salts, starch, pregelatinized starch, powdered sugar, dextrin, etc. Examples of liquid carriers include syrup, peanut oil, olive oil and water. Examples of gaseous carriers include carbon dioxide and nitrogen. In the preparation of pharmaceutical oral Formulations, any convenient pharmaceutical medium may be employed. For example, water, glycols, oils, alcohols, flavor enhancers, preservatives, colorants, etc. can be used in oral liquid preparations such as suspensions, elixirs and solutions; and carriers such as starches, sugars, Microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, etc. can be used for oral solid preparations such as powders, capsules and tablets. For ease of administration, tablets and capsules are preferred for oral Formulations. Alternatively, the tablet coating can use standard aqueous or non-aqueous Formulation techniques.
- Tablets containing the compounds or pharmaceutical compositions of the present invention may be prepared by mixing, compressing or molding, optionally with one or more accessory ingredients or adjuvants. Compressed tablets may be prepared by compressing the active ingredient in a free-flowing form such as powder or granules with a lubricant, inert diluent, surface-active or dispersing agent, by compression in a suitable machine. Molded tablets may be made by wetting the powdered compound or pharmaceutical composition with an inert liquid diluent and molding in a suitable machine. Preferably, each tablet contains about 0.01 mg to 5 g of active ingredient and each cachet or capsule contains about 0.1 mg to 0.5 g of active ingredient. For example, a dosage form intended for oral administration to humans contains from about 0.1 mg to about 0.5 g of the active ingredient in admixture with suitable and conveniently metered adjunct materials ranging from about 5% to 99.99% of the total pharmaceutical composition . Unit dosage forms generally contain from about 0.1 mg to about 0.5 g of the active ingredient, typically 0.1 mg, 0.2 mg, 0.5 mg, 1 mg, 2 mg, 2.5 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg mg, 200 mg, 300 mg, 400 mg or 500 mg.
- The pharmaceutical composition suitable for parenteral administration provided by the present invention can be prepared as an aqueous solution or suspension by adding the active ingredient to water. Suitable surfactants such as sodium lauryl sulfate, polysorbate-80 (Tween-80), polyoxyethylene hydrogenated castor oil, poloxamers may be included. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, preservatives may also be included in the pharmaceutical compositions of the present invention to prevent the growth of harmful microorganisms.
- The present invention provides pharmaceutical compositions suitable for injectable use, including sterile aqueous solutions or dispersions. Further, the above-mentioned pharmaceutical compositions can be prepared in the form of sterile powders that can be used for the extemporaneous preparation of sterile injectable solutions. In any event, the final injectable form must be sterile and, for ease of injection, must be readily flowable. Furthermore, the pharmaceutical compositions must be stable during manufacture and storage. Therefore, preservation against contamination by microorganisms such as bacteria and fungi is preferred. The carrier can be a solvent or dispersion medium, for example, water, ethanol, polyol (eg, glycerol, propylene glycol, liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.
- The pharmaceutical compositions provided by the present invention may be in a form suitable for topical administration, for example, aerosol, cream, ointment, lotion, dusting powder, or other similar dosage forms. Further, the pharmaceutical composition provided by the present invention can be in a form suitable for use in a transdermal drug delivery device. These formulations can be prepared by conventional processing methods using the compound represented by Formula I of the present invention, or a pharmaceutically acceptable salt thereof. As an example, a cream or ointment is prepared by adding a hydrophilic material and water to the above compound (the total amount of both being about 5 wt % to 50 wt % of the compound) to produce a cream or ointment having the desired consistency.
- The pharmaceutical composition provided by the present invention can be prepared in form suitable for rectal administration with solid as carrier. Suppositories of admixture to form unit doses are the most preferred dosage forms. Suitable excipients include cocoa butter and other materials commonly used in the art. Suppositories can be conveniently prepared by first mixing the pharmaceutical composition with softened or melted excipients, then cooling and moulding.
- In addition to the above-mentioned carrier components, the above-mentioned pharmaceutical preparations may also include, as appropriate, one or more additional adjuvant components, such as diluents, buffers, flavoring agents, binders, surfactants, enhancers Thickeners, lubricants, preservatives (including antioxidants), etc. Further, other adjuvants may also include osmotic enhancers that adjust the isotonic pressure of the drug and blood. The pharmaceutical composition containing the compound represented by Formula I, or a pharmaceutically acceptable salt thereof, can also be prepared in the form of a powder or a concentrated solution.
- In order to make the above content clearer and clearer, the present invention will further illustrate the technical solutions of the present invention with the following examples. The following examples are only used to illustrate the specific embodiments of the present invention, so that those skilled in the art can understand the present invention, but are not intended to limit the protection scope of the present invention. In the specific embodiments of the present invention, the technical means or methods that are not specifically described are conventional technical means or methods in the field.
- All parts and percentages herein are by weight and all temperatures are in degrees Celsius unless otherwise indicated.
- The following abbreviations are used in the examples:
- DCM: dichloromethane;
- DIEA: N,N-diisopropylethylamine;
- DIBAL-H: diisobutylaluminum hydride;
- DME: ethylene glycol dimethyl ether
- DMF: N,N-dimethylformamide;
- DMSO: dimethyl sulfoxide;
- EtOAc: ethyl acetate;
- h, hr or hrs: hours;
- LC-MS or LC-MS: liquid chromatography-mass spectrometry;
- MeCN: acetonitrile;
- MeOH: methanol;
- min or mins: minutes;
- NEt3: triethylamine;
- Prep-HPLC: Preparative high performance liquid chromatography;
- PdCl2(PPh3)2: bistriphenylphosphonium palladium dichloride;
- Pd(PPh3)4: tetrakis (triphenylphosphine) palladium;
- PE: petroleum ether;
- rt, r.t. or RT: room temperature;
- TFA: trifluoroacetic acid;
- THF: tetrahydrofuran;
- Ti(OEt)4: tetraethyl titanate;
- TLC: Thin Layer Chromatography.
-
- Under nitrogen protection, 25.00 g of compound M1-1 was dissolved in 200 mL of DMF, cooled to 0 °C, 22.70 g of NaH was added in batches, kept at 0 °C for 1 hr, and then 54.96 g of compound M6-2 was slowly added dropwise to the reaction solution, after dripping, react at 0 °C for 1 hr, and heat up to 60 °C and continue to react for 1 hr. The reaction solution was cooled to 0 °C, quenched with 500 mL of ice water, extracted with EtOAc (500 mL×3), the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was filtered through a column Chromatographic purification yielded 29.00 g of brown oil M1-3.
- 29.00g of compound M1-3 was dissolved in 50 mL of Ti(OEt)4, 34.99g of compound M1-4 was added, and then heated to 90 °C for 12 hrs. TCL detected the completion of the reaction, poured the reaction solution into 500 mL of ice water, added 300 mL of EtOAc, stirred for 1 hr, extracted with EtOAc (300 mL×3), combined the organic phases, and washed the organic phase with saturated brine (100 mL×4), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain 39.00 g of crude compound M1-5 as a brown oil.
- Under nitrogen protection, 48.00g of compound M1-5 was dissolved in 500 mL of anhydrous THF, cooled to -20 °C, 6.73g of NaHB4 was slowly added, and then the temperature was naturally raised to RT and stirred for 2 hrs. After the reaction was completed, the reaction solution was cooled to 0 °C, quenched with 300 mL of water, extracted with EtOAc (300 mL×3), the organic phases were combined, the organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. Column chromatography gave 25.40 g of compound M1-6 as brown oil.
- 10.00 g of compound M1-6 was dissolved in 100 mL of DCM solution, 28.04 g of TFA solution was added dropwise, and then reacted at RT for 1 hr. The reaction solution was cooled to 0 °C, quenched with 100 mL of saturated NaHCO3 aqueous solution, extracted with EtOAc:THF=3:1 (100 mL×3), the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and reduced pressure. Concentrated to obtain 7.64 g of brown solid, the crude product of compound M1-7, which was directly used in the next reaction.
- 1H NMR (500 MHz, DMSO-d6) δ 7.26-7.21 (m, 4H), 5.80 (d, J = 10.5 Hz, 1H), 4.43 (d, J = 10.5 Hz, 1H), 3.17-3.15 (m, 2H), 3.08 (d, J = 15.5 Hz, 1H), 2.98-2.88 (m, 2H), 2.69 (d, J = 15.5 Hz, 1H), 2.04-1.99 (m, 1H), 1.80-1.75 (m , 1H), 1.62-1.59 (m, 1H), 1.35(m, 1H), 1.22(s, 9H).
- 1.29 g of methyl 3,6-dibromopyrazine-2-carboxylate and 1.60 g of compound M1-7 were dissolved in 20 mL of tetrahydrofuran, 1.12 g of DIEA was added dropwise, and the reaction was stirred at 60 °C for 12 hours. TLC detected that the reaction was complete, concentrated under reduced pressure, added 50 mL of water, and extracted with EtOAc (50 mL×3).
- Under nitrogen protection, 1.00 g of compound M1-8 was dissolved in 30 mL of anhydrous dichloromethane, the temperature was lowered to -78 °C, and a solution of DIBAL-H (1 M, 9.6 mL) in n-hexane was added dropwise. The reaction was stirred at -78 °C for 1 hour. The temperature was slowly raised to -40 °C, and the reaction was continued for 2 hours. TLC detected that the reaction of the raw materials was complete. At 0 °C, 0.4 mL of water was slowly added dropwise, then an aqueous sodium hydroxide solution (15%, 0.4 mL) was added dropwise, and 1 mL of water was added. Warm to room temperature and stir for 15 minutes. It was dried by adding sodium sulfate, stirred for ten minutes and filtered. The filtrate was concentrated and purified by column chromatography to obtain 0.40 g of compound M1 and 0.11 g of compound M2.
-
-
- 2.00 g of compound M14-1 was dissolved in 40 mL of THF, NaOH (30 mL, 1N) was added, and then RT was reacted for 2 hrs. TLC detected that the reaction was complete, the reaction solution was poured into 100 mL of water, adjusted to pH 4-5 with 6N HCl, extracted with EtOAc (100 mL×4), the organic phases were combined, washed with 50 mL of saturated NaCl, anhydrous sodium sulfate. It was dried and concentrated under reduced pressure, and the residue was slurried with n-hexane to obtain 1.67 g of pale yellow solid M14-2.
- 1.28g of compound M14-2 was dissolved in 13 mL of DMF, the temperature was lowered to 0 °C, 3.26g of Cs2CO3 was added, and then 2.13g of CH3I was added dropwise. After dropping, the temperature was raised to 10 °C and reacted for 1hr. TLC detected that the reaction was complete, the reaction solution was cooled to 0 °C, 20 mL of EtOAc and 20 mL of water were added, the organic phase was separated, the aqueous phase was continuously extracted with 20 mL of EtOAc, the organic phases were combined, washed with saturated NaCl (5×4 mL), and anhydrous. It was dried over sodium sulfate, concentrated under reduced pressure, and the residue was purified by column chromatography to obtain 635 mg of compound M14-3.
- 359 mg of compound M14-3 and 448 mg of compound M1-7 were dissolved in 6 mL of DMAc, 860 mg of DIPEA was added, nitrogen was replaced three times, and the reaction was microwaved at 120 °C for 1 hr. TLC detected that the reaction was complete, the reaction solution was cooled to room temperature, 20 mL of water was added, and EtOAc (20 mL×3) was added for extraction. The organic phases were combined, washed with saturated NaCl (5 mL×4), dried over anhydrous sodium sulfate, and concentrated under reduced pressure, the residue was purified by column chromatography to obtain 290 mg of compound M14.
-
- 5.0 g of compound M15-SM was dissolved in 50 mL of methanol, ammonia water (60 mL, 25%) was added, and then RT was reacted for 2.5 hours. TLC detected that the reaction was complete, concentrated under reduced pressure (spin off most of the methanol), then added MeOH (10 mL), stirred for 5 minutes, filtered, washed the filter cake with MeOH (3 mL), and dried the filter cake to obtain 4.75g of solid, the compound M15-1.
- 3.5 g of compound M15-1, 3.82 g of compound M1-7, 5.04 g of DIPEA were dissolved in 40 mL of THF, and the reaction was stirred at 55 °C for 12 hrs. TLC detected that the reaction was complete, the reaction solution was filtered, the filter cake was washed with DCM (40 mL), the filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography to obtain 5.66 g of compound M15 as a white solid.
-
- Dissolve 673 mg of 3,4-dimethoxybenzyl alcohol in 30 mL of anhydrous THF, add 385 mg of sodium tert-butoxide, cool the reaction solution to -10 °C, add 1.0g of compound M16-1, and heat the reaction at -10 °C for 30 minute. At low temperature, water (50 mL) was added to quench the reaction, extracted with EA (50 mL), washed with saturated NaCl (10 mL*2), the organic phase was dried over anhydrous sodium sulfate, and purified by column chromatography to obtain 695 mg of compound M16-2 .
- 200 mg of compound M16-2 and 196 mg of compound M1-7 were dissolved in 5 mL of dioxane, 149 mg of triethylamine was added, and the reaction was heated at 75 °C for 2 hours. TLC detected that the reaction was complete, the reaction solution was spun dry, and purified by column chromatography to obtain 186 mg of compound M16.
-
- 10.00 g of compound M30-1 and 7.59 g of compound M30-2 were dissolved in 170 mL of chloroform, 350 mg of iodine was added, and the reaction was stirred at room temperature for 24 hours. TLC detected that the reaction was complete, the compound was poured into aqueous sodium thiosulfate solution (100 mL, 0.4 mol/L), then aqueous sodium hydroxide solution (70 mL, 40%) was added, and then extracted with chloroform (150 mL×2). The organic layers were combined, dried with sodium sulfate, and desolvated, and recrystallized from dichloromethane/n-hexane to obtain 8.77 g of compound M30-3.
- 8.77 g of compound M30-3 was dissolved in 300 mL of anhydrous tetrahydrofuran, cooled to -30 °C, n-butyllithium (2.5 M, 16 mL) in n-hexane was added dropwise, and the mixture was stirred for 1 hour. Subsequently, 8.15 g of compound M30-4 was dissolved in 30 mL of tetrahydrofuran and slowly added dropwise to the reaction solution. After the dropwise addition, the temperature was raised to -10 °C and the reaction was continued for 2.5 hours. The reaction solution was quenched with 200 mL of saturated brine, extracted with EtOAc (300 mL×2), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography to obtain 11.06 g of compound M30-5.
- 11.06 g of compound M30-5 was dissolved in a mixed solution of water (40 mL) and dichloromethane (200 mL), followed by 3.17 g of pyridine, 12.83 g of compound M30-6 and 0.86 g of tetrabutylammonium bromide in this order. Stir at room temperature for 24 hours. The reaction solution was quenched with 100 mL of saturated brine, extracted with DCM (100 mL×3), the organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography to obtain 5.46 g of compound M30-7.
- 5.46 g of compound M30-7 and 2.84 g of potassium tert-butoxide were dissolved in 85 mL of anhydrous tetrahydrofuran, and after 3 times of nitrogen replacement, the reaction was microwaved at 70 °C for 5 minutes. The solvent was removed under reduced pressure, 100 mL of saturated brine was added, and extracted with EtOAc (100 mL×2). The organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography to obtain 2.91 g of compound M30-8.
- Dissolve 1.30 g of compound M30-8 and 1.56 g of (R)-(+)-tert-butylsulfinamide in a mixed solution of tetraethyl titanate (10 mL) and anhydrous tetrahydrofuran (2 mL), and replace with nitrogen. After 3 times, react at 90 °C for 8 hours. Heating was stopped, the reaction solution was poured into 200 mL of ice water, 150 mL of ethyl acetate was added, and the mixture was stirred for 1 hour. The filter residue was removed by filtration. The filtrate was extracted with ethyl acetate (100 mL×2), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain 1.90 g of compound M30-9.
- 1.30 g of compound M30-9 was dissolved in 25 mL of anhydrous tetrahydrofuran, 344 mg of sodium borohydride was added in batches at -20 °C, slowly warmed to room temperature, and stirred at room temperature for 3 hours. At 0 °C, 100 mL of water was added, followed by extraction with EtOAc (80 mL×3). The organic phases were combined, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography to obtain 0.94 g of compound M30-10.
- 0.94 g of compound M30-10 was dissolved in 10 mL of dichloromethane, 2.62 g of trifluoroacetic acid was added dropwise, and the mixture was stirred at room temperature for an hour. The reaction solution was lowered to 0 °C, and then a saturated aqueous sodium bicarbonate solution was added to adjust the pH to weakly alkaline. Extracted with a mixed solution of EtOAc:THF=1:1 (60 mL×4), combined the organic phases, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. 692 mg of compound M30 were obtained.
-
- 100 mg of compound M1, 40 mg of compound A01-1 (phenyl propargyl ether), 14 mg of PdCl2(PPh3)2, 2 mg of CuI were dissolved in DMF (3 mL) and NEt3 (0.5 mL), after nitrogen replacement, 60 °C reaction 2.5 hours. LC-MS and TLC detected that the reaction was complete, 10 mL of ethyl acetate was added, the insolubles were filtered off, the filtrate was dispersed in 20 mL of water, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by preparative plate to obtain 40 mg gray solid compound A01-1.
- 40 mg of compound A01-1 was dissolved in 2.5 mL of dioxane and 0.5 mL of MeOH, 2N HCl (0.1 mL, methanol solution) was added, and the reaction was stirred at RT for 1 hour. LC-MS and TLC detected that the reaction was complete, and the reaction solution was concentrated under reduced pressure. The residue was dissolved in H2O (1.0 mL), the solution was adjusted to pH=8 with saturated NaHCO3, extracted with dichloromethane (3×3 mL), the organic phase was dried and concentrated in vacuo, and purified by preparative plate to obtain 19 mg of off-white solid compound A01.
[M+H+]=441.4. - A01: 1H NMR (500 MHz, DMSO-d6) δ 8.22 (s, 1H), 7.35-7.30 (m, 3H), 7.19-7.15 (m, 3H), 7.05-7.04 (m, 2H), 7.00-6.97 (m, 1H), 5.44 (t, J = 6.0 Hz, 1H), 5.08 (s, 2H), 4.46 (d, J = 6.0 Hz, 2H), 3.87 (s, 1H), 3.84-3.76 (m, 2H), 3.16 -3.10 (m, 2H), 3.04 (d, J = 15.6 Hz, 1H), 2.62 (d, J = 15.6 Hz, 1H), 1.92-1.85 (m, 1H), 1.88-1.73 (m , 1H), 1.78-1.72 (m, 1H), 1.14-1.12 (m, 1H).
-
- Dissolve 0.18 g m-methoxyphenol and 0.80 g potassium carbonate in acetone (5 mL), heat at 60 °C for 0.5 h, add 0.23 g bromopropyne, and continue stirring for 2 h. TLC detected that the reaction was complete, filtered, concentrated the filtrate, and purified the crude product by column chromatography to obtain 164 mg of light yellow transparent oil, namely compound A02-1.
- 100 mg of compound M1, 99 mg of compound A02-1, 7.1 mg of PdCl2(PPh3)2, and 1.9 mg of CuI were dissolved in THF (2 mL) and NEt3 (0.2 mL), and after nitrogen replacement, the reaction was carried out at 60 °C for 3 hours. LC-MS and TLC detected that the reaction was complete, 10 mL of ethyl acetate was added, 20 mL of water was added to disperse, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by column chromatography to obtain 103 mg of pale yellow solid. Namely compound A02-2.
- 103 mg of compound A02-2 was dissolved in 5 mL of dioxane and 1 mL of EtOH, 2N HCl (134 µL, ethyl acetate solution) was added, and the reaction was stirred at RT for 0.5 h. LC-MS and TLC detected that the reaction was complete, and the reaction solution was concentrated under reduced pressure. The residue was dissolved in H2O (1.0 mL), the solution was adjusted to pH=8 with saturated NaHCO3, extracted with dichloromethane (3×3 mL), the organic phase was dried and concentrated in vacuo, and purified by preparative plate to obtain 25.4 mg of off-white solid compound A02.
- [M+H+]=471.3
- A02: 1H NMR (500 MHz, DMSO-d6 ) δ 8.21 (s, 1H), 7.30 (d, J = 6.7 Hz, 1H), 7.22 (t, J = 8.2 Hz, 1H), 7.19-7.11 (m, 3H), 6.65-6.54 (m, 3H), 5.42 (t, J = 5.9 Hz, 1H), 5.06 (s, 2H), 4.47 (d, J = 5.9 Hz, 2H), 3.84 (s, 1H), 3.81-3.75 (m, 2H), 3.74 (s, 3H), 3.19-3.06 (m, 2H), 3.03 (d, J = 15.5 Hz, 1H), 2.57 (d, J = 15.5 Hz, 1H), 1.91-1.81 (m, 1H), 1.81-1.71 (m, 1H), 1.55-1.48 (m, 1H), 1.14-1.08 (m, 1H).
-
- 1.00 g of m-nitrophenol and 1.49 g of potassium carbonate were dissolved in DMF (10 mL), reacted at room temperature for 0.5 hour, 1.03 g of bromopropyne was added, and stirring was continued for 2 hours. TLC detected the completion of the reaction, added water (20 mL), extracted with ethyl acetate (3 × 15 mL), combined the organic phases, washed with saturated brine successively, dried over anhydrous sodium sulfate, filtered, concentrated the filtrate, and purified the crude product by column chromatography 1.10 g of brownish-yellow liquid was obtained, namely compound A03-1.
- Dissolve 1.10g A03-1, 1.30g iron powder, and 2.08g ammonium chloride in ethanol/water (8 mL/8 mL), and react at 80 °C for 1 hour. TLC detected that the reaction was complete, the reaction solution was cooled to room temperature, filtered, the ethanol in the filtrate was removed by spin, the residue was extracted with ethyl acetate (3 × 10 mL), the combined organic phases were dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and the crude product was Purified by column chromatography to obtain 900 mg of brown-red liquid, namely compound A03-2.
- 100 mg of compound M1, 45 mg of compound A03-2, 7.1 mg of PdC12(PPh3)2, 1.9 mg of CuI were dissolved in DMF (2 mL) and NEt3 (0.2 mL), and after nitrogen replacement, the reaction was performed at 60 °C for 18 hours. LC-MS and TLC detected the completion of the reaction, added 10 mL of ethyl acetate, dispersed in 10 mL of water, washed the organic phase with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by column chromatography to obtain 76 mg of pale yellow solid, namely compound A03-3.
- 76 mg of compound A03-3 was dissolved in 2 mL of methanol, 2N HCl (200 µL, ethyl acetate solution) was added, and the reaction was stirred at RT for 0.5 h. LC-MS and TLC detected that the reaction was complete, and the reaction solution was concentrated under reduced pressure. The residue was dissolved in H2O (1.0 mL), the solution was adjusted to pH=8 with saturated NaHCO3, extracted with dichloromethane (3×3 mL), the organic phase was dried and concentrated in vacuo, and purified by preparative plate to obtain 17 mg of pale yellow solid, compound A03.
- [M+H+]=456.3.
- 1H NMR (500 MHz, DMSO-d6) δ 8.22 (s, 1H), 7.30 (d, J = 6.5 Hz, 1H), 7.18-7.15 (m, 3H), 6.93 (t, J = 8.0 Hz, 1H) , 6.22-6.17 (m, 3H), 5.43 (t, J = 6.0 Hz, 1H), 5.10 (s, 2H), 4.94 (s, 2H) , 4.47 (d, J = 6.0 Hz, 2H), 3.86- 3.76 (m, 3H), 3.16-3.09 (m, 2H), 3.03 (d, J = 15.5 Hz, 1H), 2.60 (d, J = 15.5 Hz, 1H), 1.89-1.84 (m, 1H), 1.79 -1.73 (m, 1H), 1.53-1.50 (m, 1H), 1.12-1.10 (m, 1H).
-
- 200 mg of A03-2 and 159 mg of acetic anhydride were dissolved in THF (5 mL) and reacted at room temperature for 0.5 h. TLC detected the completion of the reaction, added water (10 mL), extracted with ethyl acetate (3 × 10 mL), combined the organic phases, washed with saturated brine successively, dried over anhydrous sodium sulfate, filtered, concentrated the filtrate, and purified the crude product by column chromatography 200 mg of brownish-yellow solid were obtained, namely compound A04-1.
- 260 mg of compound M1, 150 mg of compound A04-2, 18.60 mg of PdCl2(PPh3)2, 5.0 mg of CuI were dissolved in DMF (2 mL) and NEt3 (0.4 mL), and after nitrogen replacement, the reaction was carried out at 60 °C for 18 hours. LC-MS and TLC detected that the reaction was complete, 20 mL of ethyl acetate was added, dispersed in 15 mL of water, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by column chromatography to obtain 150 mg of pale yellow solid. Namely compound A04-2.
- 44 mg of compound A04-2 was dissolved in 2 mL of methanol, 2N HCl (200 µL, ethyl acetate solution) was added, and the reaction was stirred at RT for 0.5 h. LC-MS and TLC detected that the reaction was complete, and the reaction solution was concentrated under reduced pressure. The residue was dissolved in H2O (1.0 mL), the solution was adjusted to pH=8 with saturated NaHCO3, extracted with dichloromethane (3×3 mL), the organic phase was dried and concentrated in vacuo, and purified by preparative plate to obtain 14.8 mg of pale yellow solid compound A04.
- [M+H+]=498.3.
- 1H NMR (500 MHz, DMSO-d6) δ9.95 (s, 1H), 8.23 (s, 1H), 7.38-7.37 (m, 1H), 7.30 (d, J = 6.5 Hz, 1H), 7.23 (t , J = 8.0 Hz, 1H), 7.18-7.14 (m, 4H), 6.74-6.72 (m, 1H), 5.42 (t, J = 6.0 Hz, 1H), 5.03 (s, 2H), 4.47 (d, J = 6.0 Hz, 2H), 3.84-3.77 (m, 3H), 3.14-3.07 (m, 2H), 3.03 (d, J = 15.5 Hz, 1H), 2.60 (d, J = 15.5 Hz, 1H), 2.03 (s, 3H), 1.89-1.83 (m, 1H), 1.79-1.74 (m, 1H), 1.53-1.50 (m, 1H), 1.15-1.10 (m, 1H).
-
- Under nitrogen protection, 1.00 g of m-methoxythiophenol, 1.02 g of bromopropyne and 1.48 g of potassium carbonate were dissolved in DMF (10 mL) and reacted at room temperature for 2 hours. TLC detected that the reaction was complete, filtered, concentrated the filtrate, and purified the crude product by column chromatography to obtain 840 mg of colorless and transparent oil A06-1.
- 150 mg of compound M1, 49 mg of compound A06-1, 6.4 mg of PdCl2(PPh3)2, 3.5 mg of CuI, and 4.8 mg of PPh3 were dissolved in DMF (2 mL) and NEt3 (0.5 mL), and the reaction was carried out at 60 °C after nitrogen replacement 2.5 hours. LC-MS and TLC detected that the reaction was complete, 10 mL of ethyl acetate was added, insolubles were filtered off, the filtrate was dispersed in 20 mL of water, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by column chromatography to obtain 35 mg of pale yellow solid, namely compound A06-2.
- 35 mg of compound A06-2 was dissolved in 2 mL of dioxane and 0.5 mL of MeOH, 2 M HCl (50 µL, ethyl acetate solution) was added, and the reaction was stirred at RT for 1 hour. LC-MS and TLC detected that the reaction was complete, and the reaction solution was concentrated under reduced pressure. The residue was dissolved in H2O (1.0 mL), the solution was adjusted to pH=8 with saturated NaHCO3, extracted with dichloromethane (3×3 mL), the organic phase was dried and concentrated in vacuo, and purified by preparative plate to obtain 5.1 mg of yellow solid compound A06.
- [M+H+]=487.31.
- 1H NMR (500 MHz, DMSO-d6) δ 8.11 (s, 1H), 7.32 (d, J = 6.4 Hz, 1H), 7.28 (t, J = 7.9 Hz, 1H), 7.19-7.14 (m, 3H) , 7.06-6.98 (m, 2H), 6.83-6.80 (m, 1H), 4.45 (s, 2H), 4.17 (s, 2H), 3.89 (s, 1H), 3.79-3.73 (m, 5H), 3.13 -3.02 (m, 3H), 2.63 (d, J = 15.6 Hz, 1H), 1.89-1.85 (m, 1H), 1.79-17.3 (m, 1H), 1.52-1.49 (m, 1H), 1.17-1.13 (m, 1H).
-
- Dissolve 0.50 g of aniline and 0.74 g of potassium carbonate in DMF (5 mL), react at room temperature for 0.5 hour, add 0.70 g of bromopropyne, and continue stirring for 2 hours. TLC detected the completion of the reaction, added water (15 mL), extracted with ethyl acetate (3 × 10 mL), combined the organic phases, washed with saturated brine successively, dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and the crude product was purified by column chromatography 300 mg of pale yellow transparent liquid was obtained, namely compound A07-1.
- 100 mg of compound M1, 35 mg of compound A07-1, 7.1 mg of PdCl2(PPh3)2, 1.9 mg of CuI were dissolved in DMF (2 mL) and NEt3 (0.2 mL), and after nitrogen replacement, the reaction was performed at 60 °C for 3 hours. LC-MS and TLC detected that the reaction was complete, 10 mL of ethyl acetate was added, 10 mL of water dispersed, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by column chromatography to obtain 70 mg of pale yellow solid. Namely compound A07-2.
- 70 mg of compound A07-2 was dissolved in 2 mL of methanol, 2N HCl (200 µL, ethyl acetate solution) was added, and the reaction was stirred at RT for 0.5 h. LC-MS and TLC detected that the reaction was complete, and the reaction solution was concentrated under reduced pressure. The residue was dissolved in H2O (1.0 mL), the solution was adjusted to pH=8 with saturated NaHCO3, extracted with dichloromethane (3×3 mL), the organic phase was dried and concentrated in vacuo, and purified by preparative plate to obtain 15.3 mg of pale yellow solid, compound A07.
- [M+H+]=440.3.
- 1H NMR (500 MHz, DMSO-d6) δ 8.14 (s, 1H), 7.30 (d, J = 6.5 Hz, 1H), 7.18-7.11 (m, 5H), 6.69 (d, J = 8.0 Hz, 2H) , 6.61 (t, J = 7.5 Hz, 1H), 6.09 (t, J = 6.0 Hz, 1H), 5.40 (t, J = 6.0 Hz, 1H), 4.44 (d, J = 6.0 Hz, 2H), 4.15 (d, J = 6.5 Hz, 2H), 3.84 (s, 1H), 3.77-3.70 (m, 2H), 3.13-3.06 (m, 2H), 3.02 (d, J = 15.5 Hz, 1H), 2.59 (d, J = 15.5 Hz, 1H), 1.89-1.83 (m, 1H), 1.79-1.73 (m, 1H), 1.52-1.48 (m, 1H), 1.12-1.09 (m, 1H).
-
- Under nitrogen protection, 1.00 g of acetAminophen, 1.2 g of bromopropyne and 1.37 g of potassium carbonate were dissolved in DMF (10 mL) and reacted at room temperature for 2 hours. TLC detected that the reaction was complete, filtered, concentrated the filtrate, and purified the crude product by column chromatography to obtain 935 mg of white solid A08-1.
- 150 mg of compound M1, 69 mg of compound A08-1, 6.4 mg of PdCl2(PPh3)2, 3.5 mg of CuI, and 4.8 mg of PPh3 were dissolved in DMF (2 mL) and NEt3 (0.5 mL), and the reaction was carried out at 60 °C after nitrogen replacement 8 hours. LC-MS and TLC detected that the reaction was complete, 10 mL of ethyl acetate was added, insolubles were filtered off, the filtrate was dispersed in 20 mL of water, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by column chromatography to obtain 166 mg of pale yellow solid, namely compound A08-2.
- 166 mg of compound A08-2 was dissolved in 2 mL of dioxane and 0.5 mL of MeOH, 2 M HCl (0.3 mL, ethyl acetate solution) was added, and the reaction was stirred at RT for 1 hour. LC-MS and TLC detected that the reaction was complete, and the reaction solution was concentrated under reduced pressure. The residue was dissolved in H2O (1.0 mL), the solution was adjusted to pH=8 with saturated NaHCO3, extracted with dichloromethane (3×3 mL), the organic phase was dried and concentrated in vacuo, and purified by preparative plate to obtain 4.6 mg of white solid compound A08.
- [M+H+]=498.34
- 1H NMR (500 MHz, DMSO-d6) δ 9.81 (s, 1H), 8.21 (s, 1H), 7.50 (d, J = 8.9 Hz, 2H), 7.30 (d, J = 6.8 Hz, 1H), 7.22 -7.11 (m, 3H), 6.97 (d, J = 8.8 Hz, 2H), 5.42 (t, J = 6.0 Hz, 1H), 5.03 (s, 2H), 4.46 (d, J = 6.0 Hz, 2H) , 3.84-3.76 (m, 3H), 3.17-3.01 (m, 3H), 2.60 (d, J = 16.0 Hz, 1H), 1.89-1.83 (m, 1H), 1.78-1.73 (m, 1H), 1.53 -1.49 (m, 1H), 1.15-1.12 (m, 1H).
-
- Under nitrogen protection, 1.00 g of p-methoxyphenol, 1.15 g of bromopropyne and 4.45 g of potassium carbonate were dissolved in CH3CN (10 mL) and heated at 60 °C for 2 hours. TLC detected that the reaction was complete, filtered, concentrated the filtrate, and purified the crude product by column chromatography to obtain 900 mg of colorless and transparent oil A09-1.
- 100 mg of compound M1, 49 mg of compound M1, 14 mg of PdCl2(PPh3)2, and 2 mg of CuI were dissolved in DMF (3 mL) and NEt3 (0.5 mL). After nitrogen replacement, the reaction was performed at 60 °C for 2.5 hours. LC-MS and TLC detected that the reaction was complete, 10 mL of ethyl acetate was added, the insolubles were filtered off, the filtrate was dispersed in 20 mL of water, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by preparative plate to obtain 40 mg pale yellow solid, namely compound A09-2.
- 40 mg of compound A09-2 was dissolved in 2.5 mL of dioxane and 0.5 mL of MeOH, 2N HCl (0.1 mL, methanol solution) was added, and the reaction was stirred at RT for 1 hour. LC-MS and TLC detected that the reaction was complete, and the reaction solution was concentrated under reduced pressure. The residue was dissolved in H2O (1.0 mL), the solution was adjusted to pH=8 with saturated NaHCO3, extracted with dichloromethane (3×3 mL), the organic phase was dried and concentrated in vacuo, and purified by preparative plate to obtain 16 mg of off-white solid compound A09.
- [M+H+]=471.4.
- 1H NMR (500 MHz, DMSO-d6) δ 8.21 (s, 1H), 7.31-7.30 (m, 1H), 7.19-7.15 (m, 3H), 6.99-6.97 (m, 2H), 6.90-6.88 (m , 2H), 5.42 (t, J = 6.0 Hz, 1H), 5.00 (s, 2H), 4.47 (d, J = 6.0 Hz, 2H), 3.86 (s, 1H), 3.83- 3.76 (m, 2H), 3.71 (s, 3H), 3.16 -3.10 (m, 2H), 3.04 (d, J = 15.6 Hz, 1H), 2.62 (d, J = 15.6 Hz, 1H), 1.92 -1.85 (m, 1H), 1.88 - 1.83 (m, 1H), 1.78-1.73 (m, 1H), 1.14-1.12 (m, 1H).
-
- Under nitrogen protection, 1.00 g of m-trifluoromethylphenol, 1.10 g of bromopropyne and 1.71 g of potassium carbonate were dissolved in DMF (10 mL) and reacted at room temperature for 4 h. TLC detected that the reaction was complete, filtered, concentrated the filtrate, and purified the crude product by column chromatography to obtain 1.10 g of colorless and transparent oil A13-1.
- 100 mg of compound M1, 60.9 mg of compound A13-1, 4.3 mg of PdCl2(PPh3)2, 3.2 mg of PPh3, 2.4 mg of CuI were dissolved in DMF (2 mL) and NEt3 (0.5 mL), after nitrogen replacement, 60 °C reaction for 14h. LC-MS and TLC detected that the reaction was complete, 10 mL of ethyl acetate was added, insolubles were filtered off, the filtrate was dispersed in 20 mL of water, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by preparative plate to obtain 90 mg pale yellow solid, namely compound A13-2.
- 90 mg of compound A13-2 was dissolved in 4.0 mL of dioxane and 1.0 mL of MeOH, 1N HCl (0.3 mL, ethyl acetate solution) was added, and the reaction was stirred at RT for 0.5 h. LC-MS and TLC detected that the reaction was complete, and the reaction solution was concentrated under reduced pressure. The residue was dissolved in H2O (1.0 mL), the solution was adjusted to pH=8 with saturated NaHCO3, extracted with EA (3×3 mL), the organic phase was dried and concentrated in vacuo, and purified by preparative plate to obtain 28 mg of off-white solid compound A13.
- [M+H+]=509.32.
- 1H NMR (500 MHz, DMSO) δ 8.23 (s, 1H), 7.71 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 6.4 Hz, 1H), 7.24 (d, J = 8.4 Hz, 2H) ), 7.19-7.13 (m, 3H), 5.42 (t, J = 6.0 Hz, 1H), 5.20 (s, 2H), 4.47 (d, J = 5.0 Hz, 2H), 3.88-3.73 (m, 3H) , 3.16-3.11 (m, 2H), 3.03 (d, J = 15.7 Hz, 1H), 2.61 (d, J = 15.6 Hz, 1H), 1.89-1.83 (m, 1H), 1.79-1.72 (m, 1H) ), 1.52-1.49 (m, 1H), 1.13-1.11 (m, 1H).
-
- Under nitrogen protection, 1.00 g of p-hydroxybenzamide, 1.04 g of bromopropyne and 1.51 g of potassium carbonate were dissolved in DMF (10 mL) and reacted at room temperature for 2 hours. TLC detected that the reaction was complete, filtered, concentrated the filtrate, and purified the crude product by column chromatography to obtain 1.08 g of white solid A17-1.
- 150 mg of compound M1, 64 mg of compound A17-1, 6.4 mg of PdCl2(PPh3)2, 3.5 mg of CuI, and 4.8 mg of PPh3 were dissolved in DMF (2 mL) and NEt3 (0.5 mL), and the reaction was carried out at 60 °C after nitrogen replacement. 8 hours. LC-MS and TLC detected that the reaction was complete, 10 mL of ethyl acetate was added, insolubles were filtered off, the filtrate was dispersed in 20 mL of water, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by column chromatography to obtain 127 mg of pale yellow solid, namely compound A17-2.
- 127 mg of compound A17-2 was dissolved in 2 mL of dioxane and 0.5 mL of MeOH, 2 M HCl (0.3 mL, ethyl acetate solution) was added, and the reaction was stirred at RT for 1 hour. LC-MS and TLC detected that the reaction was complete, the reaction solution was concentrated under reduced pressure, slurried with dichloromethane and methyl tert-butyl ether in sequence, and filtered to obtain 109.5 mg of a yellow solid, the hydrochloride of compound A17.
- [M+H+]=484.36
- 1H NMR (500 MHz, DMSO-d6) δ 8.25 (s, 1H), 7.88 (d, J = 8.8 Hz, 3H), 7.57 (d, J = 7.4 Hz, 1H), 7.37-7.27 (m, 3H) , 7.12-7.04 (m, 2H), 5.16 (s, 2H), 4.48 (s, 2H), 4.36 (d, J = 5.4 Hz, 1H), 3.92-3.88 (m, 2H), 3.21-3.11 (m , 3H), 2.97 (d, J = 16.2 Hz, 1H), 1.89-1.81 (m, 2H), 1.58-1.55 (m, 1H), 1.52-1.49 (m, 1H).
-
- Dissolve 0.5 g of 4-hydroxypyridine and 1.45 g of potassium carbonate in acetone (5 mL), heat at 50 °C for 0.5 hour reaction, add 1.25 g of bromopropyne, and continue stirring for 2 hours. TLC detected that the reaction was complete, filtered, concentrated the filtrate, and purified the crude product by column chromatography to obtain 384 mg of brown solid, namely compound A18-1.
- 100 mg of compound M1, 48.5 mg of compound A18-1, 7.1 mg of PdCl2(PPh3)2, 1.9 mg of CuI were dissolved in THF (2 mL) and NEt3 (0.2 mL), and after nitrogen replacement, the reaction was carried out at 60°C for 3 hours. LC-MS and TLC detected that the reaction was complete, 10 mL of dichloromethane and 20 mL of water were added for extraction, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by preparative plate to obtain 101 mg of yellow solid, namely Compound A18-2.
- 101 mg of compound A18-2 was dissolved in 3 mL of dioxane and 0.8 mL of EtOH, 2N HCl (138 µL, ethyl acetate solution) was added, and the reaction was stirred at RT for 1 hour. LC-MS and TLC detected that the reaction was complete, and the reaction solution was concentrated under reduced pressure. The residue was dissolved in H2O (1.0 mL), the solution was adjusted to pH=8 with saturated NaHCO3, extracted with dichloromethane (3×3 mL), the organic phase was dried and concentrated in vacuo, and purified by preparative plate to obtain 22.7 mg of yellow solid, compound A18.
- [M+H+]=442.3.
- 1H NMR (500 MHz, DMSO-d6) δ 8.24 (s, 1H), 7.75 (d, J = 7.5 Hz, 2H), 7.30 (d, J = 6.8 Hz, 1H), 7.18-7.12 (m, 3H) , 6.14 (d, J = 7.5 Hz, 2H), 5.43 (t, J = 5.5 Hz, 1H), 5.10 (s, 2H), 4.47 (d, J = 5.5 Hz, 2H), 3.88-3.76 (m, 3H), 3.19-3.07 (m, 2H), 3.03 (d, J = 15.6 Hz, 1H), 2.60 (d, J = 15.6 Hz, 1H), 1.90-1.82 (m, 1H), 1.80-1.71 (m , 1H), 1.55-1.48 (m, 1H), 1.13-1.07 (m, 1H).
-
- Dissolve 1.0 g of 1-acetyl-4-(4-hydroxyphenyl)piperazine and 2.51 g of potassium carbonate in acetone (8 mL), heat at 50 °C for 0.5 hours, add 0.73 g of bromopropyne, and continue stirring for 2 hours . TLC detected that the reaction was complete, filtered, concentrated the filtrate, and purified the crude product by column chromatography to obtain 1.09 g of an off-white solid, namely compound A21-1.
- 100 mg of compound M1, 47.1 mg of compound A21-1, 7.1 mg of PdCl2(PPh3)2, 1.9 mg of CuI were dissolved in THF (2 mL) and NEt3 (0.2 mL), and after nitrogen replacement, the reaction was carried out at 60 °C for 3 hours. LC-MS and TLC detected that the reaction was complete, added 10 mL of dichloromethane, dispersed in 20 mL of water, washed the organic phase with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. A21-2.
- 76 mg of compound A21-2 was dissolved in 3 mL of dioxane and 0.7 mL of EtOH, 2N HCl (85 µL, ethyl acetate solution) was added, and the reaction was stirred at RT for 2 hours. LC-MS and TLC detected that the reaction was complete, and the reaction solution was concentrated under reduced pressure. The residue was dissolved in H2O (1.0 mL), the solution was adjusted to pH=8 with saturated NaHCO3, extracted with dichloromethane (3×3 mL), the organic phase was dried and concentrated in vacuo, and purified by preparative plate to obtain 20.7 mg of yellow solid compound A21.
- [M+H+]=567.4.
- 1H NMR (500 MHz, DMSO-d6) δ 8.21 (s, 1H), 7.30 (d, J = 6.8 Hz, 1H), 7.19-7.12 (m, 3H), 6.96-6.92 (m, 4H), 5.43 (t, J = 5.9 Hz, 1H), 4.99 (s, 2H), 4.46 (d, J = 5.9 Hz, 2H), 3.86-3.74 (m, 3H), 3.57-3.54 (m, 4H), 3.20-3.10 (m, 3H), 3.05-3.01 (m, 2H), 2.98-2.95 (m, 2H), 2.60 (d, J = 15.6 Hz, 1H), 2.03 (s, 3H), 1.91-1.82 (m, 1H) ), 1.80-1.72 (m, 1H), 1.56-1.47 (m, 1H), 1.14-1.07 (m, 1H).
-
- Under nitrogen protection, 1.00 g of 7-hydroxy-3,4-dihydroquinolone, 1.09 g of bromopropyne and 1.69 g of potassium carbonate were dissolved in DMF (10 mL) and reacted at room temperature for 24 h. TLC detected that the reaction was complete, filtered, concentrated the filtrate, and beat the crude product with (PE:EA=3:1) to obtain 0.90 g of pale yellow solid A22-1.
- 200 mg of compound M1, 89.7 mg of compound A22-1, 14 mg of PdCl2(PPh3)2, and 4.0 mg of CuI were dissolved in DMF (4 mL) and Et3N (0.4 mL), and the reaction was carried out at 60 °C for 10 h after nitrogen replacement. LC-MS and TLC detected that the reaction was complete, the reaction solution was spun off with triethylamine, then cooled to room temperature, 20 mL of water was added, a solid was precipitated, filtered, the filter cake was washed with water, the solid was dissolved in DCM, dried, and the crude product was purified by a preparative plate to obtain 135 mg of pale yellow solid, namely compound A22-2.
- 200 mg of compound A22-2 was dissolved in 4.0 mL of dioxane and 1.0 mL of MeOH, 1N HCl (0.65 mL, ethyl acetate solution) was added, and the reaction was stirred at RT for 0.5 h. LC-MS and TLC detected that the reaction was complete, and the reaction solution was concentrated under reduced pressure. The residue was dissolved in H2O (1.0 mL), the solution was adjusted to pH=8 with saturated NaHCO3, a solid was precipitated, filtered, and the filter cake was dissolved in DCM, dried and concentrated in vacuo, and purified by HPLC to obtain 16.8 mg of off-white solid compound A22.
- [M+H+]=510.36.
-
- 1.00 g of 2-amino-4-hydroxypyridine and 3.96 g of di-tert-butyl dicarbonate were dissolved in n-butanol (10 mL) and heated at 50 °C for 5 hours. TLC detected that the reaction no longer proceeded, 10 mL of ethyl acetate was added, dispersed in 20 mL of water, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by column chromatography to obtain 1.02 g of a white solid, namely compound A26 -1.
- 350 mg of compound A26-1 and 135 mg of sodium hydroxide were dissolved in methanol (5 mL) and reacted at 65 °C for 1.5 hours. LC-MS and TLC detected that the reaction was complete, filtered, and the filtrate was concentrated. The crude product, 268 mg of bromopropyne, and 312 mg of potassium carbonate were dissolved in acetone (5 mL), and the reaction was carried out at 60 °C for 2 hours. LC-MS and TLC detected that the reaction was complete, filtered, and concentrated the filtrate. The crude product was purified by preparative plate to obtain 310 mg of white solid, namely compound A26-2.
- Dissolve 200 mg of compound M1, 100.6 mg of compound A26-2, 14.2 mg of PdCl2(PPh3)2, 3.9 mg of CuI in tetrahydrofuran (4 mL) and triethylamine (1 mL), after nitrogen replacement, react at 60 °C for 4 hours, An additional 100.6 mg of compound A26-2 was added, and the reaction was carried out at 60 °C for 12 hours. LC-MS and TLC detection reaction no longer proceeded, 10 mL of dichloromethane was added, 20 mL of water dispersed, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by preparative plate to obtain 158 mg of yellow solid, Namely compound A26-3.
- 158 mg of compound A26-3 was dissolved in dioxane (4 mL) and ethanol (1 mL), 2N HCl (179 µL, ethyl acetate solution) was added, and the reaction was stirred at RT for 1 hour. LC-MS and TLC detected that the reaction was complete, and the reaction solution was concentrated under reduced pressure. The residue was dissolved in H2O (1.0 mL), the solution was adjusted to pH=8 with saturated NaHCO3, extracted with dichloromethane (3×3 mL), the organic phase was dried and concentrated in vacuo, and purified by preparative plate to obtain 65 mg of yellow solid, namely compound A26-4 .
- 65 mg of compound A26-4 was dissolved in dichloromethane (1.5 mL) and trifluoroacetic acid (1.5 mL), and the reaction was stirred at RT for 1 hour. LC-MS and TLC detected that the reaction was complete, and the reaction solution was concentrated under reduced pressure. The residue was dissolved in H2O (1.0 mL), the solution was adjusted to pH=8 with saturated NaHCO3, extracted with
- dichloromethane (3×3 mL), the organic phase was dried and concentrated in vacuo, and purified by preparative plate to obtain 27.5 mg of white solid compound A26.
- [M+H+]=457.3.
- 1H NMR (500 MHz, DMSO-d6) δ 8.23 (s, 1H), 7.78 - 7.74 (m, 1H), 7.32 - 7.27 (m, 1H), 7.20 - 7.12 (m, 3H), 6.21 (dd, J = 5.8, 2.3 Hz, 1H), 6.05 (d, J = 2.3 Hz, 1H), 5.88 (s, 2H), 5.44 (t, J = 6.0 Hz, 1H), 5.04 (s, 2H), 4.47 (d , J = 6.0 Hz, 2H), 3.84 (s, 1H), 3.82 - 3.77 (m, 2H), 3.20 - 3.07 (m, 2H), 3.03 (d, J = 15.6 Hz, 1H), 2.60 (d, J = 15.6 Hz, 1H), 1.93 - 1.82 (m, 1H), 1.81 - 1.71 (m, 1H), 1.56 - 1.46 (m, 1H), 1.14 - 1.08 (m, 1H).
-
- Under nitrogen protection, 1.00 g m-acetamidophenol, 0.87 g bromopropyne and 1.51 g potassium carbonate were dissolved in DMF (10 mL) and reacted at room temperature for 8 h. TLC detected that the reaction was complete, filtered, concentrated the filtrate, and purified the crude product by column chromatography to obtain 0.70 g of colorless and transparent oil A27-1.
- 200 mg of compound M1, 107.0 mg of compound A27-1, 8.5 mg of PdCl2(PPh3)2, 6.4 mg of PPh3, 4.8 mg of CuI were dissolved in DMF (4 mL) and Et3N (1 mL), and the reaction was performed at 60 °C after nitrogen replacement 14h. LC-MS and TLC detected that the reaction was complete, 10 mL of ethyl acetate was added, insolubles were filtered off, the filtrate was dispersed in 20 mL of water, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by preparative plate to obtain 170 mg pale yellow solid, namely compound A27-2.
- 160 mg of compound A27-2 was dissolved in 6.0 mL of dioxane and 1.5 mL of MeOH, 1N HCl (0.43 mL, ethyl acetate solution) was added, and the reaction was stirred at RT for 0.5 h. LC-MS and TLC detected that the reaction was complete, and the reaction solution was concentrated under reduced pressure. The residue was dissolved in H2O (1.0 mL), the solution was adjusted to pH=8 with saturated NaHCO3, extracted with EA (5×3 mL), the organic phase was dried and concentrated in vacuo, and purified by preparative plate to obtain 69.4 mg of off-white solid compound A27.
- [M+H+]=484.36.
- 1H NMR (500 MHz, DMSO) δ 8.21 (s, 1H), 7.97 (br, 1H), 7.54-7.49 (m, 2H), 7.42-7.35 (m, 2H), 7.30 (d, J = 6.5 Hz, 1H), 7.20-7.12 (m, 4H), 5.43 (t, J = 5.8 Hz, 1H), 5.13 (s, 2H), 4.46 (d, J = 5.4 Hz, 2H), 3.88-3.75 (m, 3H) ), 3.18-3.09 (m, 2H), 3.03 (d, J = 15.6 Hz, 1H), 2.60 (d, J = 15.6 Hz, 1H), 1.89-1.83 (m, 1H), 1.79-1.72 (m, 1H), 1.52-1.49 (m, 1H), 1.12-1.11 (m, 1H).
-
- Under nitrogen protection, 1.00 g of p-benzenesulfonamide Aminophenol, 0.68 g of bromopropyne and 0.96 g of potassium carbonate were dissolved in DMF (10 mL) and reacted at room temperature for 4 h. TLC detected that the reaction was complete, filtered, concentrated the filtrate, and purified the crude product by column chromatography to obtain 0.80 g of colorless and transparent oil A32-1.
- 200 mg of compound M1, 171.0 mg of compound A32-1, 8.5 mg of PdCl2(PPh3)2, 6.4 mg of PPh3, 4.8 mg of CuI were dissolved in DMF (4 mL) and Et3N (1 mL), and the reaction was carried out at 60 °C after nitrogen replacement 14h. LC-MS and TLC detected that the reaction was complete, 10 mL of ethyl acetate was added, insolubles were filtered off, the filtrate was dispersed in 20 mL of water, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by preparative plate to obtain 120 mg pale yellow solid, namely compound A32-2.
- 120 mg of compound A32-2 was dissolved in 4.0 mL of dioxane and 1.0 mL of MeOH, 1N HCl (0.38 mL, ethyl acetate solution) was added, and the reaction was stirred at RT for 0.5 h. LC-MS and TLC detected that the reaction was complete, and the reaction solution was concentrated under reduced pressure. The residue was dissolved in H2O (1.0 mL), the solution was adjusted to pH=8 with saturated NaHCO3, extracted with EA (5×3 mL), the organic phase was dried and concentrated in vacuo, and purified by preparative plate to obtain 44.3 mg of off-white solid compound A32.
- [M+H+]=520.32.
- 1H NMR (500 MHz, DMSO) δ 8.22 (s, 1H), 7.79 (d, J = 8.8 Hz, 2H), 7.30 (d, J = 6.5 Hz, 1H), 7.24-7.14 (m, 7H), 5.42 (t, J = 5.9 Hz, 1H), 5.19 (s, 2H), 4.46 (d, J = 5.8 Hz, 2H), 3.84-3.76 (m, 3H), 3.17-3.11 (m, 2H), 3.03 (d, J = 15.6 Hz, 1H), 2.62 (d, J = 15.5 Hz, 1H), 1.89-1.85 (m, 1H), 1.78-1.72 (m, 1H), 1.52-1.49 (m, 1H), 1.12 -1.10 (m, 1H).
-
- 400 mg of compound M16 was dissolved in DCM (4.0 mL), after nitrogen replacement, 675 mg of CF3COOH was added, and the reaction was stirred at room temperature for 3 h. LC-MS and TLC detected the reaction was complete, and 10 mL of saturated sodium bicarbonate was added to adjust the pH to 8 ~9, extracted with ethyl acetate (3×20 mL), washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the crude product was purified by column chromatography to obtain 270 mg of white solid compound A33-1.
- 200 mg of compound A33-1, 99.8 mg of compound 4-(prop-2-yn-1-yloxo)benzamide, 8.0 mg of PdCl2(PPh3)2, 4.4 mg of CuI, 6.0 mg of PPh3 were dissolved in DMF (4.0 mL) and Et3N (1.0 mL), after nitrogen replacement, the reaction was stirred at room temperature for 10 min, and stirred at 50 °C for 15 h under nitrogen protection. LC-MS and TLC detected that the reaction was complete, quenched by adding 20 mL of water, ethyl acetate (3×20 mL) extraction, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the crude product was purified by preparative plate to obtain 12 mg of compound A33-2 as a pale yellow solid.
- 12 mg of compound A33-2 was dissolved in 2.0 mL of dioxane, 0.5 mL of MeOH was added, 0.02 mL of HCl in EA solution (2M) was added dropwise with stirring, and the mixture was stirred at room temperature for 30 min. LC-MS detected that the reaction was complete, the reaction solution was concentrated under reduced pressure, the residue was dissolved in 10 mL of water, and saturated sodium bicarbonate was added dropwise to adjust the pH to 8-9, the precipitated solid was collected, and purified with a preparative plate to obtain 4.5 mg of light yellow solid compound A33 .
- [M+H+]=470.19.
-
- 200 mg of 3,6-dibromopyrazine-2-carboxamide, 248 mg of M1-7 and 110 mg of triethylamine were dissolved in THF (5 mL) and reacted at room temperature for 3 hours. TLC detected the completion of the reaction, added water (10 mL), extracted with ethyl acetate (3 × 10 mL), combined the organic phases, washed successively with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated the filtrate, and purified the crude product by column chromatography 220 mg of yellow solid were obtained, namely compound A41-1.
- 223 mg of compound A41-1, 100 mg of compound A04-1, 15.5 mg of PdCl2(PPh3)2, 4.2 mg of CuI were dissolved in DMF (2 mL) and NEt3 (0.4 mL), and the reaction was performed at 60 °C for 18 hours after nitrogen replacement. LC-MS and TLC detected the completion of the reaction, added 20 mL of ethyl acetate, dispersed in 15 mL of water, washed the organic phase with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by column chromatography to obtain 150 mg of pale yellow solid. Namely compound A41-2.
- 150 mg of compound A41-2 was dissolved in 2 mL of methanol, 2N HCl (200 µL, ethyl acetate solution) was added, and the reaction was stirred at RT for 0.5 h. LC-MS and TLC detected that the reaction was complete, and the reaction solution was concentrated under reduced pressure. The residue was dissolved in H2O (1.0 mL), the solution was adjusted to pH=8 with saturated NaHCO3, extracted with dichloromethane (3×3 mL), the organic phase was dried and concentrated in vacuo, and purified by preparative plate to obtain 80.0 mg of pale yellow solid compound A41.
- [M+H+]=511.3.
- 1H NMR (500 MHz, DMSO-d6) δ 9.95 (s, 1H), 8.26 (s, 1H), 8.04 (s, 1H), 7.61 (s, 1H), 7.38-7.37 (m, 1H), 7.30 ( d, J = 6.5 Hz, 1H), 7.24-7.21 (m, 1H), 7.16 - 7.14 (m, 4H), 6.73-6.71 (m, 1H), 5.76 (s, 1H), 5.02 (s, 2H) , 3.98 - 3.93 (m, 2H), 3.81 (s, 1H), 3.25 - 3.17 (m, 2H), 3.04 (d, J = 15.5 Hz, 1H), 2.61 (d, J = 15.5 Hz, 1H), 2.03 (s, 3H), 1.78-1.73 (m, 1H), 1.69-1.64 (m, 1H), 1.49 - 1.47 (m, 1H), 1.10 - 1.07 (m, 1H).
-
- Under nitrogen protection, 1.00 g of benzoic acid was dissolved in 15 mL of DCM, 1.46 g of carbonyldiimidazole was added, and the reaction was carried out at RT for 30 minutes, and then 496 mg of propargylamine was added, and the reaction was carried out at room temperature overnight. TLC detected that the reaction was complete, water was added, extracted with DCM, the organic phase was washed with 10% citric acid, then washed with 10% sodium bicarbonate, dried and filtered over anhydrous sodium sulfate, the filtrate was concentrated, and the crude product was slurried with n-hexane to obtain 960 mg of white solid, namely Compound A45-1.
- 150 mg of compound M1, 72 mg of compound A45-1, 10 mg of PdCl2(PPh3)2, 2.9 mg of CuI were dissolved in DMF (3 mL) and Et3N (0.5 mL), and after nitrogen replacement, the reaction was carried out at 60 °C for 4 h. LC-MS and TLC detected that the reaction was complete, the reaction solution was spun to remove triethylamine, cooled to room temperature, added 20 mL of water to precipitate a solid, filtered, the filter cake was washed with water, the filter cake was dissolved in DCM, dried over anhydrous sodium sulfate, and directly applied to the column. Flash preparation and purification gave 120 mg of pale yellow solid, namely compound A45-2.
- 120 mg of compound A45-2 was dissolved in 4.0 mL of dioxane and 2.0 mL of MeOH, 2N HCl (0.32 mL, ethyl acetate solution) was added, and the reaction was stirred at RT for 0.5 h. LC-MS and TLC detected that the reaction was complete, the reaction solution was neutralized by adding ammonia water, and then concentrated under reduced pressure. The residue was purified by preparative plate to give 8.3 mg of off-white solid compound A45.
- [M+H+]=468.37.
- 1H NMR (500 MHz, DMSO-d6) δ 9.08 (t, J = 5.6 Hz, 1H), 8.20 (s, 1H), 7.92-7.86 (m, 2H), 7.57-7.54 (m, 1H), 7.50- 7.47 (m, 2H), 7.36-7.30 (m, 1H), 7.21-7.15 (m, 3H), 4.47 (s, 2H), 4.35 (d, J = 5.5 Hz, 2H), 3.92 (s, 1H) , 3.81-3.71 (m, 2H), 3.17-3.09 (m, 2H), 3.03 (d, J = 16.0 Hz, 1H), 2.67 (d, J = 15.5 Hz, 1H), 1.89-1.83 (m, 1H) ), 1.79-1.74 (m, 1H), 1.52-1.49 (m, 1H), 1.18-1.16 (m, 1H).
-
- Under nitrogen protection, 1.00 g of 3-butynyl p-toluenesulfonate and 0.62 g of aniline were dissolved in 10 mL of DMF, 1.38 g of potassium carbonate and 0.74 g of potassium iodide were added, and the reaction was heated at 90 degrees for 4 hours. TLC detected the completion of the reaction, cooled to room temperature, quenched the reaction with ammonium chloride, extracted with EA (30 mL∗3), combined the organic phases, washed with saturated brine (10 mL∗4), dried over anhydrous sodium sulfate and filtered, and the filtrate was concentrated, the crude product was purified by column chromatography to obtain 285 mg of oily substance, namely compound A46-1.
- 150 mg of compound M1, 66 mg of compound A46-1, 10 mg of PdCl2(PPh3)2, 2.9 mg of CuI were dissolved in DMF (4 mL) and Et3N (0.5 mL), and after nitrogen replacement, the reaction was performed at 60 °C overnight. LC-MS and TLC detected that the reaction was complete, 10 mL of ethyl acetate was added, the insolubles were filtered off, the filtrate was dispersed in 20 mL of water, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by preparative plate to obtain 32 mg pale yellow solid, namely compound A46-2.
- 32 mg of compound A46-2 was dissolved in 2.0 mL of dioxane and 1.0 mL of MeOH, 2N HCl (0.05 mL, ethyl acetate solution) was added, and the reaction was stirred at RT for 0.5 h. LC-MS and TLC detected that the reaction was complete, the reaction solution was neutralized by adding ammonia water, and then concentrated under reduced pressure. The residue was purified by preparative plate to give 8.3 mg of off-white solid compound A46.
- [M+H+]=484.38.
-
- 1.00 g of 3,4-dimethoxyaniline was dissolved in DMF (10.0 mL), 1.35 g of K2CO3 was added and stirred at room temperature for 10 min, 0.76 mL of bromopropyne was added dropwise, and after nitrogen replacement, the reaction was stirred at room temperature for 1 h, LC-MS and TLC detected the completion of the reaction, added 40 mL of water, extracted with ethyl acetate (3×40 mL), washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, the crude product was purified by column chromatography to obtain 430 mg of white solid, Namely compound A47-1.
- 150 mg of compound M1, 21 mg of PdCl2(PPh3)2, 3 mg of CuI, and 87 mg of compound A47-1 were dissolved in DMF (20.0 mL) and Et3N (0.75 mL). After nitrogen replacement, the reaction was carried out at 60 °C for 3 hours. LC-MS and TLC detected that the reaction was complete, 20 mL of ethyl acetate was added, the filter residue was filtered off, the filtrate was dispersed in 20 mL of water, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by column chromatography to obtain 148 mg pale yellow solid, namely compound A47-2.
- 90 mg of compound A47-2 was dissolved in 6.0 mL of dioxane, 1.5 mL of MeOH was added, 0.2 mL of HCl in EA solution (2M) was added dropwise with stirring, and the mixture was stirred at room temperature for 30 min. LC-MS detected that the reaction was complete, the reaction solution was concentrated under reduced pressure, the residue was dissolved in 10 mL of water, and saturated sodium bicarbonate was added dropwise to adjust the pH to 8-9, the precipitated solid was collected, and purified with a preparative plate to obtain 6.8 mg of yellow solid compound A47.
- [M+H+]=500.35.
- 1H NMR (500 MHz, DMSO) δ 8.14 (d, J = 2.0 Hz, 1H), 7.31 (s, 1H), 7.17 (d, J = 5.6 Hz, 3H), 6.77 (d, J = 6.4 Hz, 1H) ), 6.40 (s, 1H), 6.23-6.13 (m, 1H), 5.71 (s, 1H), 5.39 (s, 1H), 4.47-4.43 (m, 2H), 4.14-4.09 (m, 2H), 3.88-3.85 (m, 1H), 3.79-3.73 (m, 1H), 3.72-3.68 (m, 3H), 3.65-3.62 (m, 3H), 3.19-3.06 (m, 2H), 3.03 (d, J = 15.6 Hz, 1H), 2.60 (d, J = 15.6 Hz, 1H), 1.89-1.82 (m, 1H), 1.79-1.72 (m, 1H), 1.54-1.48 (m, 1H), 1.13-1.07 (m, 1H).
-
- 1.00 g of p-Aminobenzamide, 0.87 g of bromopropyne and 1.20 g of potassium carbonate were dissolved in DMF (10 mL) and reacted at room temperature for 12 hours. TLC detected that the reaction no longer proceeded, 50 mL of water was added, 50 mL of ethyl acetate was added for extraction, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by column chromatography to obtain 0.31 g of an off-white solid, which is the compound A48-1.
- 200 mg of compound M1, 150 mg of A48-1, 9.5 mg of PdCl2(PPh3)2 and 3.6 mg of CuI were dissolved in DMF (5 mL) and triethylamine (1 mL), and then reacted at 60°C for 2 hours after nitrogen replacement. LC-MS and TLC detected that the reaction was complete, quenched by adding 10 mL of water, extracted with ethyl acetate (3×20 mL), washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by preparative plate to obtain 60 mg of yellow solid , namely compound A48-2.
- 60 mg of compound A48-2 was dissolved in dioxane (4 mL) and methanol (1 mL), 2N HCl (0.3 mL, ethyl acetate solution) was added, and the reaction was stirred at RT for 1 hour. LC-MS and TLC detected that the reaction was complete, and the reaction solution was concentrated under reduced pressure. The residue was dissolved in H2O (1.0 mL), the solution was adjusted to pH=8 with saturated NaHCO3, extracted with dichloromethane (3×3 mL), the organic phase was dried and concentrated in vacuo, and purified by preparative plate to obtain 43 mg of pale yellow solid, namely Compound A48.
- [M+H+]=483.37.
- 1H NMR (500 MHz, DMSO-d6) δ 8.15 (s, 1H), 7.71 - 7.67 (m, 2H), 7.59 (s, 1H), 7.31-7.29 (m, 1H), 7.19 -7.11 (m, 3H) ), 6.91 (s, 1H), 6.69 - 6.63 (m, 3H), 5.40 (t, J = 6.0 Hz, 1H), 4.44 (d, J = 6.0 Hz, 2H), 4.22 (d, J = 6.0 Hz, 2H), 3.85 (s, 1H), 3.78-3.71 (m, 2H), 3.14-3.05 (m, 1H), 3.02 (d, J = 15.5 Hz, 1H), 2.61 (d, J = 15.5 Hz, 1H), 1.89-1.82 (m, 1H), 1.79- 1.71 (m, 1H), 1.51-1.49 (m, 1H), 1.12-1.10 (m, 1H).
-
- 1.00 g of 2-methoxy-4-pyridinol, 0.95 g of bromopropyne and 1.1 g of potassium carbonate were dissolved in DMF (10 mL) and reacted at room temperature for 12 hours. TLC detected the completion of the reaction, added 50 mL of ethyl acetate, dispersed in 50 mL of water, washed the organic phase with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by column chromatography to obtain 0.78 g of an off-white solid, namely compound A49- 1.
- 200 mg of compound M1, 150 mg of A49-1, 9.5 mg of PdCl2(PPh3)2 and 3.6 mg of CuI were dissolved in DMF (5 mL) and 1 mL of triethylamine, and after nitrogen replacement, the reaction was performed at 60°C for 2 hours. LC-MS and TLC detected that the reaction was complete, quenched by adding 10 mL of water, extracted with ethyl acetate (3×20 mL), washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by preparative plate to obtain 88 mg of yellow Solid compound A49-2.
- 88 mg of compound A49-2 was dissolved in dioxane (4 mL) and methanol (1 mL), 2N HCl (0.3 mL, ethyl acetate solution) was added, and the reaction was stirred at RT for 1 hour. LC-MS and TLC detected that the reaction was complete, and the reaction solution was concentrated under reduced pressure. The residue was dissolved in H2O (1.0 mL), the solution was adjusted to pH=8 with saturated NaHCO3, extracted with dichloromethane (3 × 3 mL), the organic phase was dried and concentrated in vacuo, and purified by preparative plate to obtain 43 mg of pale yellow solid as compound A49.
- [M+H+]=472.30.
- 1H NMR (500 MHz, DMSO-d6) δ8.22 (s, 1H), 7.96 (d, J = 3.0 Hz, 1H), 7.50 (dd, J = 9.0, 3.0 Hz, 1H), 7.31 (d, J = 6.5 Hz, 1H), 7.21-7.13 (m, 3H), 6.81 (d, J = 9.0 Hz, 1H), 5.43 (t, J = 6.0 Hz, 1H), 5.09 (s, 2H), 4.47 (d , J = 6.0 Hz, 2H), 3.88 - 3.75 (m, 6H), 3.17 - 2.99 (m, 2H), 3.03 (d, J = 15.5 Hz, 1H), 2.62 (d, J = 15.5 Hz, 1H) , 1.89-1.82 (m, 1H), 1.78-1.74 (m, 1H), 1.53-1.50 (m, 1H), 1.15-1.12 (m, 1H).
-
- 1.00 g of raw material 2-fluoro-4-hydroxybenzonitrile and 23 mg of Parkin's reagent were dissolved in 6 mL of ethanol and 2 mL of water, and reacted at 80 °C for 12 h. After TLC (PE:EA=1:1) monitoring showed that the reaction was complete, it was concentrated under reduced pressure and purified by column chromatography (DCM:MeOH=12:1) to obtain 512 mg of white powder A50-1.
- 512 mg of compound A50-1, 432 mg of 3-bromo-1-propyl, and 684 mg of potassium carbonate were dissolved in 10 mL of DMF, and reacted at room temperature for 2 h. After TLC (PE:EA=1:1) monitoring showed that the reaction was complete, 10 mL of water was added, extracted with 10 mL of EA, the organic phase was washed with 3×10 mL of saturated sodium chloride solution, the organic phase was separated, and dried over anhydrous sodium sulfate, concentrated under reduced pressure to obtain 488 mg of white powder of compound A50-2.
- 117 mg of compound A50-2, 200 mg of M1, 8.5 mg of Pd(PPh3)2Cl2, and 4.6 mg of CuI were dissolved in 3 mL of DMF and 0.5 mL of triethylamine, replaced by N2, and reacted at 60 °C for 12 h. After TLC (DCM:MeOH=10:1) showed that the reaction of the raw materials was complete, 10 mL of ethyl acetate and 10 mL of water were added for extraction, and the organic phase was separated. It was dried, separated and purified by column chromatography (DCM:MeOH=24:1) to obtain 166 mg of pale yellow powder, namely compound A50-3.
- 166 mg of compound A50-3 was dissolved in 4 mL of dioxane and 1 mL of methanol solution, replaced with nitrogen, and 0.27 mL of HCl in EA solution (2 M) was added dropwise with stirring, and stirred at room temperature for 30 min. LC-MS detected that the reaction was complete, the reaction solution was concentrated under reduced pressure, the residue was dissolved in 5 mL of water, and saturated sodium bicarbonate solution was added dropwise to pH 8∼9, the precipitated solid was collected, and then separated and purified by a thick preparation plate to obtain 35.9 mg of light yellow powder, namely Compound A50.
- [M+H+]=502.33.
- 1H NMR (500 MHz, DMSO-d6) δ 8.23 (s, 1H), 7.69 (t, J = 8.7 Hz, 1H), 7.50 (s, 2H), 7.34-7.27 (m, 1H), 7.19-7.15 ( m, 4.6 Hz, 3H), 7.00 (dd, J = 12.8, 2.5 Hz, 1H), 6.95 (dd, J = 8.7, 2.5 Hz, 1H), 5.43 (t, J = 5.9 Hz, 1H), 5.18 ( s, 2H), 4.47 (d, J = 5.3 Hz, 2H), 3.86 (s, 1H), 3.85-3.76 (m, 2H), 3.18-3.07 (m, 2H), 3.04 (d, J = 15.6 Hz , 1H), 2.62 (d, J = 15.8 Hz, 1H), 1.90-1.81 (m, 1H), 1.80-1.71 (m, 1H), 1.54-1.46 (m, 1H), 1.19-1.12 (m, 2H)).
-
- 1.00 g of 5-hydroxy-isoindolin-1-one, 0.95 g of bromopropyne and 1.1 g of potassium carbonate were dissolved in DMF (10 mL) and reacted at room temperature for 12 hours. TLC detected that the reaction was complete, 50 mL of water was added, and 50 mL of ethyl acetate was added for extraction. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by column chromatography to obtain 0.50 g of an off-white solid, namely compound A51 -1.
- 300 mg of compound M1, 160 mg of A51-1, 9.5 mg of PdCl2(PPh3)2 and 3.6 mg of CuI were dissolved in DMF (5 mL) and triethylamine (1 mL), and after nitrogen replacement, the reaction was carried out at 60 °C for 2 hours. LC-MS and TLC detected that the reaction was complete, quenched by adding 10 mL of water, extracted with ethyl acetate (3×20 mL), washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by preparative plate to obtain 180 mg of yellow Solid, namely compound A51-2.
- 180 mg of compound A51-2 was dissolved in dioxane (4 mL) and methanol (1 mL), 2N HCl (0.3 mL, ethyl acetate solution) was added, and the reaction was stirred at RT for 1 hour. LC-MS and TLC detected the completion of the reaction, the reaction solution was concentrated under reduced pressure, the residue was dissolved in H2O (1.0 mL), the solution was adjusted to pH=8 with saturated NaHCO3, extracted with dichloromethane (3×3 mL), the organic phase was dried and concentrated in vacuo, purified by preparative plate to obtain 53.3 mg of pale yellow solid, namely compound A51.
- [M+H+]=496.33.
- 1H NMR (500 MHz, DMSO-d6) δ 8.42 (s, 1H), 8.29 (s, 1H), 7.67 (d, J = 8.5 Hz, 1H), 7.37-7.35 (m, 1H), 7.30-7.29 ( m, 1H), 7.24 - 7.17 (m, 4H), 5.48 (t, J = 6.0 Hz, 1H), 5.24 (s, 2H), 4.53 (d, J = 5.0 Hz, 2H), 4.40 (s, 2H) ), 3.90 (s, 1H), 3.88 - 3.82 (m, 2H), 3.24 - 3.13 (m, 2H), 3.08 (d, J = 15.5 Hz, 1H), 2.66 (d, J = 15.5 Hz, 1H) , 1.95-1.89 (m, 1H), 1.82-1.81 (m, 1H), 1.59-1.56 (m, 1H), 1.18-1.15 (m, 1H).
-
- 0.50g of 6-hydroxy-3,4-dihydroisoquinolin-1(2H)-one,0.437g of 3-bromopropyne and 0.847 g of potassium carbonate were dissolved in DMF (4 mL) andreacted at room temperature for 16 hours. TLC detected that the reaction was complete, cooled to room temperature, quenched by adding 20 mL of water, extracted with DCM (3×10 mL), washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the crude product was purified by column chromatography to obtain 570 mg of light yellow solid, Namely compound A52-1.
- 306 mg of compound A52-1, 600 mg of M1, 42 mg of PdCl2(PPh3)2, and 11.6 mg of CuI were dissolved in DMF (4.0 mL) and Et3N (1.0 mL), and heated at 60 °C for 16 hours after nitrogen replacement. LC-MS and TLC detected that the reaction was complete, cooled to room temperature, quenched by adding 20 mL of water, extracted with ethyl acetate (3×20 mL), washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the crude product was subjected to column chromatography purified to obtain 700 mg of pale yellow solid, namely compound A52-2.
- 400 mg of compound A52-2 was dissolved in 4.0 mL of dioxane, 1 mL of MeOH was added, 0.49 mL of HCl in EA solution (2M) was added dropwise with stirring, and the mixture was stirred at room temperature for 1 hour. LC-MS detected the completion of the reaction, added saturated sodium bicarbonate dropwise to adjust the pH to 8∼9, quenched by adding 20 mL of water, extracted with dichloromethane (3×10 mL), washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and prepared with the plate was purified to obtain 95 mg of yellow solid, namely compound A52.
- [M+H+]=510.37.
- 1H NMR (500 MHz, DMSO) δ 8.23 (s, 1H), 7.80 (d, J = 8.5 Hz, 1H), 7.76 (s, 1H), 7.30 (d, J = 6.2 Hz, 1H), 7.21 - 7.09 (m, 3H), 7.04 - 6.92 (m, 2H), 5.43 (t, J = 5.9 Hz, 1H), 5.15 (s, 2H), 4.47 (d, J = 5.9 Hz, 2H), 3.84 (s, 1H), 3.83 - 3.73 (m, 2H), 3.37 - 3.34 (m, 2H), 3.14 - 3.08 (m, 2H), 3.03 (d, J = 15.6 Hz, 1H), 2.88 (t, J = 6.5 Hz , 2H), 2.60 (d, J = 15.6 Hz, 1H), 1.91 - 1.81 (m, 1H), 1.80 - 1.69 (m, 1H), 1.55 - 1.44 (m, 1H), 1.17 - 1.05 (m, 1H) ).
-
- 1.0 g of 3-cyanophenol was dissolved in DMF (10.0 mL), 1.74 g of K2CO3 was added, and the reaction was stirred at room temperature for 10 min. 0.98 mL of bromopropyne was added dropwise. After nitrogen replacement, the reaction was stirred at room temperature for 1 h. LC-MS and TLC After detecting that the reaction was complete, 40 mL of water was added, extracted with ethyl acetate (3×40 mL), washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by column chromatography to obtain 0.92 g of white solid, namely compound A53- 1.
- 150 mg of compound M1, 21 mg of PdCl2(PPh3)2, 3 mg of CuI, and 72 mg of compound A47-1 were dissolved in DMF (20.0 mL) and Et3N (0.75 mL), and after nitrogen replacement, the reaction was carried out at 60 °C for 3 hours. LC-MS and TLC detected that the reaction was complete, 20 mL of ethyl acetate was added, the filter residue was filtered off, the filtrate was dispersed in 20 mL of water, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by column chromatography to obtain 60 mg pale yellow solid, namely compound A53-2.
- 60 mg of compound A53-2 was dissolved in 6.0 mL of dioxane, 1.5 mL of MeOH was added, 0.2 mL of HCl in EA solution (2M) was added dropwise with stirring, and the mixture was stirred at room temperature for 30 min. LC-MS detected that the reaction was complete, the reaction solution was concentrated under reduced pressure, the residue was dissolved in 10 mL of water, and saturated sodium bicarbonate was added dropwise to adjust the pH to 8-9, the precipitated solid was collected, and purified with a preparative plate to obtain 20 mg of pale yellow solid, namely Compound A53.
- [M+H+]=466.30.
- 1H NMR (500 MHz, CDCl3) δ 8.20 (s, 1H), 7.45-7.38 (m, 1H), 7.37-7.25 (m, 5H), 7.21 (s, 3H), 4.99 (s, 2H), 4.65 ( s, 2H), 4.00 (s, 1H), 3.66-3.52 (m, 2H), 3.25-3.12 (m, 2H), 3.11-3.02 (m, 1H), 2.77-2.64 (m, 1H), 1.97- 1.87 (m, 1H), 1.87-1.79 (m, 1H), 1.68-1.57 (m, 1H), 1.45-1.36 m, 1H), 1.22-1.16(m, 1H).
-
- Dissolve 0.53 g of 2-chloro-4-hydroxybenzamide in DMF (10.0 mL), add 0.63 g of K2CO3 and stir at room temperature for 10 min, add dropwise 0.40 mL of bromopropyne, replace with nitrogen, and heat up to 60 °C to stir the reaction After 2.5 h, LC-MS and TLC detected the reaction was complete, 40 mL of water was added, extracted with ethyl acetate (3×40 mL), washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by column chromatography to obtain 610 mg white solid, namely compound A54-1.
- 1.00 g of compound M1, 0.14 g of PdCl2(PPh3)2, 20 mg of CuI, and 0.64 g of compound A54-1 were dissolved in DMF (20.0 mL) and Et3N (5.0 mL), and the reaction was carried out at 60 °C for 10 hours after nitrogen replacement. LC-MS and TLC detected that the reaction was complete, 50 mL of ethyl acetate was added, the filter residue was filtered off, the filtrate was dispersed in 50 mL of water, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by column chromatography to obtain 0.80 g pale yellow solid, namely compound A54-2.
- 100 mg of compound A54-2 was dissolved in 6.0 mL of dioxane, 1.5 mL of MeOH was added, 0.26 mL of HCl in EA solution (2M) was added dropwise with stirring, and the mixture was stirred at room temperature for 30 min. LC-MS detected that the reaction was complete, the reaction solution was concentrated under reduced pressure, the residue was dissolved in 10 mL of water, and saturated sodium bicarbonate was added dropwise to adjust the pH to 8-9, the precipitated solid was collected, and purified with a preparative plate to obtain 35 mg of yellow solid compound A54.
- [M+H+]=518.26.
- 1H NMR (500 MHz, DMSO) δ 8.22 (s, 1H), 7.77 (s, 1H), 7.47 (d, J = 11.3 Hz, 1H), 7.44 (s, 1H), 7.30 (d, J = 6.5 Hz , 1H), 7.23 - 7.08 (m, 4H), 7.05 (dd, J = 8.6, 2.5 Hz, 1H), 5.43 (t, J = 5.9 Hz, 1H), 5.17 (s, 2H), 4.46 (d, J = 5.9 Hz, 2H), 3.83 (s, 1H), 3.82 - 3.74 (m, 2H), 3.19 - 3.06 (m, 2H), 3.03 (d, J = 15.6 Hz, 1H), 2.60 (d, J = 15.6 Hz, 1H), 1.89 - 1.82 (m, 1H), 1.79 - 1.72 (m, 1H), 1.54 - 1.48 (m, 1H), 1.13 - 1.07 (m, 1H).
-
- 0.18 g of 4-(prop-2-p-1-amino)benzamide, 0.17 g of methyl iodide and 0.21 g of potassium carbonate were dissolved in DMF (3 mL) and reacted at room temperature for 3 hours. TLC detected that the reaction was complete, 50 mL of water was added, 50 mL of ethyl acetate was added for extraction, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by column chromatography to obtain 0.12 g of a yellow solid, namely compound A55-1 .
- 120 mg of compound M1, 54.4 mg of A55-1, 8.5 mg of PdCl2(PPh3)2 and 2.3 mg of CuI were dissolved in DMF (5 mL) and triethylamine (1 mL), and the reaction was performed at 60 °C for 2 hours after nitrogen replacement. LC-MS and TLC detected that the reaction was complete, quenched by adding 10 mL of water, extracted with ethyl acetate (3×20 mL), washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by preparative plate to obtain 50 mg of yellow Solid compound A55-2.
- 50 mg of compound A55-2 was dissolved in dioxane (2 mL) and methanol (1 mL), 2N HCl (0.1 mL, ethyl acetate solution) was added, and the reaction was stirred at RT for 1 hour. LC-MS and TLC detected that the reaction was complete, and the reaction solution was concentrated under reduced pressure. The residue was dissolved in H2O (1.0 mL), the solution was adjusted to pH=8 with saturated NaHCO3, extracted with dichloromethane (3×3 mL), the organic phase was dried and concentrated in vacuo, and purified by preparative plate to obtain 34.2 mg of a pale yellow solid, namely compound A55 .
- [M+H+]=497.37.
- 1H NMR (500 MHz, DMSO-d6) δ8.13 (s, 1H), 7.79 - 7.75 (m, 2H), 7.68 (s, 1H), 7.30-7.28 (m, 1H), 7.18-7.12 (m, 3H), 6.99 (s, 1H), 6.89-6.85 (m, 2H), 5.40 (t, J = 6.0 Hz, 1H), 4.50 (s, 2H), 4.43 (d, J = 6.0 Hz, 2H), 3.83 (s, 1H), 3.78-3.71 (m, 2H), 3.12 -2.97 (m, 6H), 2.65-2.56 (m, 1H), 1.90-1.82 (m, 1H), 1.78 - 1.72 (m, 1H) ), 1.54-1.48 (m, 1H), 1.11-1.08 (m, 1H).
-
- 2.0 g of 4-iodophenol was dissolved in DMF (10.0 mL), 2.5 g of K2CO3 was added to stir the reaction for 3 min, 1.48 mL of PMBCl was added dropwise, and the reaction was stirred at 60 °C for 1.5 h. LC-MS and TLC detected the reaction was complete, and 40 mL of extracted with water, ethyl acetate (3×40 mL), washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the crude product was purified by column chromatography to obtain 2.38 g of white solid compound A57-1.
- Dissolve 2.38 g of compound A57-1, 0.54 g of dimethyl phosphorus oxide in dioxane (10.0 mL), and stir under nitrogen protection for 10 min to obtain a raw material mixture. In addition, 0.13 g of Pd2dba3, 80 mg of Xantphos and 1.44 mL of tris Ethylamine was dissolved in dioxane (10.0 mL), and stirred under nitrogen protection for 10 min to obtain a catalyst mixture. The catalyst mixture solution was injected into the raw material mixture solution, and the temperature was raised to 60 °C and stirred for 24 h. After LC-MS and TLC were detected, the reaction was complete, added 40 mL of water, extracted with DCM (3×40 mL), washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by column chromatography to obtain 1.96 g of off-white solid, namely compound A57-2.
- 0.10 g of compound A57-3 was dissolved in DCM (5.0 mL), 0.3 mL of TFA was added dropwise in an ice bath, stirred at room temperature for 1 h, the reaction was complete by LC-MS and TLC, concentrated in vacuo, and the crude product was purified by column chromatography to obtain 0.55 g Light yellow oily liquid, namely compound A57-3.
- 0.60 g of compound A57-3 was dissolved in DMF (10.0 mL), 0.73 g of K2CO3 was added, and the reaction was stirred at room temperature for 10 min, and 0.41 mL of bromopropyne was added dropwise. TLC detected the completion of the reaction, added 40 mL of water, extracted with ethyl acetate (3×40 mL), washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by column chromatography to obtain 0.57 g of a purple-red liquid, which is the compound A57-4.
- 200 mg of compound M1, 28 mg of PdCl2(PPh3)2, 4 mg of CuI, and 126 mg of compound A47-1 were dissolved in DMF (20.0 mL) and Et3N (1.3 mL), and after nitrogen replacement, the reaction was carried out at 60 °C for 3 hours. LC-MS and TLC detected that the reaction was complete, 20 mL of ethyl acetate was added, the filter residue was filtered off, the filtrate was dispersed in 20 mL of water, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by column chromatography to obtain 0.17 g yellow solid, namely compound A57-5.
- 0.17 g of compound A57-5 was dissolved in 12.0 mL of dioxane, 3 mL of MeOH was added, 0.3 mL of HCl in EA solution (2M) was added dropwise with stirring, and the mixture was stirred at room temperature for 30 min. LC-MS detected that the reaction was complete, the reaction solution was concentrated under reduced pressure, the residue was dissolved in 10 mL of water, and saturated sodium bicarbonate was added dropwise to adjust the pH to 8-9, the precipitated solid was collected, and purified with a preparative plate to obtain 95 mg of pale yellow solid, namely Compound A57.
- [M+H+]=517.35.
- 1H NMR (500 MHz, DMSO) δ 8.23 (s, 1H), 7.72 (dd, J = 11.0, 8.7 Hz, 2H), 7.30 (d, J = 6.9 Hz, 1H), 7.21-7.07 (m, 6H) , 5.43 (t, J = 5.9 Hz, 1H), 5.16 (s, 2H), 4.46 (d, J = 5.8 Hz, 2H), 3.79-3.73 (m, 1H), 3.72-3.68 (m, 2H), 3.18-3.06 (m, 2H), 3.03 (d, J = 15.6 Hz, 1H), 2.60 (d, J = 15.6 Hz, 1H), 1.89-1.82 (m, 1H), 1.79-1.72 (m, 1H) , 1.63 (s, 3H), 1.54-1.48 (m, 1H), 1.13-1.07 (m, 1H).
-
- 2.00 g of methyl 3,6-dibromopyrazine-2-carboxylate and 2.27 g of compound M12 were dissolved in 12 mL of tetrahydrofuran, 1.95 mL of DIEA was added dropwise, and the reaction was stirred at 60 °C. for 2 hours. TLC detected that the reaction was complete, concentrated under reduced pressure, added 50 mL of water, extracted with EtOAc (50 mL×3), combined the organic layers, dried over sodium sulfate, and desolvated, and purified by column chromatography to obtain 3.50 g, namely compound A58-1.
- Under nitrogen protection, 3.00 g of compound A58-1 was dissolved in 40 mL of anhydrous dichloromethane, the temperature was lowered to -78 °C, a solution of DIBAL-H (1 M, 27 mL) in n-hexane was added dropwise, and the solution was stirred at -78 °C React for 1 hour. The temperature was slowly raised to -40°C, and the reaction was continued for 2 hours. TLC detected that the reaction of the raw materials was complete. At 0 °C, 1.08 mL of water was slowly added dropwise, then an aqueous sodium hydroxide solution (15%, 1.08 mL) was added dropwise, and 2.7 mL of water was added. Warm to room temperature and stir for 15 minutes. It was dried by adding sodium sulfate, stirred for ten minutes and filtered. The filtrate was concentrated and purified by column chromatography to obtain 2.80 g, namely compound A58-2
- Under nitrogen protection, 2.80 g of compound A58-2 was dissolved in 20 mL of tetrahydrofuran, 0.41 g of sodium borohydride was added, and the reaction was carried out at room temperature for 0.5 hours. TLC detected that the reaction of the raw materials was complete. At 0 °C, 2 mL of saturated ammonium chloride was added to quench the reaction, 50 mL of water was added, and then extracted with EtOAc (50 mL × 3). The organic layers were combined, dried over sodium sulfate, and then desolvated. purified by column chromatography to obtain 2.30 g, namely compound A58-3.
- 300 mg of compound M1, 150 mg of 4-(prop-2-p-1-oxy)benzamide, 20.1 mg of PdCl2(PPh3)2 and 5.5 mg of CuI were dissolved in DMF (10 mL) and triethylamine (1 mL), after nitrogen replacement, the reaction was carried out at 60 °C for 12 hours. LC-MS and TLC detected that the reaction was complete, quenched by adding 10 mL of water, extracted with ethyl acetate (3×20 mL), washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the crude product was purified by column chromatography to obtain 160 mg yellow solid, namely compound A58-4.
- 160 mg of compound A58-4 was dissolved in dioxane (3 mL) and methanol (1 mL), 2N HCl (2 mL, ethyl acetate solution) was added, and the reaction was stirred at RT for 1 hour. LC-MS and TLC detected the completion of the reaction, the reaction solution was concentrated under reduced pressure, the residue was dissolved in H2O (1.0 mL), the solution was adjusted to pH=8 with saturated NaHCO3, extracted with dichloromethane (3×3 mL), the organic phase was dried and concentrated in vacuo, purified by preparative plate to obtain 81 mg of pale yellow solid compound A58.
- [M+H+]=514.34.
- 1H NMR (500 MHz, DMSO-d6) δ 8.22 (s, 1H), 7.88-7.85 (m, 3H), 7.21 (s, 1H), 7.10-7.05 (m, 3H), 6.89 (d, J = 2.5 Hz, 1H), 6.69 (dd, J = 8.0, 2.5 Hz, 1H), 5.43 (t, J = 6.0 Hz, 1H), 5.15 (s, 2H), 4.46 (d, J = 6.0 Hz, 2H), 3.84-3.77 (m, 3H), 3.72 (s, 3H), 3.16-3.04 (m, 2H), 2.95 (d, J = 15.6 Hz, 1H), 2.52 (d, J = 15.6 Hz, 1H), 1.89 -1.83 (m, 1H), 1.77-1.70 (m, 1H), 1.54-1.49 (m, 1H), 1.11-1.08 (m, 1H).
-
- 2.00 g m-hydroxyphenylacetic acid was dissolved in MeOH (30.0 mL), then concentrated sulfuric acid (0.1 mL) was slowly added dropwise, heated at 60 °C for 5 hours, TLC detected the reaction was complete, cooled to room temperature, the reaction solution was concentrated under reduced pressure, added 20 mL of dichloromethane, washed with saturated brine (3×10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain 2.15 g of an oily product, namely compound A59-1
- 2.15 g of compound A59-1 was dissolved in 25% ammonia water (11 mL) and reacted at room temperature for 6 hours. LC-MS detected that the reaction was complete, and concentrated under reduced pressure to obtain 2.22 g of a light yellow solid, namely compound A59-2.
- 1.00 g of compound A59-2, 0.866 g of 3-bromopropyne and 1.83 g of potassium carbonate were dissolved in DMF (8 mL) and reacted at 80 °C for 3 hours. The reaction was completed by TLC, cooled to room temperature, quenched by adding 20 mL of water, extracted with DCM (3×10 mL), washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the crude product was purified by column chromatography to obtain 135 mg of pale yellow solid, namely compound A59-3.
- 135 mg of compound A59-3, 234 mg of M1, 20 mg of PdCl2(PPh3)2, 5.4 mg of CuI were dissolved in DMF (4.0 mL) and Et3N (1.0 mL), and the reaction was carried out at 60 °C for 16 hours after nitrogen replacement. LC-MS and TLC detected that the reaction was complete, cooled to room temperature, quenched by adding 20 mL of water, extracted with ethyl acetate (3×20 mL), washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the crude product was subjected to column chromatography purified to obtain 250 mg of pale yellow solid, namely compound A59-4.
- 250 mg of compound A59-4 was dissolved in 2.0 mL of dioxane, 0.5 mL of MeOH was added, 0.19 mL of HCl in EA solution (2M) was added dropwise with stirring, and the mixture was stirred at room temperature for 1 hour. LC-MS detected the completion of the reaction, added saturated sodium bicarbonate dropwise to adjust the pH to 8-9, quenched by adding 20 mL of water, extracted with dichloromethane (3×10 mL), washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and prepared with plate purification yielded 33 mg of a yellow solid, compound A59.
- [M+H+]=498.41.
- 1H NMR (500 MHz, DMSO) δ 8.23 (s, 1H), 7.44 (s, 1H), 7.30 (d, J = 6.6 Hz, 1H), 7.25 (t, J = 7.9 Hz, 1H), 7.20 - 7.11 (m, 3H), 6.96 - 6.83 (m, 4H), 5.44 (t, J = 6.0 Hz, 1H), 5.06 (s, 2H), 4.46 (d, J = 6.0 Hz, 2H), 3.83-3.76 (m, 2H), 3.35 (s, 2H), 3.18 - 2.97 (m, 3H), 2.61 (d, J = 15.6 Hz, 1H), 1.92 - 1.80 (m, 1H), 1.80 - 1.70 (m, 1H) , 1.56 - 1.44 (m, 1H), 1.16 - 1.07 (m, 1H).
-
- 1.00 g of 2-Aminooxazole, 3.37 g of BOC acid anhydride and 0.15 g of 4-DMAP were dissolved in DMF (10.0 mL) and DMF (3.9 mL), and the reaction was stirred at room temperature for 4 h. LC-MS and TLC detected that the reaction was complete. 20 mL of water, extracted with ethyl acetate (3×20 mL), washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the crude product was purified by column chromatography to obtain 700 mg of white solid, namely compound A60-1.
- Under nitrogen protection, 0.2 g of A60-1, 0.16 g of bromopropyne and 0.23 g of potassium carbonate were dissolved in DMF (4 mL) and reacted at 40 °C for 16 h. TLC detected that the reaction was complete, filtered, concentrated the filtrate, and purified the crude product by column chromatography to obtain 0.20 g of a yellow solid, namely compound A60-2.
- 160 mg of compound M1, 6.4 mg of PdCl2(PPh3)2, 3.5 mg of CuI, and 108 mg of compound A60-2 were dissolved in DMF (4.0 mL) and Et3N (1.0 mL), and after nitrogen replacement, reacted at 60 °C for 2 h. LC-MS and TLC detected that the reaction was complete, 10 mL of ethyl acetate was added, the filter residue was filtered off, the filtrate was dispersed in 20 mL of water, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by preparative plate to obtain 190 mg of light yellow Solid, namely compound A60-3.
- 190 mg of compound A60-3 was dissolved in DCM (4.0 mL) and trifluoroacetic acid (0.5 mL) and stirred at room temperature for 2 h. LC-MS detected that the reaction was complete, the reaction solution was concentrated under reduced pressure, the residue was dissolved in 10 mL of water, and saturated sodium bicarbonate was added dropwise to adjust the pH to 8-9, solid was precipitated, filtered, and dried to obtain a solid, namely compound A60-4, which was directly proceed to the next reaction.
- 160 mg of compound A60-4 was dissolved in 6 mL of dioxane, 2 mL of MeOH was added, 0.30 mL of HCl in EA solution (2M) was added dropwise with stirring, and the mixture was stirred at room temperature for 30 min. LC-MS detected that the reaction was complete, the reaction solution was concentrated under reduced pressure, the residue was dissolved in 10 mL of water, and saturated sodium bicarbonate was added dropwise to adjust the pH to 8-9, the precipitated solid was collected, and purified with a preparative plate to obtain 54.3 mg of a yellow solid, the compound A60.
- [M+H+]=431.34.
- 1H NMR (500 MHz, DMSO) δ 8.17 (s, 1H), 7.67 (t, J = 6.1 Hz, 1H), 7.49 (d, J = 1.0 Hz, 1H), 7.30 (d, J = 7.1 Hz, 1H) ), 7.20 - 7.11 (m, 3H), 6.81 (d, J = 0.9 Hz, 1H), 5.42 (t, J = 6.0 Hz, 1H), 4.46 (d, J = 5.9 Hz, 2H), 4.23 (d , J = 6.1 Hz, 2H), 3.83 (s, 1H), 3.80-3.69 (m, 2H), 3.15 - 3.08 (m, 2H), 3.03 (d, J = 15.6 Hz, 1H), 2.59 (d, J = 15.6 Hz, 1H), 1.90 - 1.85 (m, 1H), 1.78 - 1.73 (m, 1H), 1.52 - 1.50 (m, 1H), 1.07 - 1.04 (m, 1H).
-
- Dissolve 1.0 g of 1-methyl-5-Aminopyrazole in DMF (15.0 mL), add 2.13 g of K2CO3 and stir at room temperature for 10 min, drop 1.35 g of bromopropyne, replace with nitrogen, and stir at 60 °C for 18 h, LC-MS and TLC detected the reaction was complete, 20 mL of water was added, extracted with ethyl acetate (3×20 mL), washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the crude product was purified by column chromatography to obtain 700 mg of white solid compound A61-1.
- 150 mg of compound M1, 6.4 mg of PdCl2(PPh3)2, 3.5 mg of CuI and 144 mg of compound A61-1 were dissolved in DMF (4.0 mL) and Et3N (1.0 mL), and the reaction was carried out at 60 °C for 14 h after nitrogen replacement. LC-MS and TLC detected that the reaction was complete, 20 mL of water was added, extracted with 10 mL of ethyl acetate, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by preparative plate to obtain 140 mg of pale yellow solid A61-2.
- 140 mg of compound A61-2 was dissolved in 9 mL of dioxane, 3 mL of MeOH was added, 0.26 mL of HCl in EA solution (2M) was added dropwise with stirring, and the mixture was stirred at room temperature for 30 min. LC-MS detected that the reaction was complete, the reaction solution was concentrated under reduced pressure, the residue was dissolved in 10 mL of water, and saturated sodium bicarbonate was added dropwise to adjust the pH to 8-9, the precipitated solid was collected, and purified with a preparative plate to obtain 71 mg of yellow solid compound A61.
- [M+H+]=444.39.
- 1H NMR (500 MHz, DMSO) δ 8.16 (s, 1H), 7.30 (d, J = 7.1 Hz, 1H), 7.19-7.08 (m, 4H), 6.01 (t, J = 6.0 Hz, 1H), 5.51 (d, J = 1.8 Hz, 1H), 5.40 (t, J = 6.0 Hz, 1H), 4.46 (d, J = 5.9 Hz, 2H), 4.08 (d, J = 6.0 Hz, 2H), 3.83 (s , 1H), 3.81-3.70 (m, 2H), 3.54 (s, 3H), 3.14-3.05 (m, 2H), 3.02 (d, J = 15.7 Hz, 1H), 2.59 (d, J = 15.6 Hz, 1H), 1.90-1.83 (m, 1H), 1.79-1.73 (m, 1H), 1.5-1.50 (m, 1H), 1.12-1.08 (m, 1H).
-
- 0.150 g of 2,4-dibromopyrazine and 0.203 g of compound M1-7 were dissolved in DMF (10 mL), 0.274 mL of triethylamine was added, and the reaction was heated at 80 °C overnight. TLC detected that the reaction of the raw materials was complete, the reaction solution was cooled to room temperature, 20 mL of water was added, a solid was precipitated, the solid was filtered, the filter cake was washed with water, and dried to obtain 0.175 g of a pale yellow solid, namely compound A62-1.
- Dissolve 150 mg of compound A62-1, 121 mg of compound A54-1, 8 mg of PdCl2(PPh3)2, 2.0 mg of CuI in DMF (4 mL) and triethylamine (1 mL), replace with nitrogen, and react at 60 °C overnight. LC-MS and TLC detected that the reaction of the raw materials was complete, 10 mL of water was added to precipitate a solid, filtered, the filter cake was dissolved in DCM, dried over sodium sulfate, and concentrated under reduced pressure.
- 95 mg of compound A62-2 was dissolved in dioxane (3 mL) and methanol (1.5 mL), 2N HCl (0.36 mL, ethyl acetate solution) was added, and the reaction was stirred
- at RT for 1 hour. LC-MS and TLC detected that the reaction was complete, the reaction solution was adjusted to pH=8 with saturated NaHCO3, and the reaction solution was concentrated under reduced pressure to obtain a crude product. The crude product was purified by a preparative plate to obtain 62.3 mg of a pale yellow solid, namely compound A62.
- [M+H+]=488.23.
- 1H NMR (500 MHz, DMSO-d6) δ 8.32 (d, J = 1.5 Hz, 1H), 8.18 (d, J = 1.4 Hz, 1H), 7.76 (s, 1H), 7.47 (s, 1H), 7.44 (d, J = 8.5 Hz, 1H), 7.32-7.26 (m, 1H), 7.20-7.11 (m, 4H), 7.05 (dd, J = 8.5, 2.5 Hz, 1H), 5.14 (s, 2H), 4.30-4.18 (m, 2H), 3.82 (s, 1H), 3.26-3.12 (m, 2H), 3.07 (d, J = 15.7 Hz, 1H), 2.62 (d, J = 15.7 Hz, 1H), 1.77 -1.71 (m, 1H), 1.66-1.60 (m, 1H), 1.55-1.47 (m, 1H), 1.13-1.06 (m, 1H).
-
- 1 g of raw material 3-Aminobenzamide, 917 mg of 3-bromo-1-propyne, and 1.52 g of potassium carbonate were dissolved in 10 mL of DMF, and reacted at room temperature for 2 h. After TLC (DCM:MeOH=7:1) monitoring showed that the reaction was complete, 10 mL of water was added, extracted with 10 mL of EA, the organic phase was washed with 3×10 mL of saturated sodium chloride solution, the organic phase was separated, and dried over anhydrous sodium sulfate, concentrated under reduced pressure, and subjected to column chromatography (DCM:MeOH=10:1) to obtain 680 mg of light yellow powder of compound A81-1.
- 174 mg of compound A81-1, 150 mg of M1, 6.4 mg of Pd(PPh3)2Cl2, and 3.5 mg of CuI were dissolved in 2 mL of DMF and 0.4 mL of triethylamine, replaced with N2, and reacted at 60 °C for 12 h. After TLC (DCM:MeOH=10:1) detection showed that the reaction of the raw materials was complete, 10 mL of ethyl acetate and 10 mL of water were added for extraction, the organic phase was separated, the organic phase was washed with 3×10 mL of saturated sodium chloride solution, separated and dried, separation and purification by column chromatography (DCM:MeOH=19:1) gave 121 mg of pale yellow powder, namely compound A81-2.
- 121 mg of compound A81-2 was dissolved in 4 mL of dioxane and 2 mL of methanol solution, replaced with nitrogen, 0.2 mL of HCl in EA solution (2 M) was added dropwise with stirring, and stirred at room temperature for 20 min. LC-MS detected that the reaction was complete, the reaction solution was concentrated under reduced pressure, the residue was dissolved in 5 mL of water, a saturated sodium bicarbonate solution was added dropwise to pH 8-9, the precipitated solid was collected, and 50.7 mg of yellow powder was obtained by separation and purification on a thick plate, namely compound A81.
- [M+H+]=483.31.
- 1H NMR (500 MHz, DMSO-d6) δ 8.14 (s, 1H), 7.80 (s, 1H), 7.35-7.27 (m, 1H), 7.25-7.06 (m, 8H), 6.83 (dd, J = 8.0 , 2.4 Hz, 1H), 6.28 (t, J = 6.3 Hz, 1H), 5.41 (t, J = 6.0 Hz, 1H), 4.44 (d, J = 5.7 Hz, 2H), 4.20 (d, J = 6.2 Hz, 2H), 3.86 (s, 1H), 3.79-3.70 (m, 2H), 3.15-3.05 (m, 2H), 3.03 (d, J = 15.6 Hz, 1H), 2.61 (d, J = 15.8 Hz , 1H), 1.89-1.83 (m, 1H), 1.78-1.74 (m, 1H), 1.51-1.49 (m, 1H), 1.13-1.11 (m, 1H).
-
- 0.200 g of 4-hydroxypyrazole, 0.513 g of potassium carbonate and 0.340 g of bromopropyne were dissolved in DMF (2 mL) and reacted overnight at room temperature. TLC detected that the reaction of the raw materials was complete, 10 mL of water was added, extracted with ethyl acetate (10 mL×3), the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by column chromatography to obtain a solid of 0.190 g, namely compound A82-1.
- 0.215 g of compound A82-1, 0.487 g of potassium carbonate and 0.364 g of bromopropyne were dissolved in DMF (4 mL), and heated at 50 °C to react for 4 hours. TLC detected that the reaction of the raw materials was complete, 10 mL of water was added, extracted with ethyl acetate (10 mL × 4), the organic phases were combined, washed with saturated brine (5 mL × 4), dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by column chromatography to obtain 0.211 g of solid, namely compound A82-2.
- 180 mg of compound M1, 98 mg of compound A82-2, 12.8 mg of PdCl2(PPh3)2, 3.5 mg of CuI were dissolved in DMF (5 mL) and triethylamine (1 mL), and after nitrogen replacement, the reaction was carried out at 60 °C for 5 hours . LC-MS and TLC detected that the reaction was complete, 10 mL of water was added, (EA:THF=1:1) extraction (10 mL×4), the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, concentrated in vacuo, and the crude product was subjected to column chromatography purified to obtain solid 0.190 g, namely compound A82-3.
- 190 mg of compound A82-3 was dissolved in dioxane (5 mL) and methanol (1.5 mL), 2N HCl (0.45 mL, ethyl acetate solution) was added, and the reaction was stirred at RT for 1 hour. LC-MS and TLC detected that the reaction was complete, and the reaction solution was concentrated under reduced pressure. The residue was dissolved in H2O (1.0 mL), adjusted to pH=8 with saturated NaHCO3, extracted with dichloromethane (5×3 mL), the organic phase was dried and concentrated in vacuo, and purified by preparative plate to obtain 85.0 mg of pale yellow solid, compound A82 .
- [M+H+]=488.34.
- 1H NMR (500 MHz, DMSO-d6): δ 8.24 (s, 1H), 7.57 (s, 1H), 7.39 (s, 1H), 7.315-7.29 (m, 2H), 7.23 (s, 1H), 7.21 -7.11 (m, 3H), 5.45 (t, J = 5.5 Hz, 1H), 4.88 (s, 2H), 4.65 (s, 2H), 4.47 (d, J = 5.5 Hz, 2H), 3.87-3.75 ( m, 3H), 3.16-3.12 (m , 3H), 3.04 (d, J = 15.6 Hz, 1H), 2.61 (d, J = 15.6 Hz, 1H), 1.89-1.81 (m, 1H), 1.78-1.71 (m, 1H), 1.53-1.50 (m, 1H), 1.12-1.10 (m, 1H).
- Through different reaction starting materials, suitable reagents (both starting materials and reagents are commercially available) and intermediates prepared by the present invention, the compounds in Table 2 were prepared by methods similar to the previous examples.
Table 2 Example Structure Chemical Name [M+H]+ Example5 (A05) (S)-(3-(1-amino-1,3-dihydrospiro[ indene-2,4'-piperidin]-1'-yl)-6-(3-( 3-chloro-2-fluorophenoxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol 493.17 Example 10 (A10) (S)-(3-(1-amino-1,3-dihydrospiro[ indene-2,4'-piperidin]-1'-yl)-6-(3-( 2-methoxyphenoxy)prop-1-yn-1 -yl) pyrazin-2-yl)methanol 471.23 Example 11 (A11) (S)-(3-(1-amino-1,3-dihydrospiro[ indene-2,4'-piperidin]-1'-yl)-6-(3-( 3,4-dimethoxyphenoxy)prop-1-yn-1-y l)pyrazin-2-yl)methanol 501.24 Example 12 (A12) (S)-4-((3-(5-(1-amino-1,3-dihydro spiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)pr op-2-yn-1-yl)oxy)benzonitrile 466.22 Example 14 (A14) (S)-(3-(1-amino-1,3-dihydrospiro[ indene-2,4'-piperidin]-1'-yl)-6-(3-( 4-(trifluoromethyl)phenoxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol 509.21 Example 15 (A15) (S)-(3-(1-amino-1,3-dihydrospiro[ indene-2,4'-piperidin]-1'-yl)-6-(3-( 3-(trifluoromethoxy)phenoxy)pro p-1-yn-1-yl)pyrazin-2-yl)methano 1 525.20 Example 16 (A16) (S)-1-(3-((3-(5-(1-amino-1,3-dihy drospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-y l)prop-2-yn-1-yl)oxy)phenyl)etha n-1-one 483.23 Example 19 (A19) (S)-(3-(1-amino-1,3-dihydrospiro[ indene-2,4'-piperidin]-1'-yl)-6-(3-( (2-Aminopyrimidine-5-yl)oxy)pro p-1-yn-1-yl)pyrazin-2-yl)methano 1 458.22 Example20 (A20) (S)-(3-(1-amino-1,3-dihydrospiro[ indene-2,4'-piperidin]-1'-yl)-6-(3-( 4-morpholinoloxy)prop-1-yn-1-yl )pyrazin-2-yl)methanol 526.27 Example23 (A23) (S)-6-((3-(5-(1-amino-1,3-dihydro spiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)pr op-2-yn-1-yl)oxy)-2Hbenzo[b] [1, 4]oxazin-3(4H)-one 512.22 Example24 (A24) (S)-7-((3-(5-(1-amino-1,3-dihydro spiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)pr op-2-yn-1-yl)oxy)quinolin-2(1H)-one 508.23 Example25 (A25) (S)-6-((3-(5-(1-amino-1,3-dihydro spiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)pr op-2-yn-1-yl)oxy)indol-2-one 496.23 Example28 (A28) (S)-(3-(1-amino-1,3-dihydrospiro[ indene-2,4'-piperidin]-1'-yl)-6-(3-( benzo[d][1,3]dioxyol-5-oxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol 485.21 Example29 (A29) (S)-(3-(1-amino-1,3-dihydrospiro[ indene-2,4'-piperidin]-1'-yl)-6-(3-( (((2,3-dihydrobenzo[b][1,4]dioxin -6-yl)oxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol 499.23 Example30 (A30) (S)-5-((3-(5-(1-amino-1,3-dihydro spiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)pr op-2-yn-1-yl)oxy)-1-methylpyridi n-2(1H)-one 472.23 Example31 (A31) (S)-(6-(3-((1H-Indolazol-6-yl)oxy )prop-1-yn-1-yl)-3-(1-amino-1,3-d ihydrospiro[indene-2,4'-piperidin] -1'-yl)pyrazin-2-yl)methanol 481.23 Example34 (A34) (S)-N-(3-((3-(2-(1-amino-1,3-dihy drospiro [indene-2,4'-piperidin] -1'-yl)-1-methyl-6-oxo-1,6-dihydropy rimidin-5-yl)prop-2-yn-1-yl)oxy)p henyl)acetamide 498.24 Example35 (A35) (S)-3-((3-(5-(1-amino-1,3-dihydro spiro[indene-2,4'-piperidine]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl) prop-2-yn-1-yl)oxy)-N-methylben zamide 498.24 Example36 (A36) (S)-3-((3-(5-(1-amino-1,3-dihydro spiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)pr op-2-yn-1-yl)oxy)-N,N-dimethylb enzamide 512.26 Example37 (A37) (S)-(3-(1-amino-1,3-dihydrospiro[ indene-2,4'-piperidin]-1'-yl)-6-(3-( 3-(methylthio)phenoxy)prop-1-yn -1-yl)pyrazin-2-yl)methanol 519.20 Example3 8 (A38) (S)-(3-((3-(5-(1-amino-1,3-dihydr ospiro[indene-2,4'-piperidin]-1'-yl )-6-(hydroxymethyl)yl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)phenyl)dim ethylphosphine oxide 517.23 Example39 (A39) (S)-4-((3-(5-(1-amino-1,3-dihydro spiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)pr op-2-yn-1-yl)oxy)-1-methylpyridi n-2(1H)-one 472.23 Example40 (A40) (S)-4-((3-(5-(1-amino-1,3-dihydro spiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)pr op-2-yn-1-yl)oxy)-N-picoline amide 499.24 Example42 (A42) (S)-3-(1-amino-1,3-dihydro spiro[i ndene-2,4'-piperidin]-1'-yl)-6-(3-( (3-oxoisooctanol)-5-yl)oxy)prop-1-yn-1-yl)pyrazine-2- formamide 509.22 Example43 (A43) (S)-5-(5-(1-amino-1,3-dihydrospir o[indene-2,4'-piperidin]-1'-yl)-6-( hydroxymethyl)pyrazine-2-yl)-1 -phenylpent-4-yn-1 -one 467.24 Example44 (A44) (S)-4-(5-(1-amino-1,3-dihydrospir o[indene-2,4'-piperidin]-1'-yl)-6-( hydroxymethyl)pyrazine-2-yl)-N-phenyl-3-alkynamide 468.23 Example56( A56) (S)-5-((3-(5-(1-amino-1,3-dihydro spiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)pr op-2-yn-1-yl)oxy)pyridineamide 485.34 Example63( A63) (S)-(3-(1-amino-1,3-dihydrospiro[ indene-2,4'-piperidin]-1'-yl)-6-(3-( (6-(trifluoromethyl)pyridin-3-yl)a mino)prop-1-yn-1-yl)pyrazin-2-yl )methanol 509.32 Example64( A64) (S)-7-((3-(5-(1-amino-1,3-dihydro spiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)pr op-2-yn-1-yl)amino)-3,4-dihydroq uinolin-2(1H)-one 509.32 Example65( A65) (S)-N-(3-((3-(5-(1-amino-1,3-dihy drospiro [indene-2,4'-piperidin] -1'-yl)-6-(hydroxylmethyl)pyrazin-2-yl)prop-2-yn-1-yl)amino)phenyl)a cetamide 497.33 Example66( A66) (S)-6-((3-(5-(1-amino-1,3-dihydro spiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)pr op-2-yn-1 -yl)oxy)isoindol-1 -one 496.31 Example67( A67) (S)-(6-(3-((1H-Indazol-5-yl)oxy)p rop-1-yn-1-yl)-3-(1-amino-1,3-dih ydrospiro[Indene-2,4'-piperidin]-1 '-yl)pyrazin-2-yl)methanol 481.32 Example68( A68) (S)-(3-(1-amino-1,3-dihydrospiro[ indene-2,4'-piperidin]-1'-yl)-6-(3-( (2-(methylAmino)pyrimidin-5-yl) oxy)prop-1-yn-1-yl)pyrazin-2-yl) methanol 472.34 Example69( A69) (S)-(3-(1-amino-1,3-dihydrospiro[ inden-2,4'-piperidin]-1'-yl)-6-(3-(( 2-Aminobenzo[d]oxazol-5-yl)oxy )prop-1-yn-1-yl)pyrazin-2-yl)met hanol 497.3 Example70( A70) (S)-(3-(1-amino-1,3-dihydrospiro[ indene-2,4'-piperidin]-1'-yl)-6-(3-( (6-(trifluoromethyl)pyridin-3-yl)o xy)prop-1-yn-1-yl)pyrazin-2-yl)m ethanol 510.27 Example71( A71) (S)-2-(4-((3-(5-(1-amino-1,3-dihy drospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxylmethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)phenyl)ace tamide 498.34 Example72( A72) (S)-4-((3-(5-(1-amino-1,3-dihydro spiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)pr op-2-yn-1-yl)oxy)-N-methylbenza mide 498.33 Example73( A73) (S)-(3-(1-amino-1,3-dihydrospiro[ indene-2,4'-piperidin]-1'-yl)-6-(3-( (2-methyl-1H-Benzo[d]imidazol-5-yl)oxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol 495.31 Example74( A74) (S)-4-((3-(5-(1-amino-1,3-dihydro spiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)pr op-2-yn-1-yl)oxy)-2-methylbenza mide 498.38 Example75( A75) (S)-6-((3-(5-(1-amino-1,3-dihydro spiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)pr op-2-yn-1-yl)oxy)pyridin-3-ol 458.3 Example76( A76) (S)-4-((3-(5-(1-amino-1,3-dihydro spiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)pr op-2-yn-1-yl)oxy)-N-cyclopropyl benzamide 524.33 Example77( A77) (S)-(3-(1-amino-1,3-dihydrospiro[ indene-2,4'-piperidin]-1'-yl)-6-(3-( 4-((1-methyl)yl-1H-pyrazol-5-yl)a mino)phenoxy)prop-1-yn-1-yl)pyr azin-2-yl)methanol 536.38 Example 8 3 (A83) (R)-4-((3-(5-(3-amino-3H-spiro[b enzofuran-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazine -2-yl)prop-2-yn-1-yl)oxy)benzami de 486.21 Example84 (A84) (S)-4-((3-(5-(5-amino-5,7-dihydro spiro[cyclopenta[b]pyridin-6,4'-pi peridin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)pro p-2-yn-1-yl)oxy)benzamide 485.22 Example85 (A85) (S)-4-((3-(5-(4-amino-4,6-dihydro spiro [cyclopenta[d]thiazol-5,4'-pi peridin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)pro p-2-yn-1-yl)oxy)benzamide 491.18 Example86 (A86) (S)-4-((3-(5-(4-amino-4,6-dihydro spiro[cyclopenta[d]oxazol-5,4'-pi peridin]-1'-yl)-6 -(hydroxymethyl)pyrazin-2-yl)pro p-2-yn- 1-yl)oxy)benzamide 475.20 Example87 (A87) (S)-4-((3-(5-(4-amino-4,6-dihydro -1H-spiro[cyclopenta[d]imidazol-5,4'-piperidin]-1'-yl)-6-(hydroxym ethyl)pyrazin-2-yl)prop-2-yn-1-yl )oxy)benzamide 474.22 - Compound A56: 1H NMR (500 MHz, DMSO) δ 8.39 (d, J = 2.8 Hz, 1H), 8.23 (s, 1H), 8.04 (d, J = 8.7 Hz, 1H), 7.96 (s, 1H), 7.66 - 7.62 (m, 1H), 7.51 (s, 1H), 7.30 (d, J = 6.6 Hz, 1H), 7.19 - 7.12 (m, 3H), 5.43 (t, J = 5.6 Hz, 1H), 5.28 (s, 2H), 4.46 (d, J = 5.3 Hz, 2H), 3.84 - 3.79 (m, 3H) , 3.17- 3.08 (m, 2H), 3.03 (d, J = 15.6 Hz, 1H), 2.60 (d, J = 15.6 Hz, 1H), 1.90 - 1.85 (m, 1H), 1.78 - 1.73 (m, 1H), 1.52 - 1.50 (m, 1H), 1.12- 1.10 (m, 1H)
-
- 2.00 g of p-hydroxybenzaldehyde, 3.70 g of TBSCI and 0.20 g of DMAP were dissolved in DMF (50.0 mL) and Et3N (3.6 mL), and the reaction was stirred at room temperature for 4 h. LC-MS and TLC detected that the reaction was complete, 20 mL of water was added, It was extracted with ethyl acetate (3×20 mL), washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by column chromatography to obtain 3.02 g of colorless transparent liquid, namely compound A80-1.
- Under nitrogen protection, 1.50 g of compound A80-1, 1.35 g of TMSCF3 and 0.088 g of potassium carbonate were dissolved in DMF (20 mL) and reacted at room temperature for 4 h. TLC detected the completion of the reaction, added 20 mL of water, extracted with ethyl acetate (3×20 mL), washed with saturated brine, dried over anhydrous sodium sulfate, and the organic phase was concentrated in vacuo to obtain 1.80 g of colorless and transparent liquid, namely compound A80-2 , proceed directly to the next reaction.
- Under nitrogen protection, 1.80 g of compound A80-2 was dissolved in DMF (20 mL), and then TBAF (2M, 0.76 mL) was added to react at room temperature for 4 h. TLC detected the completion of the reaction, added 20 mL of water, extracted with ethyl acetate (3 × 20 mL), washed with saturated brine, dried over anhydrous sodium sulfate, concentrated the organic phase in vacuo, and purified by column chromatography to obtain 0.50 g of white solid, namely compound A80 -3.
- Under nitrogen protection, 0.50 g of compound A80-3, 0.37 g of bromopropyne and 0.54 g of potassium carbonate were dissolved in DMF (10 mL) and reacted at 40 °C for 4 h. TLC detected the completion of the reaction, added 20 mL of water, extracted with ethyl acetate (3×20 mL), washed with saturated brine, dried over anhydrous sodium sulfate, concentrated the organic phase in vacuo, and obtained 0.55 g of colorless and transparent liquid by column chromatography, which is the compound A80-4.
- 150 mg of compound M22-2, 6.4 mg of PdCl2(PPh3)2, 3.5 mg of CuI and 105 mg of compound A80-4 were dissolved in DMF (4.0 mL) and Et3N (1.0 mL), and after nitrogen replacement, the reaction was carried out at 60 °C for 2 h. LC-MS and TLC detected that the reaction was complete, 10 mL of ethyl acetate was added, the insolubles were filtered off, the filtrate was dispersed in 20 mL of water, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo. The crude product was purified by column chromatography to obtain 180 mg Light yellow solid, namely compound A80-5.
- 180 mg of compound A80-5 was dissolved in 6 mL of dioxane, 2 mL of MeOH was added, 0.28 mL of HCl in EA solution (2M) was added dropwise with stirring, and the mixture was stirred at room temperature for 30 min. LC-MS detected that the reaction was complete, the reaction solution was concentrated under reduced pressure, the residue was dissolved in 10 mL of water, and saturated sodium bicarbonate was added dropwise to adjust the pH to 8-9, the precipitated solid was collected, and purified with a preparative plate to obtain 101.5 mg of light yellow solid, namely Compound A80.
- [M+H+]=431.34.
- 1H NMR (500 MHz, DMSO) δ 8.22 (s, 1H), 7.44 (d, J = 8.2 Hz, 2H), 7.30 (d, J = 6.1 Hz, 1H), 7.16 (d, J = 6.7 Hz, 3H) ), 7.07 (d, J = 8.2 Hz, 2H), 6.74 (d, J = 5.1 Hz, 1H), 5.43 (s, 1H), 5.10 (s, 3H), 4.46 (d, J = 4.6 Hz, 2H) ), 3.86 - 3.72 (m, 3H), 3.16 - 3.09 (m, 2H), 3.03 (d, J = 15.8 Hz, 1H), 2.61 (d, J = 15.7 Hz, 1H), 1.90 - 1.85 (m, 1H), 1.78 - 1.73 (m, 1H), 1.52 - 1.50 (m, 1H), 1.07 - 1.04 (m, 1H).
- Through different reaction starting materials, suitable reagents (both starting materials and reagents are commercially available) and intermediates prepared by the present invention, the compounds in Table 3 were prepared by methods similar to Example 80.
Table 3 Example Structure Name [M+H]+ Example78 (A78) 1-(4-((3-(5-((S)-1-amino-1,3-dihy drospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxyl) methyl)pyrazin-2-yl)prop-2-yn-1-yl)o xy)phenyl)ethan-1-ol 485.25 Example79 (A79) (S)-2-(4-((3-(5-(1-amino-1,3-dihydros piro[indene-2,4'-piperidin]-1'-yl)-6-(hy droxyl Methyl)pyrazin-2-yl)prop-2-yn-1-yl)o xy)phenyl)propan-2-ol 499.26 - SHP2 is allosterically activated by binding of a bis-tyrosyl-phosphorylated peptide to its Src homology 2 (SH2) domain. This later activation step results in the release of the autoinhibitory interface of SHP2, which in turn activates the SHP2 protein tyrosine phosphatase (PTP) and is available for substrate recognition and reaction catalysis. The catalytic activity of SHP2 was monitored using the surrogate DiFMUP in a rapid fluorescence assay format.
experiment procedure: - (1) Compound preparation:
The compounds of the present invention (10 mM stock solution) were diluted to appropriate times with 100% DMSO, and the final test concentrations of the compounds of the present invention were 10 µM, 3.3333 µM, 1.1111 µM, 0.3704 µM, 0.1235 µM, 0.0412 µM, 0.0137 µM, 0.0046 µM, 0.0015 µM, 0.00 µM; - (2) Prepare the enzyme reaction working solution:
Perform SHP2 enzymatic assays in 96-well black polystyrene plates (flat bottom, low flange, non-binding surface) (Perki Elmer, Cat#6005270) at room temperature using a final reaction volume of 50 µL and the following assay buffer conditions: 60 mM HEPES, 75 mM NaCl, 75 mM KCl, 0.05% BRIJ-35, 1 mM EDTA, 5 mM DTT. - (3) Enzyme-catalyzed reaction and data monitoring:
Add the compound of the present invention to the corresponding 96-well plate, and set the blank test well without compound and enzyme only with buffer. Thaw SHP2 Activating Peptide (IRS1_pY1172(dPEG8)pY1222) on ice, add 25 µM to each well, then add 0.2 ng of SHP2 protein sample to the corresponding well plate and incubate at room temperature for 1 hour. The surrogate substrate DiFMUP (Invitrogen, Cat #D6567) was added to the reaction and allowed to react for 1 hour at room temperature. Fluorescence signals were monitored using a microplate reader (Envision, Perki Elmer) using excitation and emission wavelengths of 340 nM and 450 nM, respectively. - (4) Data analysis:
Calculation Formula: - Among them: Conversion_sample is the conversion rate reading of the sample; Conversion_min is the average value of blank control wells, representing the conversion rate readings of wells without enzymatic activity; Conversion_max is the mean ratio of positive control wells, representing the conversion rate readings of wells without compound inhibition. The log(inhibitor) vs. response-Variable slope of the analysis software GraphPad Prism was used to fit the dose-response curve, and the IC50 value of the compound for the enzymatic activity was calculated.
- The IC50 data of some examples are shown in Table 4.
Table 4 No. SHP2 enzymatic activity IC50 (nM) No. SHP2 enzymatic activity IC50 (nM) A01 1.2 A47 4 A02 0.7 A48 2 A03 1.1 A49 1.4 A04 2.9 A50 1.7 A05 4.9 A51 2.4 A06 6.8 A52 1.6 A07 2.5 A53 3.3 A08 3.3 A54 0.7 A09 0.9 A55 2.7 A10 3.7 A57 4.3 A11 1.5 A58 1.5 A12 1 A59 1.1 A13 5.8 A60 1.6 A15 11 A61 1.8 A16 2.4 A62 1.5 A17 2.4 A63 5 A18 35.0 A64 2.6 A20 3.8 A65 3.5 A21 2.1 A66 2.1 A22 4.6 A67 3.1 A24 2.4 A68 2.1 A25 1.7 A69 2.1 A26 1.6 A70 2.6 A27 1.9 A71 2.9 A28 1.5 A72 2.6 A32 1.3 A73 3.1 A34 5.3 A74 1.1 A35 2.2 A75 7.8 A36 7.2 A76 3.4 A37 2 A77 5.9 A41 14 A80 2.8 A42 15 A45 4.7 - The compounds of the present invention have an allosteric inhibitory effect on SHP2 protein.
- The effects of the compounds of the invention on the proliferation of leukemia cells MV-4-11 and lung cancer cells NCI-H358 were evaluated using in vitro cell assays. The detection method used in the experiment is the CELL TITER-GLO (CTG) luminescence method, which can detect the number of viable cells by quantifying ATP. Because ATP participates in a variety of enzymatic reactions in vivo, it is an indicator of the metabolism of living cells, and its content directly reflects the number and state of cells. During the experiment, CellTiter-Glo™ reagent was added to the cell culture medium to measure the luminescence value. The value is proportional to the amount of ATP, and ATP is positively related to the number of living cells, so the cell viability can be examined by detecting the ATP content. experiment procedure:
- (1) Cell plating:
- Take a bottle of MV-4-11 cells in logarithmic growth phase, resuspend the cells by centrifugation and count them. After adjusting the cell density, they were seeded into a 96-well plate (Corning #3917). After culturing in a 5% CO2 incubator for 24hrs, the compound of the present invention was added for treatment;
- Take a bottle of NCI-H358 cells in logarithmic growth phase, digest and resuspend the cells, count them, adjust the cell density, and inoculate them into a 96-well transparent ultra-low adsorption cell culture plate (Corning #3474), inoculate 2000 cells per well. The plate was placed in an incubator at 37°C and 5% CO2 for 24hrs, and then the compound of the present invention was added for treatment;
- (2) Cell compound treatment:
An appropriate amount of the compound of the present invention was prepared for cell treatment. The final concentration of the compound from high to low was 1000 nM, 333.3 nM, 111.1 nM, 37.04 nM, 12.35 nM, 4.115 nM, 1.372 nM, 0.4572 nM, 0.1524 nM, and 0 nM. The plate was placed in a 37 °C, 5% CO2 incubator for 120 hrs. Only adding medium without cell wells was set as the blank group; the group with compound concentration of 0 nM was the zero-adjusting group. - (3) CTG detection:
- After NCI-H358 cells were cultured for 96 hrs, 50 µL of CellTiter-Glo® Luminescent Cell Viability Assay solution was added to each well, shaken gently for 2 mins, and incubated at room temperature for 10 mins. The cell reaction system was transferred to a white-bottomed 96-well plate. Read the detection value of each well on a multi-function microplate reader.
- After MV-4-11 cells were cultured for 120 hrs, 50 µL of CellTiter-Glo® Luminescent Cell Viability Assay solution was added to each well, gently shaken for 2 mins, and incubated at room temperature for 10 mins. Check the value.
- (4) Data analysis:
Calculate the inhibition rate from the luminescence value readings, - The log(inhibitor) vs. response-Variable slope of GraphPad Prism was fitted to dose-response curves and IC50s of compounds that inhibited cell proliferation were calculated.
- The experimental data are shown in Table 5.
Table 5 No. MV-4-11 cells IC50(nM) NCI-H358 cells IC50(nM) A01 2.6 7.3 A02 5.0 7.8 A03 1.5 2.5 A04 3.6 4 A05 14 15 A06 8 11 A07 5.5 12 A08 2.1 3.8 A09 2.6 4.9 A10 4.4 4.3 A11 2.6 6.3 A12 3.8 7.4 A13 18 28 A16 6.9 11 A17 1 1.5 A20 12 14 A21 11 12 A22 2.9 2.3 A24 1.3 1.5 A25 0.9 2.3 A26 1.8 5.2 A27 1.4 1.5 A28 6.1 7 A32 3.4 9 A34 25 51 A35 3.0 3.6 A36 14 48 A37 11 9.6 A45 20 40 A47 17 48 A48 1.7 12 A49 6.7 8.5 A50 2.2 3.3 A51 1.0 0.8 A52 1.5 4.6 A53 8.1 27 A54 1.6 2.2 A55 9.6 26 A57 10 22 A58 0.8 4.0 A59 1 5.8 A60 13 41 A61 5.1 9.4 A62 14 56 A63 11 36 A64 0.9 2.1 A65 2.8 25 A66 2.7 6.4 A67 1.0 0.9 A68 8.6 26 A69 0.7 2.1 A70 6.2 17 A71 2.3 4.3 A72 1.8 3.5 A73 1.1 3.4 A74 1.7 6.4 A75 7.3 78 A76 3.3 19 A77 11 36 A80 10.4 / A81 1.8 6.3 A82 9 40 Note: "/" means not tested. - The compounds of the present invention have a good inhibitory effect on the proliferation of MV-4-11 cells and NCI-H358 cells.
- Dilute the test sample diluent in sequence with extracellular fluid to prepare detection solutions with final concentrations of 0.3 µM, 1µM, 3µM, 10 µM and 30 µM. The solubility of the samples to be tested was visually checked.
- The cell line was derived from HEK293 cells and cultured in a 37 °C, 5% CO2 incubator. In order to prevent cell senescence caused by contact inhibition, when the cell culture confluence should not exceed 80%, the cells should be passaged every 3/4 days, and the inoculation density of each T175 flask should be 2*106 cells. Pre-wash with Phosphate Buffered Saline (PBS), then trypsin/EDTA for 2-3 minutes, stop digestion by adding cell culture medium, and transfer to a new culture bottle.
- HEK293 cells overexpressing the hERG potassium channel were cultured overnight at a cell density below 50%. Experimental cells were transferred to a cell bath embedded in an inverted microscope stage(Diaphot, Nikon) and perfused with extracellular fluid. The extracellular fluid contained 130 mM NaCl, 4 mM KCI, 1.8 mM CaCl2, 1 mM MgCl2, 10 mM glucose and 10 mM HEPES (pH 7.4 with NaOH) at a perfusion rate of 4 ml/min. The inner tube contains 130 mM KCl, 1 mM MgCl2, 5 mM EGTA, 5 mM MgATP and 10 mM HEPES (pH 7.2 with KOH). Membrane currents were recorded using a HEKA EPC-10 patch-clamp amplifier and PATCHMASTER acquisition system (HEKA Instruments Inc., D-67466 Lambrecht, Pfalz, Germany). All experiments were done at room temperature (22-23 °C).
- Electrodes (BF150-86-10) were straightened during the experiments using a P-97 microelectrode puller (Sutter Instrument Company, One Digital Drive, Novato, CA 94949). The inner diameter of the electrode is 1-1.5 mm, and the water entry resistance after filling with internal liquid is 2-4 MΩ.
- When the whole-cell seal is formed, wait for the current to stabilize for 2 minutes (the current decay is less than 5% within 5 minutes, and the tail current value is greater than 500 pA). At this time, the peak value of the tail current is the control current value. The extracellular fluid containing the drug to be tested is then perfused. The same procedure was repeated 3-5 times, exposing each cell to 4-6 increasing concentrations of compounds. Blocking and deactivation of hERG during compound exposure and washout were continuously recorded.
- When the whole-cell seal was formed, the cell membrane voltage was clamped at -80 mV, depolarized for 2 seconds every 12 seconds, and the clamping voltage was depolarized from -80 mV to -50 mV under a 5-second repolarization pulse of -50 mV. Measure the peak tail current.
- Parametric analysis:
Peak hERG tail currents were measured under a 5 s repolarization pulse of -50 mV. Each drug concentration was plotted against the current inhibition rate as a function of the logarithm of the compound concentration. The following Hill equation was used to fit a concentration-response curve to fit IC50. - Y: test value; Bottom: the lowest test value (0); Top: the highest test value (1); Hillcoefficient: the maximum absolute value of the slope of the curve.
- Experimental data were collected using PATCHMASTER (HEKA Instruments Inc., D-67466 Lambrecht, Pfalz, Germany) and analyzed and statistically analyzed using Origin (OriginLab Corporation, Northampton, MA).
- Data are presented as mean ± standard deviation. Using t-Test test, whether there is a significant difference compared with the control group, when p<0.05, it is considered to have a significant difference.
- The experimental data are shown in Table 6.
Table 6 No. hERG (µM) A18 >20 A32 >20 A41 >20 A48 >20 A71 >20 A57 >20 A59 26 -
- Dissolve 1900 mg of MgCl2 in 400 mL of ultrapure water.
- Dissolve 17.42 g K2HPO4 and 13.65 g KH2PO4 into 1000 mL of ultrapure water, respectively. Mix a certain proportion of K2HPO4 and KH2PO4 to adjust the pH to 7.30 ± 0.10.
- Prepare a solution of 10 ng/mL labetalol and 10 ng/mL glyburide in acetonitrile and store at 4 °C.
- Prepare 10 mM verapamil (positive control) and test article stock solutions in DMSO. Then, with MeOH/ACN/H2O solution (1:1:2 by volume), diluted to 50 µM and 200 µM working solutions, respectively.
experiment procedure: - 1) Add 40 µL MgCl2 and 306 µL PBS to 96 wells (set blank control group, positive control group, test compound sample group, and negative control group at the same time)
- 2) Add 4 µL of compound working solution to each well (4 µL of PBS buffer for blank group) (Note: the final concentration of DMSO volume in the system is ≤ 0.5%)
- 3) Add 10 µL of liver microsomes (concentration: 20 mg/mL) to each well, mix well, and pre-incubate at 37 °C for 10 minutes.
- 4) Add 40 µL of 10 mM NADPH working solution to each well to start the reaction (add equal volume of PBS buffer for blank control group and negative control group respectively), the total reaction volume is 400 µL.
- 5) Take out 50 µL samples from the above reaction solution at 0, 5, 15, and 45 minutes, and add 400 µL of reaction stop solution to stop the reaction
- 6) Shake the sample after the termination of the reaction on a shaker for 5 minutes.
- 7) Centrifuge the sample at 3200 rcf for 10 minutes. After the centrifugation is complete, transfer 50 µL of the supernatant to 200 µL of H2O for dilution for LC-MS/MS analysis.
- data analysis
- Calculations of t1/2 and CLint are performed using the first-order kinetic equations:
- where k represents the elimination constant, calculated from a log-linear plot of percentage remaining versus time. t1/2 represents half-life. Cprotein is the concentration of liver microsomes.
- The experimental data are shown in Table 7.
Table 7 No. CLint (µL/min/mg protein) human rat mouse monkey dog A12 0.2 5.5 8.3 7.3 6.2 A13 6.3 2.4 6.6 2.6 0.9 A14 1.4 1.8 6.4 3.1 7.8 A17 0.4 15.9 12.0 5.0 10.6 A19 8.2 31.6 21.4 21.2 18.3 A22 1.6 20.7 13.2 21.0 13.6 A24 1.6 11.0 8.3 9.9 8.8 A25 9.0 33.2 5.1 19.7 13.2 A26 2.2 9.0 9.8 6.3 1.2 A27 4.0 7.5 17.7 15.9 4.8 A32 2.2 14.7 10.6 10.1 1.9 A37 19.1 16.7 18.9 28.7 10.8 A40 11.0 11.7 11.0 15.5 7.8 A45 5.2 7.9 6.3 3.2 9.6 A81 14.2 18.4 11.5 4.0 13.5 A48 7.3 15.8 15.2 8.6 26.3 A50 7.4 11.4 3.1 5.9 5.2 A51 9.9 12.5 16.7 26.2 22.2 A54 12.1 12.8 10.4 13.7 12.8 A55 14.7 24.7 14.3 20.0 20.7 A59 10.7 16.2 16.8 15.9 14.9 A82 8.6 5.3 10.5 4.5 3.9 A60 9.9 10.4 15.1 16.9 10.8 A61 13.0 15.9 14.1 6.1 14.5 A62 2.6 8.1 9.7 19.2 2.9 A80 2.7 14.0 9.0 1.0 3.1 - BALB/c nude mice, female, 6-8 weeks, weighing about 18-22 grams. Each mouse was subcutaneously inoculated with 0.2 mL (1×107 cells) MIA-PaCa2 cells (plus Matrigel, 1:1 by volume). Dosing was initiated when the mean tumor volume reached approximately 100-150 cubic millimeters. Test compounds were administered orally daily at a dose of 10 mpk QD. Tumor volume was measured twice a week, and the volume was measured in cubic millimeters and was calculated by the following Formula: V=0.5a×b2, where a and b were the long and short diameters of the tumor, respectively. The tumor-inhibitory efficacy of the compounds was evaluated by TGI (%). TGI (%), reflecting tumor growth inhibition rate. Calculation of TGI (%): TGI (%) = [(1-(average tumor volume at the end of administration of a certain treatment group - average tumor volume at the beginning of administration of this treatment group))/(average tumor volume at the end of treatment in the solvent control group Volume - the average tumor volume of the solvent control group at the beginning of treatment)] × 100%.
- In conclusion, most of the compounds listed in the present invention are highly potent and show significant improvement in safety and pharmacokinetics and excellent antitumor activity in in vivo models.
- Although the present invention has been fully described in terms of its embodiments, it is worth noting that various changes and modifications will be apparent to those skilled in the art. Such changes and modifications are intended to be included within the scope of the appended claims of the present invention.
Claims (32)
- A compound shown in Formula I, or a pharmaceutically acceptable salt, deuterated substance, cis-trans isomer, tautomer, solvate, chelate, non-covalent complex or prodrug thereof:- - - - - - is a single bond or a double bond;ring A is selected from 5- to 10- membered heteroaryl or 5- to 10- membered heterocyclyl; wherein, the 5- to 10- membered heteroaryl or the 5- to 10- membered heterocyclyl contains one or more O, N or S heteroatom; the 5- to 10- membered heterocyclyl contains at least one double bond;ring C is selected from 3- to 10- membered saturated or partially saturated heterocyclyl, C6-10 aryl and 5- to 10- membered heteroaryl;each Rc is independently selected from hydrogen, halogen, -CN, -NO2, oxo, -SF5, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 aryl, 5- to 10- membered heteroaryl, -OR5, -SR6, -NR7R8, -(C=O)R9, -C(=O)OR10, -C(=O)NR11R12, -S(=O)2R13, -S(=O)2OR14, -S(=O)2NR15R16, -O(CH2)sOR17, -O(CH2)sNR18R19, -NR20(CH2)tNR21R22, -NR23(CH2)tOR24, -NR25C(=O)R26, -OS(=O)2R27, -NR28S(=O)2R29, -OC(=O)R30, -S(=O)R31, -P(=O)R32R33, OC2-6 alkenyl C1-6 alkoxy, -OC2-6 alkenyl C6-10 aryl,two Rc with the atoms they are attached form C3-8 carbocyclyl, 3- to 10-membered heterocyclyl, C6-10 aryl, or 5- to 10- membered heteroaryl; wherein the C3-8 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 membered aryl, and 5- to 10-membered heteroaryl are optionally substituted by one or more substituents; the substituents are independently selected from hydrogen, halogen, -CN, -NO2, oxo, -SF5, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 aryl, 5- to 10- membered heteroaryl, -OR5, -SR6, -NR7R8, -(C=O)R9, -C(=O)OR10, -C(=O)NR11R12, -S(=O)2R13, -S(=O)2OR14, -S(=O)2NR15R16, -O(CH2)sOR17, -O(CH2)sNR18R19, -NR20(CH2)tNR21R22, -NR23(CH2)tOR24, -NR25C(=O)R26, -OS(=O)2R27, -NR28S(=O)2R29, -OC(=O)R30, -S(=O)R31, -P(=O)R32R33, OC2-6 alkenyl C1-6 alkoxy, -OC2-6 alkenyl C6-10 aryl,Rc1, Rc2 are independently selected from hydrogen, halogen, C1-4 alkyl and -OR5;or Rc1 and Rc2 together with the atoms to which they are attached form C3-6 carbocyclyl, or 3- to 6- membered heterocyclyl;each R1 is independently selected from hydrogen, halogen, -CN, -NO2, oxo, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 carbocyclyl, 3- to 6- membered heterocyclyl, C6-10 aryl, 5- to 10- membered heteroaryl, -OR5, -SR6, -NR7R8, -(C=O)R9, -C(=O)OR10, -C(=O)NR11R12, -S(=O)2R13, -S(=O)2OR14, -S(=O)2NR15R16, -O(CH2)sOR17, -O(CH2)sNR18R19, -NR20(CH2)tNR21R22, -NR23(CH2)tOR24, -NR25C(=O)R26, -OS(=O)2R27, -NR28S(=O)2R29, -OC(=O)R30, -S(=O)R31, and -P(=O)R32R33, wherein, the C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 carbocyclyl, 3-to 6- membered heterocyclyl, C6-10-membered aryl, or 5- to 10- membered heteroaryl is optionally substituted by one or more substituents; the substituents are selected from hydrogen, halogen, -CN, -NO2, oxo, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 carbocyclyl, 3- to 6- membered heterocyclyl, C6-10 aryl, 5- to 10- membered heteroaryl, -OR5, -SR6, -NR7R8, -(C=O)R9, -C(=O)OR10 and -C(=O)NR11R12;X is selected from -O-, -N(R1X)-, -S-, -C(=O)-, -C(=O)O-, -C(=O)N(R2X)-, -S(=O)2-, -S(=O)2O-, -S(=O)2N(R3X)-, -S(=O)-, -S(=O)O-, -S(=O)N(R4X)-, -OS(=O)2O-,R1X, R2X, R3X, R4X, R5X, R6X, R7X, R8X, R9X, R10X, R11X are independently selected from hydrogen, C1-3 alkyl, C3-6 cycloalkyl and 3- to 6- membered heterocyclyl;M is selected from -O-, -NR1a- and -CR1bR1c-;R1a is selected from hydrogen, C1-3 alkyl, C3-6 cycloalkyl, 3- to 6- membered heterocyclyl or absent;R1b, R1c are independently selected from hydrogen, C1-3 alkyl, C3-6 cycloalkyl, 3-to 6- membered heterocyclyl, -OR1d, -NR1eR1f or absent;R1d, R1e, R1f are independently selected from hydrogen, C1-3 alkyl, C3-6 cycloalkyl and 3- to 6- membered heterocyclyl;Y1 is selected from -NR3a or -CR3bR3c;R3a is selected from hydrogen, C1-3 alkyl, C3-6 cycloalkyl, 3- to 6- membered heterocyclyl or absent;R3b, R3c are independently selected from hydrogen, C1-3 alkyl, C3-6 cycloalkyl, 3-to 6- membered heterocyclyl or absent;Y2 is selected from -NR4a or -CR4bR4c;R4a is selected from hydrogen, C1-3 alkyl, C3-6 cycloalkyl, 3- to 6- membered heterocyclyl or absent;R4b, R4c are independently selected from hydrogen, C1-3 alkyl, C3-6 cycloalkyl, 3-to 6- membered heterocyclyl or absent;ring D is a C6-10 aryl, a 5- to 10- membered heteroaryl, a C3-8 carbocyclyl, or a 3-to 8- membered heterocyclyl; wherein, the C3-8 carbocyclyl or a 3- to 8- membered heterocyclyl optionally contains a double bond;each R4 is independently selected from hydrogen, halogen, -CN, -NO2, oxo, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 aryl, 5- to 10- membered heteroaryl, -OR5, -SR6, -NR7R8, -(C=O)R9, -C(=O)OR10, -C(=O)NR11R12, -S(=O)2R13, -S(=O)2OR14, -S(=O)2NR15R16, -O(CH2)sOR17, -O(CH2)sNR18R19, -NR20(CH2)tNR21R22, and -NR23(CH2)tOR24; wherein, the C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 carbocyclyl, 3- to 10-membered heterocyclyl, C6-10 membered aryl, or 5- to 10- membered heteroaryl is optionally substituted by one or more substituents; the substituents are selected from hydrogen, halogen, -CN, -NO2, oxo, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-10 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 aryl, and 5- to 10- membered heteroaryl;R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R13, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, or R40 is independently selected from hydrogen, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 aryl, and 5- to 10- membered heteroaryl; wherein, the C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 aryl, or 5- to 10- heteroaryl is optionally substituted with one or more substituents; the substituents are selected from hydrogen, halogen, -CN, -NO2, oxo, -OH, -NH2, C1-4 alkyl, C1-4 alkoxy, C2-4 alkenyl, C2-4 alkynyl, C3-10 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 aryl, and 5- to 10- membered heteroaryl;n is 0, 1, 2 or 3;p is 0, 1, 2, or 3;q is 0, 1, 2, 3 or 4;r is 0, 1, 2, 3 or 4;s is 1, 2, 3 or 4; andt is 1, 2, 3 or 4.
- The compound or the pharmaceutically acceptable salt, deuterated substance, cis-trans isomer, tautomer, solvate, chelate, non-covalent complex or prodrug thereof of claim 1, characterized in that ring A is selected from a 6- membered heteroaryl or a 6- membered heterocyclyl; the 6-membered heterocyclyl contains at least one double bond.
- The compound or the pharmaceutically acceptable salt, deuterated substance, cis-trans isomer, tautomer, solvate, chelate, non-covalent complex or prodrug thereof of any one of claims 1-2, characterized in that ring A is
- The compound or the pharmaceutically acceptable salt, deuterated substance, cis-trans isomer, tautomer, solvate, chelate, non-covalent complex or prodrug thereof of any one of claims 1-6, characterized in that the compound is selected from Formula II:ring C is selected from 3- to 10- membered saturated or partially saturated heterocyclyl, C6-10 aryl and 5- to 10- membered heteroaryl;each Rc is independently selected from hydrogen, halogen, -CN, -NO2, oxo, -SF5, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 aryl, 5- to 10- membered heteroaryl, -OR5, -SR6, -NR7R8, -(C=O)R9, -C(=O)OR10, -C(=O)NR11R12, -S(=O)2R13, -S(=O)2OR14, -S(=O)2NR15R16, -O(CH2)sOR17, -O(CH2)sNR18R19, -NR20(CH2)tNR21R22, -NR23(CH2)tOR24, -NR25C(=O)R26, -OS(=O)2R27, -NR28S(=O)2R29, -OC(=O)R30, -S(=O)R31, -P(=O)R32R33, -OC2-6 alkenyl C1-6 alkoxy, -OC2-6 alkenyl C6-10 aryl,two Rc with the atoms they are attached form C3-8 carbocyclyl, 3- to 10-membered heterocyclyl, C6-10 aryl, or 5- to 10- membered heteroaryl; wherein the C3-8 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 membered aryl, or 5- to 10-membered heteroaryl is optionally substituted by one or more substituents; the substituents are independently selected from hydrogen, halogen, -CN, -NO2, oxo, -SF5, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 aryl, 5- to 10- membered heteroaryl, -OR5, -SR6, -NR7R8, -(C=O)R9, -C(=O)OR10, -C(=O)NR11R12, -S(=O)2R13, -S(=O)2OR14, -S(=O)2NR15R16, -O(CH2)sOR17, -O(CH2)sNR18R19, -NR20(CH2)tNR21R22, -NR23(CH2)tOR24, -NR25C(=O)R26, -OS(=O)2R27, -NR28S(=O)2R29, -OC(=O)R30, -S(=O)R31, -P(=O)R32R33, -OC2-6 alkenyl C1-6 alkoxy, -OC2-6 alkenyl C6-10 aryl,R1 is selected from hydrogen, halogen, -CN, -NO2, oxo, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, -OR5, -NR7R8, -O(CH2)sOR17, -O(CH2)sNR18R19, -NR20(CH2)tNR21R22, and -NR23(CH2)tOR24; wherein, the C1-4 alkyl, C2-4 alkenyl or C2-4 alkynyl is optionally substituted by one or more substituents; the substituent is selected from hydrogen, halogen, -CN, -NO2, oxo, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6 carbocyclyl, 3- to 6- membered heterocyclyl, C6-10 aryl, 5- to 10- membered heteroaryl, -OR5, -SR6, -NR7R8, -(C=O)R9, -C(=O)OR10 and -C(=O)NR11R12;X is selected from -O-, -N(R1X)-, -S-, -C(=O)-, -C(=O)O-, -C(=O)N(R2X)-, -S(=O)2-, -S(=O)2O-, -S(=O)2N(R3X)-, -S(=O)-, -S(=O)O-, -S(=O)N(R4X)-, -OS(=O)2O-,R1X, R2X, R3X, R4X, R5X, R6X, R7X, R8X, R9X, R10X, and R11X are independently selected from hydrogen, C1-3 alkyl, C3-6 cycloalkyl and 3- to 6- membered heterocyclyl;each R4 is independently selected from hydrogen, halogen, -CN, -NO2, oxo, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 aryl, 5- to 10- membered heteroaryl, -OR5, -SR6, -NR7R8, -(C=O)R9, -C(=O)OR10, -C(=O)NR11R12, -S(=O)2R13, -S(=O)2OR14, -S(=O)2NR15R16, -O(CH2)sOR17, -O(CH2)sNR18R19, -NR20(CH2)tNR21R22, and -NR23(CH2)tOR24, wherein, the C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 carbocyclyl, 3- to 10-membered heterocyclyl, C6-10 membered aryl, or 5- to 10- membered heteroaryl is optionally substituted by one or more substituents; the substituents are selected from hydrogen, halogen, -CN, -NO2, oxo, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-10 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 aryl, 5- to 10- membered heteroaryl, -OR5, -SR6, -NR7R8, -(C=O)R9, -C(=O)OR10, -C(=O)NR11R12, -S(=O)2R13, -S(=O)2OR14, -S(=O)2NR15R16, -O(CH2)sOR17, -O(CH2)sNR18R19, -NR20(CH2)tNR21R22, and -NR23(CH2)tOR24;R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R28, R29, R30, R31, R32, R33, R34, R35, R36, R37, R38, R39, and R40 are independently selected from hydrogen, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 aryl, and 5- to 10- membered heteroaryl; wherein, the C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 aryl, or 5- to 10- heteroaryl is optionally substituted with one or more substituents; the substituents are selected from hydrogen, halogen, -CN, -NO2, oxo, -OH, -NH2, C1-4 alkyl, C1-4 alkoxy, C2-4 alkenyl, C2-4 alkynyl, C3-10 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 aryl, and 5- to 10- membered heteroaryl;q is 0, 1, 2, 3 or 4;r is 0, 1, 2, 3 or 4;s is 1, 2, 3 or 4; andt is 1, 2, 3 or 4.
- The compound or the pharmaceutically acceptable salt, deuterated substance, cis-trans isomer, tautomer, solvate, chelate, non-covalent complex or prodrug thereof of any one of claims 1-7, wherein ring C is selected from phenyl, pyrrolyl, furyl, thienyl, oxazolyl, imidazolyl, pyrazolyl, thiazolyl, pyridyl, pyrimidinyl, pyridazine base, pyrazinyl, pyridone, indolyl, benzoxazolyl, indazolyl, benzimidazolyl, benzotriazolyl, pyrrolopyridyl, quinolyl, naphthyl, dihydroisophenyl furanyl, benzobisoxazolyl, tetrahydroquinolinyl, dihydropyrrolopyridyl, dihydronaphthyridinyl, dihydropyridopyrimidinonyl, isoindolinyl, dihydropyrazolopyrimidine base, cyclohexenyl, tetrahydrobenzazepine, dihydrobenzimidazolone, indolinone, isoindolinone, dihydroquinolinone, dihydroisoquinolinone, benzene oxazinone, quinolinone, benzobisoxazolyl, dihydrobenzodioxin, pyridinone, and indazolyl.
- The compound or the pharmaceutically acceptable salt, deuterated substance, cis-trans isomer, tautomer, solvate, chelate, non-covalent complex or prodrug thereof of any one of claims 1-10, wherein each Rc is independently selected from hydrogen, halogen, -CN, -NO2, oxo, -SF5, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-8 carbocyclyl, 3- to 10- membered heterocyclyl, C6-10 aryl, 5- to 10- membered heteroaryl, -OR5, -SR6, -NR7R8, -(C=O)R9, -C(=O)OR10, -C(=O)NR11R12, -S(=O)2R13, -S(=O)2OR14, -S(=O)2NR15R16, -O(CH2)sOR17, -O(CH2)sNR18R19, -NR20(CH2)tNR21R22, -NR23(CH2)tOR24, -NR25C(=O)R26, -OS(=O)2R27, -NR28S(=O)2R29, -OC(=O)R30, -S(=O)R31 and -P(=O)R32R33.
- The compound or the pharmaceutically acceptable salt, deuterated substance, cis-trans isomer, tautomer, solvate, chelate, non-covalent complex or prodrug thereof of any one of claims 1-11, wherein each Rc is independently selected from hydrogen, oxo, -CH3, -OCH3, -OH, -OCF3, -CN, -F, -Cl, -CF3, -NH2, -NHCH3, -NH(C=O)CH3, -CH2OH, -C(=O)CH3, -C(=O)NH2, -C(=O)NHCH3, -C(=O)N(CH3)2, -COOH, -COOEt, -S(=O)2CH3, -S(=O)2NH2, -P(=O)(CH3)2, -CH2OCH3, -CH2C(=O)NH2,
- The compound or the pharmaceutically acceptable salt, deuterated substance, cis-trans isomer, tautomer, solvate, chelate, non-covalent complex or prodrug thereof of any one of claims 1-12, wherein each Rc is independently selected from hydrogen, -CH3, -F, -Cl, -NH(C=O)CH3, -C(=O)NH2 and -C(=O)NHCH3.
- The compound or the pharmaceutically acceptable salt, deuterated substance, cis-trans isomer, tautomer, solvate, chelate, non-covalent complex or prodrug thereof of any one of claims 1-13, characterized in that R1 is selected from hydrogen, halogen and C1-4 alkyl.
- The compound or the pharmaceutically acceptable salt, deuterated substance, cis-trans isomer, tautomer, solvate, chelate, non-covalent complex or prodrug thereof of any one of claims 1-14, characterized in that R1 is hydrogen.
- The compound or the pharmaceutically acceptable salt, deuterated substance, cis-trans isomer, tautomer, solvate, chelate, non-covalent complex or prodrug thereof of any one of claims 1-15, wherein each R4 is independently selected from hydrogen, halogen, oxo, C1-8 alkyl and -OR5.
- The compound or the pharmaceutically acceptable salt, deuterated substance, cis-trans isomer, tautomer, solvate, chelate, non-covalent complex or prodrug thereof of any one of claims 1-16, wherein each R4 is independently selected from hydrogen or -OCH3.
- The compound or a pharmaceutically acceptable salt, deuterated substance, cis-trans isomer, tautomer, solvate, chelate, non-covalent complex or prodrug thereof of any one of claims 1-17, wherein X is -O-.
- The compound or the pharmaceutically acceptable salt, deuterated substance, cis-trans isomer, tautomer, solvate, chelate, non-covalent complex or prodrug thereof of any one of claims 1-17, wherein X is -N(R1X)-, wherein R1X is selected from hydrogen or methyl.
- The compound or the pharmaceutically acceptable salt, deuterated substance, cis-trans isomer, tautomer, solvate, chelate, non-covalent complex or prodrug thereof of any one of claims 1-19, wherein q is 0 or 1.
- The compound or the pharmaceutically acceptable salt, deuterated substance, cis-trans isomer, tautomer, solvate, chelate, non-covalent complex or prodrug thereof of any one of claims 1-20, wherein r is 0, 1 or 2.
- The compound or the pharmaceutically acceptable salt, deuterated compound, cis-trans isomer, tautomer, solvate, chelate, non-covalent complex or prodrug thereof of claim 1, characterized in that the compound is selected from:(S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-phenoxyprop-1-yn-1-yl)pyrazin-2-yl)methanol;(S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-(3-methoxybenzene)oxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;(S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-(3-Aminophenoxy))prop-1-yn-1-yl)pyrazin-2-yl)methanol;(S)-N-(3-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)phenyl)acetamide;(S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-(3-chloro-2-fluoro)phenoxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;(S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-((3-methoxyphenyl)thio)prop-1-yn-1-yl)pyrazin-2-yl)methanol;(S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-(phenylamino)prop-1-yn-1-yl)pyrazin-2-yl)methanol;(S)-N-(4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)phenyl)acetamide;(S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-(4-methoxybenzene)oxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;(S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-(2-methoxybenzene)oxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;(S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-(3,4-dimethylform)oxyphenoxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;(S)-4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)benzonitrile;(S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-(3-(trifluoromethyl)phenoxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;(S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-(4-(trifluoromethyl)phenoxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;(S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-(3-(trifluoromethyl)oxy)phenoxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;(S)-1-(3-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)phenyl)ethan-1-one;(S)-4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl))pyrazin-2-yl)prop-2-yn-1-yl)oxy)benzamide;(S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-(pyridin-4-oxyl)prop-1-yn-1-yl)pyrazin-2-yl)methanol;(S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-((2-aminopyrimidine-5-yl)oxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;(S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-(4-morpholinoloxy)yl)prop-1-yn-1-yl)pyrazin-2-yl)methanol;(S)-1-(4-(4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)piperazin-1-yl)ethan-1-one;(S)-7-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl))pyrazin-2-yl)prop-2-yn-1-yl)oxy)-3,4-dihydroquinolin-2(1H)-one;(S)-6-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl))pyrazin-2-yl)prop-2-yn-1-yl)oxy)-2Hbenzo[b][1,4]oxazin-3(4H)-one;(S)-7-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl))pyrazin-2-yl)prop-2-yn-1-yl)oxy)quinolin-2(1H)-one;(S)-6-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl))pyrazin-2-yl)prop-2-yn-1-yl)oxy)indol-2-one;(S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-((2-Aminopyridine-4-yl)oxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;(S)-3-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl))pyrazin-2-yl)prop-2-yn-1-yl)oxy)benzamide;(S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-(benzo[d][1,3]Dioxyol-5-oxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;(S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-((((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)oxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;(S)-5-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)-1-methylpyridin-2(1H)-one;(S)-(6-(3-((1H-Indolazol-6-yl)oxy)prop-1-yn-1-yl)-3-(1-amino-1,3-dihydro spiro[indene-2,4'-piperidin]-1'-yl)pyrazin-2-yl)methanol;(S)-4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl))pyrazin-2-yl)prop-2-yn-1-yl)oxy)benzenesulfonamide;(S)-3-((3-(2-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-oxo-1 ,6-dihydropyrimidin-5-yl)prop-2-yn-1-yl)oxy)benzamide;(S)-N-(3-((3-(2-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-1-methyl)yl-6-oxo-1,6-dihydropyrimidin-5-yl)prop-2-yn-1-yl)oxy)phenyl)acetamide;(S)-3-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl))pyrazin-2-yl)prop-2-yn-1-yl)oxy)-N-methylbenzamide;(S)-3-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl))pyrazin-2-yl)prop-2-yn-1-yl)oxy)-N,N-dimethylbenzamide;(S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-(3-(methylthio)acyl)phenoxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;(S)-(3-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)yl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)phenyl)dimethylphosphine oxide;(S)-4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl))pyrazin-2-yl)prop-2-yn-1-yl)oxy)-1-methylpyridin-2(1H)-one;(S)-4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl))pyrazin-2-yl)prop-2-yn-1-yl)oxy)-N-picoline amide;(S)-6-(3-(3-acetamidophenoxy)prop-1-yn-1-yl)-3-(1-amino-1,3-dihydrospiro[indene-2,4]'-piperidin]-1'-yl)pyrazine-2-carboxamide;(S)-3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-((3-oxoisooctanol)-5-yl)oxy)prop-1-yn-1-yl)pyrazine-2-carboxamide;(S)-5-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazine-2-yl)-1-phenylpent-4-yn-1-one;(S)-4-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazine-2-yl)-N-phenyl-3-ynamide;(S)-N-(3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl))pyrazin-2-yl)prop-2-yn-1-yl)benzamide;(S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(4-(phenylamino)butyl-1-yn-1-yl)pyrazin-2-yl)methanol;(S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-((3,4-dimethyl oxyphenyl)amino)prop-1-yn-1-yl)pyrazin-2-yl)methanol;(S)-4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)amino)benzamide;(S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin] -1'-yl)-6-(3-((2-methoxypyridine-4-yl)oxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;(S)-4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)-2-fluorobenzamide;(S)-5-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)isoindolin-1-one;(S)-6-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)-3,4-dihydroisoquinolin-1(2H)-one;(S)-3-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)benzonitrile;(S)-4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)-2-chlorobenzamide;(S)-4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)(methyl) amino)benzamide;(S)-5-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)pyridineamide;(S)-(4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)phenyl)dimethylphosphine oxide;(S)-4-((3-(5-(1-amino-6-methoxy-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)benzamide;(S)-2-(3-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)phenyl)acetamide;(S)-(3-(1-amino-1,3-dihydrospiro[inden-2,4'-piperidin]-1'-yl)-6-(3-(oxazol-2-ylamino))prop-1-yn-1-yl)pyrazin-2-yl)methanol;(S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-((1-methyl-1H-pyrazol-5-yl)amino)propyly-1-yn-1-yl)pyrazin-2-yl)methanol;(S)-4-((3-(5-(1-amino-1,3-dihydrospiro[inden-2,4'-piperidin]-1'-yl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)-2-chlorobenzamide;(S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-((6-(trifluoromethyl)yl)pyridin-3-yl)amino)prop-1-yn-1-yl)pyrazin-2-yl)methanol;(S)-7-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)amino)-3,4-dihydroquinolin-2(1H)-one;(S)-N-(3-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)amino)phenyl)acetamide;(S)-6-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)isoindol-1-one;(S)-(6-(3-((1H-Indazol-5-yl)oxy)prop-1-yn-1-yl)-3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)pyrazin-2-yl)methanol;(S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-((2-(methylAmino)pyrimidin-5-yl)oxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;(S)-(3-(1-amino-1,3-dihydrospiro[inden-2,4'-piperidin]-1'-yl)-6-(3-((2-Aminobenzo[d]oxazol-5-yl)oxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;(S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-((6-(trifluoromethyl)yl)pyridin-3-yl)oxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;(S)-2-(4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)phenyl)acetamide;(S)-4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)-N-methylbenzamide;(S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-((2-methyl-1H-benzo[d]imidazol-5-yl)oxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;(S)-4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)-2-methylbenzamide;(S)-6-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)pyridin-3-ol;(S)-4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)-N-cyclopropylbenzamide;(S)-(3-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(3-(4-((1-methyl)yl)-1H-pyrazol-5-yl)amino)phenoxy)prop-1-yn-1-yl)pyrazin-2-yl)methanol;1-(4-((3-(5-((S)-1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxyl)methyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)phenyl)-2,2,2-trifluoroethane-1-ol;1-(4-((3-(5-((S)-1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxyl)methyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)phenyl)ethan-1-ol;(S)-2-(4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)phenyl)propan-2-ol;(S)-3-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)amino)benzamide;(S)-2-(4-((3-(5-(1-amino-1,3-dihydrospiro[indene-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)-1H-pyrazol-1-yl)acetamide;(R)-4-((3-(5-(3-amino-3H-spiro[benzofuran-2,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazine-2-yl)prop-2-yn-1-yl)oxy)benzamide;(S)-4-((3-(5-(5-amino-5,7-dihydrospiro[cyclopenta[b]pyridin-6,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)benzamide;(S)-4-((3-(5-(4-amino-4,6-dihydrospiro[cyclopenta[d]thiazol-5,4'-piperidin]-1'-yl)-6-(Hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)benzamide;(S)-4-((3-(5-(4-amino-4,6-dihydrospiro[cyclopenta[d]oxazol-5,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)benzamide; and(S)-4-((3-(5-(4-amino-4,6-dihydro-1H-spiro[cyclopenta[d]imidazol-5,4'-piperidin]-1'-yl)-6-(hydroxymethyl)pyrazin-2-yl)prop-2-yn-1-yl)oxy)benzamide.
- A pharmaceutical composition comprising a therapeutically effective amount of the compound of any one of claims 1-23 and at least one pharmaceutically acceptable adjuvant, wherein a mass ratio of the compound to the adjuvant is 0.0001: 1-10.
- Use of the compound of any one of claims 1-23 or the pharmaceutical composition of claim 24 in the preparation of a medicament.
- The use of claim 25, wherein the medicament is used for treating, preventing, delaying or preventing cancer, cancer metastasis, cardiovascular disease, immune disease, fibrosis or eye disease.
- The use of claim 25, wherein the medicament is used for treating a disease mediated by SHP2; preferably, the disease is cancer.
- The use of claim 27, wherein the cancer is selected from Noonan syndrome, leopard spot syndrome, juvenile myelomonocytic leukemia, neuroblastoma, melanoma, head and neck squamous cell carcinoma, acute myeloid leukemia, breast cancer, esophageal tumor, lung cancer, colon cancer, head cancer, gastric cancer, lymphoma, glioblastoma, and pancreatic cancer, or a combination thereof.
- A method of treating and/or preventing a disease mediated by SHP2, comprising administering to a subject a therapeutically effective amount of at least one compound of any one of claims 1-23 or pharmaceutical composition.
- A method of treating cancer comprising administering to a subject a therapeutically effective amount of at least one compound of any one of claims 1-23 or pharmaceutical composition.
- The method of claim 30, wherein the cancer is selected from Noonan syndrome, leopard spot syndrome, juvenile myelomonocytic leukemia, neuroblastoma, melanoma, head and neck squamous cells carcinoma, acute myeloid leukemia, breast cancer, esophageal tumor, lung cancer, colon cancer, head cancer, gastric cancer, lymphoma, glioblastoma, and pancreatic cancer, or a combination thereof.
- The method of claim 29 or 30, wherein the subject is human.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020104473 | 2020-07-24 | ||
CN2020119590 | 2020-09-30 | ||
PCT/CN2021/107808 WO2022017444A1 (en) | 2020-07-24 | 2021-07-22 | Shp2 inhibitor and composition and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EP4186896A1 true EP4186896A1 (en) | 2023-05-31 |
EP4186896A4 EP4186896A4 (en) | 2024-08-07 |
Family
ID=79728507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21847300.7A Pending EP4186896A4 (en) | 2020-07-24 | 2021-07-22 | Shp2 inhibitor and composition and application thereof |
Country Status (5)
Country | Link |
---|---|
US (1) | US20230339882A1 (en) |
EP (1) | EP4186896A4 (en) |
CN (1) | CN115515947B (en) |
TW (1) | TW202214584A (en) |
WO (1) | WO2022017444A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR125787A1 (en) | 2021-05-05 | 2023-08-16 | Revolution Medicines Inc | RAS INHIBITORS |
WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
PE20240088A1 (en) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | RAS INHIBITORS |
IL309984A (en) | 2021-07-09 | 2024-03-01 | Kanaph Therapeutics Inc | Shp2 inhibitor and use thereof |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023230205A1 (en) | 2022-05-25 | 2023-11-30 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3517B1 (en) * | 2014-01-17 | 2020-07-05 | Novartis Ag | N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2 |
BR112020009757A2 (en) * | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | polycyclic compounds as allosteric inhibitors of shp2 |
EP3768668B1 (en) | 2018-03-21 | 2024-08-28 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
CN116003321A (en) * | 2018-05-09 | 2023-04-25 | 北京加科思新药研发有限公司 | Novel heterocyclic derivatives useful as SHP2 inhibitors |
CN112839935A (en) * | 2018-09-26 | 2021-05-25 | 北京加科思新药研发有限公司 | Novel heterocyclic derivatives useful as SHP2 inhibitors |
-
2021
- 2021-07-22 EP EP21847300.7A patent/EP4186896A4/en active Pending
- 2021-07-22 US US18/016,144 patent/US20230339882A1/en active Pending
- 2021-07-22 WO PCT/CN2021/107808 patent/WO2022017444A1/en active Application Filing
- 2021-07-22 TW TW110126966A patent/TW202214584A/en unknown
- 2021-07-22 CN CN202180033007.1A patent/CN115515947B/en active Active
Also Published As
Publication number | Publication date |
---|---|
TW202214584A (en) | 2022-04-16 |
CN115515947A (en) | 2022-12-23 |
EP4186896A4 (en) | 2024-08-07 |
US20230339882A1 (en) | 2023-10-26 |
WO2022017444A1 (en) | 2022-01-27 |
CN115515947B (en) | 2024-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4186896A1 (en) | Shp2 inhibitor and composition and application thereof | |
CN113316574B (en) | SHP2 inhibitor and application thereof | |
EP2964223B1 (en) | Compounds inhibiting leucine-rich repeat kinase enzyme activity | |
TW202043212A (en) | Shp2 inhibitor and application thereof | |
EP3061747B1 (en) | Pyridic ketone derivatives, method of preparing same, and pharmaceutical application thereof | |
EP2630122B1 (en) | Arylamide derivatives as ttx-s blockers | |
WO2018196677A1 (en) | Fluoroallylamine derivative and use thereof | |
JP6522646B2 (en) | Substituted 4,5,6,7-tetrahydro-pyrazolo [1,5-α] pyrazine derivatives as ROS1 inhibitors and 5,6,7,8-tetrahydro-4H-pyrazolo [1,5-α] [1,1 4] Diazepine derivatives | |
US20220259235A1 (en) | EGFR Inhibitor, Composition, and Preparation Method Therefor | |
EP3715341A1 (en) | Halo-allylamine ssao/vap-1 inhibitor and use thereof | |
KR20050040814A (en) | Amide derivatives as glycogen synthase kinase 3-beta inhibitors | |
EP4253373A1 (en) | Heteroaryl carboxamide compound | |
EP4289843A1 (en) | Pyridopyrimidinone derivative, preparation method therefor, and use thereof | |
JP2017508779A5 (en) | ||
EP3323817A1 (en) | Aniline pyrimidine derivatives and uses thereof | |
EP3950676A1 (en) | Preparation method for amide compound and application thereof in field of medicine | |
EP3828174A1 (en) | Pyridazinone derivative | |
EP4006031A1 (en) | Dihydro-pyrrolo-pyrimidine selective jak2 inhibitor | |
EP3865487A1 (en) | Aromatic ring-linked dioxane-quinazoline or -quinoline compounds, compositions and use thereof | |
EP3166945B1 (en) | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | |
EP3686197B1 (en) | 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof | |
EP3009424A1 (en) | Bicyclic nitrogen-containing aromatic heterocyclic amide compound | |
WO2022002100A1 (en) | Novel benzimidazole compound | |
EP3551633B1 (en) | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | |
CN115066423A (en) | PD-L1 antagonist compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230119 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20240708 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/00 20060101ALI20240702BHEP Ipc: A61P 35/02 20060101ALI20240702BHEP Ipc: A61K 31/497 20060101ALI20240702BHEP Ipc: C07D 487/04 20060101ALI20240702BHEP Ipc: C07D 471/20 20060101ALI20240702BHEP Ipc: C07D 513/10 20060101ALI20240702BHEP Ipc: C07D 413/14 20060101ALI20240702BHEP Ipc: C07D 491/10 20060101ALI20240702BHEP Ipc: C07D 401/14 20060101AFI20240702BHEP |